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Aim of the study 
        
The goal of this study is to evaluate porous carriers for oral drug delivery. The use of porous 
scaffolds as carriers for drug delivery is already well established in the field of bone implants, 
where porous bone implants are used for local drug delivery. 
 
The first part of this research work presents the development of a porous single-unit carrier as 
an alternative for conventional tablets. The preferred industrial manufacturing technique for 
conventional tablets is direct compression, whereby a powder mixture consisting of drug and 
excipients is compressed into a dense structure. This technique is suitable for the 
incorporation of most drugs into tablets. However some drugs cannot be compressed directly 
into tablets because they lack the necessary flow and bonding properties required to form a 
useful tablet. Furthermore it is still a major challenge during the manufacturing of low-dosed 
drugs to ensure content uniformity of all units. To this end porous tablet-shaped 
hydroxyapatite scaffolds were prepared by calcination and sintering and spiked with a drug 
solution. Following absorption of the solution in the porous structure of the tablet and 
evaporation of the solvent, a tablet-shaped formulation is obtained that has the drug 
incorporated in its inner pores. As the drug dose per tablet only depends on the volume spiked 
on each tablet and small volumes of liquid can be dosed with a high accuracy, the risk of drug 
inhomogeneity is minimal, what makes these tablets an innovative carrier for low-dosed 
drugs. Furthermore, as the drug is incorporated in the porous tablets after compression, this 
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manufacturing technique is also promising for processing drugs with poor tabletting 
characteristics. 
 
A second part of this research work presents the development of porous pellets as multiple-
unit drug carriers. Therefore pellets consisting of microcrystalline cellulose and sodium 
chloride were manufactured by extrusion/spheronization and after removal of the sodium 
chloride fraction via extraction, porous pellets were obtained.  
In a first section, their potential as carrier for conventional drugs was tested by loading the 
porous pellets with drugs whereby conventional (immersion and fluidized-bed layering) and 
innovative loading techniques (supercritical fluid impregnation) were evaluated. 
In a second section, the use of the porous pellets in the field of oral vaccination was 
investigated. There still is a need for delivery systems that allow easy oral administration of 
antigens as well as provide protection of the antigen against the detrimental effects of the 
gastrointestinal tract. In this research project a veterinary model was chosen since 
enterotoxigenic Escherichia coli infections have been identified as an important causal agent 
of diarrhea and mortality in neonatal and post-weaning piglets. Therefore vaccination of the 
piglets against post-weaning infections would increase economic profit. However, attempts to 
induce mucosal immunity in piglets by oral vaccination have found little or no success, due to 
insufficient induction of the protective immune mechanisms. As oral solutions are unpractical 
for regular administration to suckling animals and do not protect the antigen during gastro-
intestinal passage, a solid vaccine formulation that can be mixed with creep food and that 
protects the antigens against the detrimental effects in the gastro-intestinal tract would be 
more efficient. Previously, enteric coated pellets have been used for oral administration of 
vaccines, as they protected F4 fimbriae (antigen used as vaccine against E. coli infections) 
against the detrimental effects in stomach and duodenum. However, as incompatibility 
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between F4 proteins and the enteric coating polymer was noticed, the use of porous pellets for 
oral vaccination of suckling piglets with F4 fimbriae was evaluated in this research study. 
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Introduction 
 
1.1. POROUS MATERIALS 
Porosity in materials can be arranged in a well-defined and homogeneous manner or in a 
heterogeneous manner. It can be separated or interconnected, resulting in pores having a 
different shape, size and/or interconnectivity. The three-dimensional assemblage of a large 
number of pores possessing a specific shape leads to a solid monolith displaying what can be 
termed as a cellular structure.  
Cellular materials (manufactured using polymers, metals and ceramics) are known to have 
many interesting combinations of physical and chemical properties. For this reason, they have 
widespread applications in nearly every technology sector. Many of the applications require 
that a medium, either liquid or gaseous, is able to pass through the cellular material. There 
may be a need for various degrees of interconnectivity, ranging from very open for high flow 
rates to completely closed for load-bearing structural applications and isolation materials. A 
difference can be made whether an application is functional or structural, the difference 
between these two notions, however, is gradual (Banhart, 2001) (Fig. 1.1). 
Structural applications of cellular material can be found in various industrial sectors: 
automotive, aerospace, ship building, railway, building, machine construction, sporting 
equipment and biomedical industry. Functional applications of porous materials are filtration 
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and segregation, heat exchangers and cooling machines, supports of catalysts, storage and 
transfer of liquids, fluid flow control etc. (reviewed by Banhart, 2001).  
 
Figure 1.1.: Applications of cellular material (Banhart, 2001). 
 
1.1.1. Porous materials for biomedical applications 
The biomedical applications of cellular material are mostly found in the field of bone and 
dental implantation. The implant stability is not only a function of strength but also depends 
on the fixation established with the surrounding tissue. This was primarily achieved using 
screws and bone cements. However, nowadays improved fixation can be achieved by bone 
tissue growing into and through a porous matrix of metal or a porous layer of another 
biocompatible material on the prothesis. Furthermore, the presence of interconnected pores 
will allow extensive body fluid transport through the porous scaffolds which can trigger bone 
ingrowth.  
Although the fabrication of porous materials has been studied as early as 1943 (Simancik, 
2000), the biomedical application of porous materials has only been investigated much later, 
whereby the work of Weber and White (1972) is one of the earliest to describe the use of 
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porous materials for osteointegration. Animal studies revealed that porous ceramics, polymers 
and metals were potential candidates for porous implants which would enable bone ingrowth. 
Porous ceramics and polymers are not applied as load bearing implants due to their intrinsic 
brittleness and low compression strength, respectively, hence usually porous metals (eg. 
titanium and its alloys, stainless steel and cobalt-chrome) are used for this application. 
However, porous ceramics and metallic scaffolds coated with hydroxyapatite (HA) have 
found large scale application as filling material for bone defects in prothesis revision surgery 
and dental implantology (Stigter et al., 2004). Hydroxyapatite is the preferred material for this 
purpose due to its biocompatibility and bioresorbability (Dubok, 2000; Jarcho, 1986) and in 
form of a porous body it enables one to produce cements similar to real bones (Palazzo et al., 
2005). The presence of pores in the scaffolds enables bone ingrowth and in combination with 
the osteoinductive capacities of HA, an optimal bone replacement is obtained (Grynpas et al., 
2002).  
 
Several manufacturing techniques can be applied for the production of porous ceramics. Each 
technique results in porous material with different pore size distribution, density and pore 
structure, hence the applied technique will depend on the final application of the cellular 
material (Ryan et al., 2006). The manufacturing techniques can be crudely divided into three 
categories with a series of variations on the basic themes. 
 
• Replication techniques 
¾ Slurry coating of polymer foams 
The replication of polymer foams is one of the first manufacturing techniques developed for 
producing ceramics with controlled macroporosity (Schwartzwalder and Somers, 1963), and 
despite its age it is still the most common and widely used technique in industry. A flexible, 
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open-cell polymer foam (polyurethane, polyvinylchloride, polystyrene or cellulose) is coated 
with ceramic slurries (Padilla et al., 2002), followed by removal of the redundant ceramic 
slurry. Afterwards, the polymer and any other organic additive are removed at elevated 
temperature (350-800°C) followed by sintering to achieve the required density and strength. 
Generally, any fine ceramic powder that can be made into a suspension can be used.  
This approach generally yields an open reticulated structure with high permeability. The main 
disadvantage is attributed to the hollow struts and large number of flaws that result from 
burning out the polymer foam. Furthermore, during removal of the organic phase toxic gases 
can be released, which makes extensive scrubbing of the waste gases necessary (Binner, 
2005). 
 
¾ Electrophoretic deposition 
Electrophoretic deposition is an electrochemical method that involves two steps. First, an 
electric field is applied between two electrodes and charged particles suspended in a suitable 
liquid move toward the oppositely charged electrode. In a second step, the particles 
accumulate at the deposition electrode and create a compact. Deposition of ceramics on 
carbon fibers and carbon rods (cathodic substrate) whereby the latter is removed via heat 
treatment results in porous material (Wang et al., 2002; Ma et al., 2003). 
 
• Foaming techniques 
¾ Incorporation of an external gas phase and gelation 
One of the earliest techniques, patented by Du Pont (1967), involved the production of foams 
from aqueous suspension of very fine (< 200 nm), negatively charged colloidal silica 
particles, a cationic surfactant and binding agents such as water-soluble polymers, sugars, 
gums, starches and resins. The slurries were converted into foams via mechanical agitation by 
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using different types of mixers, by injection of gas or by introduction of an aerosol propellant. 
Once formed into the desired shape by casting the slurry into a mould, the foam is dried 
followed by sintering during which the additives are burned out. 
Nowadays, the manufacturing of a ceramic foam via this procedure begins with the selection 
of an appropriate ceramic powder. The most important step in the process is the creation of a 
stable ceramic slurry. The ceramic powder is mixed with water containing dispersants, 
initiators, catalyst and a premixed solution containing organic monomers. High-shear mixing 
is used to destroy any agglomerates. The organic monomer solution can be readily 
polymerized to form a cross-linked polymer-water gel, whereby both the ceramic powder and 
water are trapped in the foamed structure. A foaming agent (surfactant) is added to the slurry, 
prior to transfer to the foaming unit. The onset of polymerization is controlled in order to have 
sufficient time for the foam to exit the foaming unit and to be cast into an appropriate mould. 
When polymerization is completed, the structure is strong enough to be demoulded and 
transferred to the oven for drying. The polymeric binder is removed followed by sintering at 
elevated temperature, hence a strong highly porous ceramic is obtained. The gel-foaming 
method is able to produce - even before sintering - parts with excellent mechanical properties, 
allowing green machining (Sepulveda et al., 2000). When bioceramic hydroxyapatite is 
processed via this technology, this resulted in foams with excellent properties for encouraging 
bone ingrowth. 
Several variations on this manufacturing method are developed. Other additives were 
incorporated in the slurry e.g. gelling agents such as cellulose derivates (Moreno, 1992), 
alginates (Katsuki et al., 1992), compositions that intrinsically from a gel (Bagwell and 
Messing, 1996) and the use of in situ polymerization of an organic monomer (Young et al., 
1991).  
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¾ In situ gas production 
In this approach the common theme is the presence of a foaming agent that decomposes due 
to heat or a chemical reaction to generate a gas within the ceramic slurry (Almirall et al, 
2004). A patent by A.C.I. Operations (1973) described a method of producing a ceramic foam 
as a result of chemical reactions to liberate hydrogen during processing. After gel formation 
whereby the components were bound together, hydrogen gas was formed in situ via a 
chemical reaction. The surfactant present in the composition served to break up the gas 
bubbles into smaller bubbles as well as to stabilize them, thus ensuring a porous structure with 
an open celled nature.  
More recently, Colombo and Bernardo (2003) produced porous open-cell ceramic foams by in 
situ gas formation in solutions of preceramic polymers. Methyl polysiloxane resin was mixed 
with precursors of polyurethane (polyols and isocyanates) in dichloromethane, together with 
appropriate surfactants and catalysts. Blowing (expansion of gases) started by a combination 
of vigorously stirring and heating the mixture. The expansion and foam formation was a result 
of physical blowing (solvent evaporation) and chemical blowing (reaction between water 
generated by condensation of SiOH groups in the silicone resin with isocyanate to form 
carbon dioxide gas) (Takahashi et al., 2001) . 
 
• Other techniques 
The powder can be mixed with space holding material (pore forming agents) and after 
compression, the space holder material is removed by heat treatment or leaching with an 
appropriate solvent. A final sintering step can be applied to further densify the porous 
network (Bram et al., 2000). 
Three-dimensional printing is a rapid prototyping technology used to create complex three-
dimensional parts directly from a computer model, via a layered printing process the structure 
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is built layer-by-layer based on the computer model. The layering process is repeated until the 
part is completed, followed by a heat treatment in order to consolidate the bound material 
(Gbureck et al., 2007; Habibovic et al., 2008). 
 
1.1.2. Calcination and sintering 
¾ Calcination 
During the calcination process the organic components are removed, resulting in pores 
whereby pore shape and pore size are related to the original organic material. It requires 
careful control of temperature, pressure, atmosphere (air or any other type of atmosphere as 
appropriate) and time in order to achieve a non-destructive and reproducible removal of the 
additives from the green body (matrix before sintering). After calcination, the structure of the 
green body is only held together by weak cohesive forces and requires particularly careful 
handling during the following process steps. For this reason, calcination is often combined 
with a (pre)sintering step wherever possible.  
 
¾ Sintering 
Sintering is broadly defined as the consolidation upon heating of a loose mass of particles, 
which are in contact with each other, to a denser mass. It results in a decrease of specific 
surface area and porosity and in an increase of density. The thermal behavior of 
hydroxyapatite (Ca5(PO4)3OH) (HA) during sintering is determined by the Ca/P ratio. 
Usually the sinter temperature for HA powder is chosen in the range of 1150-1350°C. When 
stoichiometric HA (Ca/P ratio= 1.67) is sintered below 1350°C no other phases than HA are 
present in the end product. At 1400°C HA starts to decompose whereby α-tricalcium 
phosphate (TCP) is formed. Further increasing the temperature results in further 
decomposition of HA forming β-TCP, tertracalcium phosphate (TTCP) and calciumoxide 
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(CaO). Any deviation from the stoichiometric value of the non-sintered HA results in the 
formation of β-TCP when samples are sintered below 1350°C (Muralithran and Ramesh, 
2000; Tampieri et al., 1997). 
The driving force of the sinter process is a reduction of the surface free energy of the system 
(Δ GT) 
    ΔGT = ΔGv + ΔGb + ΔGs        (Eq. 1.1.) 
whereby ΔGv, ΔGb and ΔGs corresponds with the change in free energy associated with the 
grain volume, grain boundaries and grain surface, respectively. 
During the sintering process mass transport occurs via different diffusion mechanisms (Fig. 
1.2 . and Table 1.1.) 
 
Figure 1.2.: Different diffusion mechanisms during sintering (Kingery et al., 1976). 
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Table 1.1.: Overview of the different diffusion mechanisms during sintering. 
Nr in Fig. 1.2. transport transport mechanism 
1 surface diffusion from surface to neck via surface 
2 lattice diffusion from surface to neck via lattice 
3 evaporation transport from surface to neck via surface 
4 grain boundary diffusion from grain boundary to neck via lattice 
5 lattice diffusion from grain boundary to neck via lattice 
6 lattice diffusion from dislocation in the lattice to neck via lattice 
 
The amount of material that diffuses in function of time can be described by Fick’s first law 
of diffusion 
                            J = -D 
x
c
∂
∂                                 (Eq. 1.2.) 
where c is the concentration per volume, x represents the diffusion path, J denote the flux and 
D is the diffusion coefficient (depending on the type of transport mechanism).  
The diffusion coefficient is directly proportional with the atom mobility as described by 
                             D = kTBi                                (Eq. 1.3.) 
where k is the Boltzmann constant, T the temperature and Bi the absolute mobility. 
As the diffusion process is thermally activated, a temperature increase will result in a higher 
number of atoms that contain sufficient energy to exceed the energy barrier between two 
lattice places, resulting in a chemical potential gradient. Material transfer during sintering will 
occur in order to reduce the chemical potential gradient. As the amount of atoms with 
sufficient energy to overcome the energy barrier between two lattice places will increase at 
higher temperature, the temperature is a dominant factor in the sintering process whereas the 
influence of sinter duration is less pronounced. 
Generally, sintering occurs in three stages as presented in Fig. 1.3.  
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 Figure 1.3.: Different stages of sintering (Kingery et al., 1976). 
 
During the initial stage, contact areas between the individual particles are formed. Two 
different processes are involved: contact sintering and densification sintering. During contact 
sintering, material transfer from the grain surface to the grain neck occurs via surface or 
lattice diffusion and evaporation-condensation without a decrease in distance between the 
grain centers, hence no shrinkage occurs. During densification sintering, material is 
transferred to the neck via the lattice whereby shrinkage occurs due to the fact that the 
material transport occurs via the lattice. 
In the intermediate stage, neck growth occurs and the large number of small particles are 
replaced by a smaller number of large grains. Intensive shrinkage of open pores occurs 
between the grain boundaries. This is associated with a change in pore geometry. The highest 
densification is obtained during this stage. 
In the final stage of sintering, grain boundary and lattice diffusion are the dominant mass 
transport mechanisms. Isolated closed pores are formed which shrink in size as densification 
proceeds (Bailliez and Nzihou, 2004).  
 
During the sinter process, grain growth occurs, whereby large particles grow at the expense of 
the smaller particles, resulting in an increased mean grain size and a decrease in the total grain 
surface area. The driving force for grain growth is inversely proportional with the grain size. 
If all grain boundaries are equal in energy, they meet to form angles of 120°. If we consider a 
two-dimensional example, angles of 120° between grain size can occur only for six-sided 
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grains. Grains with fewer side have boundaries that are concave when observed from the 
center of the grain. Since grain boundaries migrate toward their center of curvature, grains 
with less than six sides tends to grow smaller and grains with more than six sides tends to 
grow larger (Fig. 1.4.).  
 
 
Figure 1.4.: Schematic drawing of polycrystalline specimen. Arrows indicate the directions in 
which boundaries migrate (Kingery et al., 1976) 
 
Two factors are able to inhibit the grain growth: the boundary of the specimen and the 
presences of inclusions. When the grains obtained a size comparable with the specimen size, 
the grain grown will stop. The presence of inclusions (impurity) can increase the energy, 
necessary for movement of a grain boundary, hence no further grain growth will occur.  
 
1.1.3. Porous materials as drug delivery systems. 
The presence of pores in ceramic foams offers the possibility to use these porous ceramics not 
only as bone substitutes but also as carriers for local and controlled delivery of drugs. This 
application is useful in the treatment of different skeletal diseases which normally require a 
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long and painful therapy. The incorporation of antibiotics (Hasegawa et al., 2003; Sivakumar 
and Rao, 2002), chemotherapeutica (Burgos et al., 2002, Itokazu et al., 1999; Lebugle et al., 
2002), NSAIDs and growth factors (Arm et al., 1996) in porous bone scaffolds is already well 
established. 
Drug release from these drug delivery devices depends on different factors such as 
microstructure, drug solubility, possible bonding between drug and matrix. Generally in case 
of porous calcium phosphate devices, the drug release is diffusion-controlled as the rate of 
ug liberation (Ginebra et al., 2006). matrix degradation is much lower than the rate of dr
         
1.2. CONVENTIONAL ORAL SOLID DOSAGE FORMS 
1.2.1. Introduction 
In this research project, the possible applications of porous drug delivery systems for oral 
drug delivery were investigated. Porous structures were manufactured of two major groups of 
oral solid dosage forms: single unit and multiple unit systems. Tablets and pellets are the most 
popular examples of a single unit and multiple unit dosage form, respectively.  
Two manufacturing techniques were selected to prepare the porous dosage forms during this 
research project: 
(1) Of all the manufacturing techniques for porous ceramics described in section 1.1.1., the 
simplest method consist of preparing a mixture of ceramic powder and space holding material 
(pore forming agents) whereby after compression, the space holder material is removed by 
heat treatment or via extraction with an appropriate solvent. The resulting porous structure 
can be sintered to increase the mechanical strength.  
 (2) To obtain porous structures with well defined pores, gelation can be used. In this study, 
agar (a natural occurring polysaccharide) is used as gelling agent.  
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After gelation and drying the green body is demouled, followed by calcination and sintering 
in order to burn out the gelling agent and other additives and to optimize the strength of the 
material, respectively. 
 
1.2.2. Tablets 
Tablets are the most widely used solid dosage form for a number of reasons: they are 
convenient, easy to manufacture and use, and offer accurate dosing and excellent stability. 
Tablets are generally defined as single-unit dosage forms made by compaction of a mixture 
consisting of drug and specific fillers or excipients in order to aid in the processing and to 
improve tablet properties (Bandelin, 1989). Tablets can be prepared without pretreatment of 
the powder mixture via direct compression, or after wet or dry granulation to improve the 
compression properties of the powder mixture (Shangraw, 1989).  
 
Figure 1.4.: Various steps involved in direct compression (adapted from Patel et al., 2006). 
 
Direct compression (Fig. 1.4.) is the preferred method for manufacturing of tablets, the most 
obvious advantage being economy: due to the reduced processing time, lower labor costs, 
_________________________________________________________________________ 
Introduction 
17
limited manufacturing steps, less process validation it is a rather cost-effective technique. 
With regards to tablet quality, the most important advantage is the fact that there is no need 
for moisture or heat during the process which is beneficial for stability of the drug.  
However this technique may not be suitable for the production of low-dosed tablets or for 
processing tablets containing drugs with poor compression characteristics. The formulator can 
resort to several strategies to overcome these problems: optimization of particle size and 
shape, selection of specific excipient grades, use of appropriate mixers, formation of ordered 
mixtures (Venables and Wells, 2001). When these are unsuccessful, wet/dry granulation can 
be used. However, these approaches cannot completely eliminate the risk of particle 
segregation (Vromans et al., 1999). 
 
1.2.3. Pellets 
Pellets are defined as small free-flowing, spherical or semi-spherical particles sized between 
500 and 1500 µm (Ghebre-Selassie, 1989). Multiparticulate dosage forms offer important 
therapeutic as well as technological advantages over single unit dosage forms (Bechgaard and 
Hagermann, 1978; Ghebre-Selassie, 1989; Krämer and Blume, 1994): 
- a predictable gastric emptying, less dependent on the nutritional state resulting in a lower 
inter- and intra-subject variability of drug plasma profiles 
- a high degree of dispersion in the digestive tract, minimizing the risk of high local drug 
concentrations which could irritate the gastric mucosa 
-  less variance in transit time through the gastrointestinal tract 
- less risk of dose dumping as every pellet acts as a single drug reservoir, a coating 
imperfection would only affect the release of a small drug portion 
- possibility to combine several active components, incompatible drugs or drugs with different 
release profiles in the same dosage unit 
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- good flow properties, minimized dust formation and easy to coat 
 
Extrusion/spheronization, first described by Conine and Hardely (1970) and Reynolds (1970), 
is the most common used manufacturing technique. It is a multi-step process involving dry 
mixing, wet granulation, extrusion, spheronization and drying.  
 
¾ Dry mixing and wet granulation 
In the first step of the process a homogeneous powder mixture must be obtained prior to wet 
granulation. During wet granulation, the granulation liquid is added in order to obtain a wet 
mass with the required plasticity or deformation characteristics. Generally, granulation is 
performed in the same equipment as dry mixing.  
 
¾ Extrusion 
During extrusion, the wet plastic mass is forced through the extrusion die in order to form 
cylinders or strands with a width corresponding to the die diameter. A variety of extruders is 
available. Based on their feed mechanism they can be divided into screw feed extruders, 
gravity feed extruders and piston feed extruders (Erkoboni, 2003) . 
 
¾ Spheronization 
Spheronization involves the rounding of extrudates into spheres or pellets due to frictional 
forces generated by particle-particle and particle-equipment interactions.  
A spheronizer consist of a bowl with a stationary cylindrical wall and a fast-rotating bottom 
plate having a grooved surface (cross-hatched or radial pattern) to increase friction. 
When placed in the spheronizer the extrudate is broken into small pieces and within a short 
period of time spherical particles are formed. Due to the centrifugal forces, the pieces move 
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outward to the wall, climb up the wall and fall back onto the rotating disk which due to its 
angular motion pushes the mass again towards the wall, resulting in a rope-like formation 
(Fig. 1.5.). 
 
Figure 1.5.: Schematic representation of the rope-like formation during spheronization (Erkoboni, 
2003). 
 
The transformation from extrudates into pellets occurs in various stages, as proposed by two 
models: Rowe (1985) describes that after the initial breaking, the extrudates are rounded off 
into cylindrical particles with rounded edges, followed by formation of dumbbell-shaped 
particles, ellipsoids and finally spherical pellets (Fig. 1.6. B). The model proposed by Baert 
and Remon (1993) suggests that the cylinders are rounded and additionally bent, followed by 
twisted dumbbell formation. The twisting action eventually causes the dumb-bell to break into 
two parts. Due to the folding of the edges of the flat side of these parts during further 
spheronization, the resulting spheres often have a cavity in their internal structure (Fig. 1.6. 
A). The exact mechanism depends on the formulation. 
_________________________________________________________________________ 
Chapter 1 
20
 Figure 1.6.: Schematic representation of the two models to describe the mechanism of 
spheronization proposed by: Baert and Remon (A) and Rowe (B) (adapted from 
Erkoboni (2003)). 
 
¾ Drying 
The wet pellets are usually dried in an oven or fluidized-bed. The major difference is the rate 
of fluid removal. During fluidized-bed drying a more rapid drying is obtained due to the 
higher air volumes and the higher inlet temperatures that are used (Erkoboni, 2003). 
 
When manufacturing conventional tablets or pellets the drug is added to the powder mixture 
prior to tabletting or extrusion/spheronization. In contrast, when using porous tablets/pellets 
the drug is only incorporated in the dosage form after manufacturing the porous carriers. 
Therefore appropriate loading techniques were examined to incorporate the drug into the 
porous tablets and pellets. 
Porous tablets were loaded with a model drug (metoprolol tartrate) by spiking the tablet 
surface with an aliquot of the drug solution. Porous pellets were loaded with a model drug 
using  different loading techniques: immersion the pellets in a metoprolol tartrate solution, 
ibuprofen impregnation via supercritical fluids and paracetamol layering via fluid-bed 
layering. 
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1.3. VACCINATION 
1.3.1. Introduction 
Next to conventional drug delivery, the use of porous pellets in the field of vaccination was 
investigated. There is an increased interest in oral vaccination due to its inherent advantages. 
However there is still a lot of research required to find an appropriate carrier for oral delivery 
of vaccines. The optimal carrier should be easy to administer and offer protection to the 
antigen during gastro-intestinal transit without damaging the vaccine itself. 
 
Most of the currently available licensed vaccines are administered parenterally whereby a 
systemic immune response rather than a mucosal immune response is obtained. However 
most pathogens do not infect their host by direct inoculation into the bloodstream, rather 
initiate their infectious process at mucosal surfaces. A protective immune response at the site 
of infection is required. Hence vaccines that can induce mucosal immunization will provide a 
first line of defense against the many pathogens that invade via the mucosal surfaces. 
Furthermore mucosal administration would avoid the pain and discomfort associated with 
injections and would eliminate the risk of infections caused by inadequately sterilized needles 
or needle re-use.  
Next to oral administration, nasal, pulmonary, rectal, urogenital, ocular and vaginal 
administration are also potential routes for mucosal immunization (O’Hagan, 1998; Walker, 
1994).  
 
1.3.2. The mucosal immune system 
The intestinal, respiratory and urogenital tract are the major ports of entry for microorganisms 
into the host, however some barriers need to be overcome. In the gastro-intestinal tract, the 
gastric acidity, proteolytic enzymes, peristalsis, common microflora and mucus will have a 
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detrimental effect on the microorganisms. Furthermore, an immunological barrier protects the 
urogenital, respiratory and intestinal mucosa: mucosal-associated lymphoid tissue (MALT). 
The MALT comprises the gut-associated lymphoid tissue (GALT), the bronchus-associated 
lymphoid tissue (BALT), the nasal-associated lymphoid tissue (NALT) and the urogenital-
associated lymphoid tissue, which all have similar characteristics. 
 
¾ Gut-associated lymphoid tissue 
The intestinal epithelial barrier is composed of a single layer of epithelial cells, mainly 
enterocytes interspersed by mucus-secreting goblet cells.  
The gut-associated lymphoid tissue, located throughout the gastrointestinal tract, consists of 
clusters of lymphoid follicles (e.g. Peyer’s patches) or solitary follicles which serve as the 
mucosal inductive sites of an immune response.  
The epithelium overlaying the lymphoid follicles is called the follicle-associated epithelium 
(FAE) and is distinguished from intestinal epithelium at other sites by the presence of 
microfold cells or M-cells. M-cells lack a brush border and have a flattened apical membrane, 
with sparse, short, irregular microvilli (Fig. 1.7.). They have a basolateral cytoplasmic 
invagination which creates a pocket (infiltrates of lymphocytes/antigen presenting cells in the 
pocket). Furthermore, reduced quantities of sIgA and mucus are found at the apical side of the 
cell. Antigen sampling (and potential drug and vaccine delivery) is thought to be facilitated by 
these characteristics (Clark, 2001; Niedergang and Kraehenbuhl, 2000). There is low to no 
antigen degradation during transport through the M-cell. 
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 Figure 1.7.: Gut-associated lymphoid tissue (A) and a detailed structure of an M-cell (B) (adapted 
from Clark et al., 2001). 
 
The possibility that delivery can be achieved by alternate routes such as dendritic cells and 
enterocytes should not be overlooked. Investigation in mice has been revealed that dendritic 
cells (DC) may directly internalize antigens from the mucosal surfaces. If this is quantitatively 
significant remains unclear. Enterocytes are also able to transport molecules by transcytose. 
Targeting and increasing the efficacy are remaining major challenges (Florence, 1997; Clark, 
2001). 
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¾ The mucosal immune response 
M-cells take up adherent macromolecules and small particles. The endocytosed molecules are 
efficiently transported through the M-cell and exocytosed inside the M-cell pocket. 
Transcytosed molecules do not appear to undergo major structural degradation during 
transport (Davis and Owen, 1997). The antigens are internalized and processed by antigen 
presenting cells (APC) such as dendritic cells and macrophages, present in the subepithelial 
dome of the Peyer’s patches. In this region B-cell follicles surrounded by T-cells (next to 
macrophages and dendritic cells) are found. Hence all cells necessary for the induction of an 
adequate immune response are present. The APC will present the antigen to B- and T-
lymphocytes. The APC is able to discriminate between harmful and non-harmful antigens. 
Harmful antigens often have specific ‘pathogenic associated molecular patterns’ (PAMPs) 
that are recognized by Toll-like receptors (TLRs) expressed by APCs. This leads to 
stimulation of T-cells (CD4+ T-helper cells and CD8+cytotoxic T-lymphocytes) and IgA-
precursor B-cells in the Peyer’s patches and the dissemination of B- and T-cells to mucosal 
effector tissues such as the lamina propria and mesenteric lymph nodes. Here the lymphocytes 
will further differentiate and maturate, and in the next phase they will migrate to the systemic 
circulation via the thoracic duct and to organs including the liver and the spleen (Nugent et 
al., 1998; Holmgren and Czerkinsky, 2005). The stimulated lymphocytes migrate 
preferentially to mucosal tissues, mediated by the expression of adhesion molecules on 
lymphocytes and on cells associated with mucosal tissue. They mainly home to the mucosal 
site where the infection was elicited. In plasma cells polymeric IgA is formed. The polymeric 
immunoglobulin receptor (pIgR) which is present on the basolateral membrane of the mucosal 
epithelial cells mediates the transport of polymeric IgA to the luminal side of the cell (Kaetzel 
et al., 1991). The complex of pIgR and polymeric IgA is endocytosed and transferred through 
vesicular compartments to the apical surface, where proteolysis of pIgR results in the release 
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of secretory IgA (sIgA). sIgA in external secretions occurs mainly in dimeric (and tetrameric) 
forms, with four (or eight) antigen binding sites, respectively. This isotype is usually not 
obtained by parenteral immunization, which is characterized by IgG and IgM. Locally 
produced sIgA molecules are the determinants of humoral secretory immunity at the mucosal 
surfaces. Next to the production of sIgA, secretion may also contain IgA (serum type), IgG, 
IgM, and components of cell-mediated immunity (T-cells), in varying amounts (Nugent et al., 
1998). 
The intestinal sIgA response to antigen exposure is relatively short. Hence memory, obtained 
by specific memory B-cells, is an import aspect in the mucosal immunity. By repeated 
exposure to the antigen it is rapidly and efficiently triggered (Holmgren, 1991). 
 
1.3.3. Oral vaccination 
Vaccines can generally be classified into cellular and acellular vaccines. Cellular vaccines 
consist of inactivated or attenuated organisms, whereas acellular vaccines consist of purified 
antigens.  
As most vaccines are still administered parenterally, a lot of research efforts are focused on 
the development of oral vaccines. The oral vaccine against polio, Salmonella typhi and 
rotavirus are some examples of oral vaccines available on the Belgian market.  
 
The development of an oral vaccine is a major challenge as the antigen has to pass through 
the gastro-intestinal tract where it is diluted in mucosal secretions, captured in mucus, 
attacked by proteases and nucleases, and excluded by epithelial barriers. Soluble antigens are 
taken up at low levels, whereas protection of the antigen against the detrimental GI-effects is 
required in order to stimulate an adequate immune response in the mucosal tissue (Neutra and 
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Kozlowski, 2006). Some examples of delivery systems that have potential as mucosal 
delivery system for antigens are: 
- biodegradable particulates whereby poly(lactide-co-glycolide) (DL-PLG) particles are 
the most promising. The rate of degradation is influenced by the lactide-to-glycolide 
ratio allowing for sustained release of the antigen. 
- liposomes are composed of bilayered phospholipid vesicles. The antigen may be 
incorporated either into the central aqueous space (water-soluble antigens) or into the 
phospholid layer (lipid-soluble antigens). Usually they will degrade within the gut 
lumen but by modifying their chemical composition their stability may increase. 
 
However, there are some drawbacks associated to particulate delivery systems. High 
temperatures, high shear forces and organic solvents, all of which will inactivate the antigen, 
are required during the production of PLG particles and liposomes. In general, the major 
consideration is the poor particle uptake by the M-cells and this is mainly due to the small 
portion of FAE occupied by M-cells. 
An increase of particle uptake by M-cells can be obtained by non-specific and specific 
interactions of the synthetic delivery systems with M-cells. The enhancement of M-cells’ 
interaction using the non-specific route involves altering of the particle size, surface charge 
and hydrophobicity. However this is a rather unreliable method. 
A more reliable method is the use of receptor–mediated M-cell targeting. To this end the 
surface of the particles is chemically modified in order to enhance the interactions with M-cell 
apical membranes. This can occur by lectin-mediated, microbial protein-mediated and 
immunoglobulin-mediated M-cell targeting (Clark, 2001; Gilligan and Po, 1991). 
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In this research work the use of porous pellets in the field of oral vaccine formulation was 
investigated. The porous network could offer some advantages: (a) incorporation of the 
vaccine only occurs after manufacturing of the porous pellet production, hence the 
manufacturing process has no detrimental effects on the vaccine; (b) the release from porous 
devices is diffusion-controlled, hence the tortuosity of the porous pellets will delay the 
absorption of gastric fluids and the release of vaccine, resulting in a lower loss of vaccine 
before reaching the target site; (c) no additional coating with an appropriate polymer is 
required as the vaccine is protected by the porous network. 
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2.1. INTRODUCTION 
As described in Chapter 1, porous bone implants are already well established in the field of 
local drug delivery. For most type of drugs incorporated in the porous bone implants, 
sustained drug release is required. Generally, porous bone implants based on calcium 
phosphate are diffusion-controlled devices, where the drug is incorporated into a non-
biodegradable matrix. Although some of the calcium phosphates are resorbable, in most cases 
the rate of matrix degradation is much lower than the rate of drug liberation, hence the 
diffusion-controlled drug release (Ginebra et al., 2006a). 
 
The objective of the research work presented in this chapter was to explore if the applications 
of porous structures could be extended to oral drug delivery. Tablets are still the favorable 
solid dosage form for oral drug delivery attributed to their advantages for both the patient and 
the manufacturer. The preparation of tablets mostly occurs by direct compression due to its 
economic benefit. However, in some cases direct compression is not recommended, e.g. for 
drugs with poor compression properties or low-dosed drugs. The challenge of this project was 
to develop an innovative carrier, a porous tablet, that could overcome these problems. 
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To manufacture these tablet-shaped porous structures two techniques were evaluated: direct 
compression and modified gelcasting, both followed by sintering. Tablets were manufactured 
using calcium hydroxyapatite (HA) and an organic material, and after removal of the latter via 
heat treatment (calcination at 500-700°C in combination with sintering at 1250-1350°C), 
porous tablets were obtained. The type of pore forming agent, sinter time and sinter 
temperature were varied to investigate their influence on the quality of the porous matrix. 
After selecting an appropriate matrix, its potential as drug carrier was evaluated based on the 
drug loading capacity of porous HA tablets and on the release profiles of metoprolol tartrate 
(used as model drug) from these matrices.  
 
2.2 MATERIALS 
For tablets manufactured via direct compression followed by sintering, hydroxyapatite (HA, 
Ca/P-ratio:1.67) was obtained from Acros Organics (Geel, Belgium). Microcrystalline 
cellulose (Avicel PH 200, FMC Biopolymer, Cork, Ireland), corn starch (Amylum, Koog a/d 
Zaan, the Netherlands) and sorbitol (Sorbidex P 16616, Cerestar, Mechelen, Belgium) were 
used as pore forming agents. Magnesium stearate (Alpha Pharma, Zwevegem, Belgium) was 
added as lubricant. 
For tablets manufactured via modified gelcasting followed by sintering, hydroxyapatite was 
obtained from Bekaert (Zwevegem, Belgium). Tergitol TMN 10 (polyethyleneoxyethanol) 
(Sigma-Aldrich, Bornem, Belgium) was used as foaming agent. Targon 1128 (ammonium 
polycarbonate) (BK Giulini, Ladenburg, Germany) and Benecel® (hypromellose) (Hercules, 
Beringen-Paal, Belgium) were used as dispersing agent and viscosity enhancer, respectively, 
required to stabilize the HA suspension. Agar (Fagron, Waregem, Belgium) was used as 
gelling agent. 
Metoprolol tartrate (10 µm) (Esteve Quimica, Barcelona, Spain) was used as model drug. 
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2.2.1. Calcium Hydroxyapatite 
Calcium hydroxyapatite (Ca5(PO4)3OH) (HA) is an inorganic component of human hard 
tissues like bone and teeth.  
The manufacturing routes of synthetic HA can be divided into solid-state reactions and wet 
methods, whereby the wet methods are the most adequate routes. The wet methods include 
precipitation (in the presence of phosphoric acid, urea or formamide), hydrolysis and spray 
pyrolysis (Ishikawa, 2000; Vallet-Régi and Gonzalez-Calbet, 2004). 
In the industry, precipitation is mostly used for the preparation of HA particles since water is 
the only by-product of the reaction. In order to obtain stoichiometric HA (molair Ca/P ratio = 
1.67), a H3PO4 solution (concentration: 25-80%) is added to a Ca(OH)2 suspension 
(concentration: 2-10%) up to a Ca/P-ratio of 1.67 and a HA precipitate is formed according to 
the reaction: 
5 Ca(OH)2 + 3 H3PO4 Ca5(PO4)3OH + 9 H2O 
The resulting precipitation is left at room temperature for more than 1 day followed by 
filtration and drying. 
The thermostability of HA powder is influenced by the rate of addition of orthophosphoric 
acid, the ripening treatment, the reaction temperature and the Ca/P ratio. To obtain a 
thermostable HA powder, the precipitate must consist of stoichiometric HA. Therefore the 
rate of addition of orthophosphoric acid must be 11 ml/min, a Ca/P ratio of 1.67 is required, a 
ripening treatment of the HA precipitates is necessary and the precipitation must be 
performed at a temperature around 25°C (Osaka et al., 1991).  
The crystal structure of HA is illustrated in Fig. 2.1. There are two kinds of Ca2+ ions in a HA 
crystal: CaI along the c axis (identified by the arrows) and CaII surrounding the OH- ions. CaI 
is more easily dissolved in aqueous solutions than CaII hence Ca deficiency will occur at CaI 
sites. Since Ca2+, PO43- and OH- of HA can be replaced by other ions, the synthesis of 
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stoichiometric HA is rather hard and requires particular attention. The composition of Ca-
deficient HA is written as Ca10-x(HPO4)6-x(OH)2-x.nH2O. The charge imbalance is 
compensated by different processes, such as protonation of PO43- to HPO42- or H2PO4-, 
replacement of PO43- by CO32- and HCO3-, occupation of Ca2+ defects by other metal ions, etc. 
For this reason incorporation of various ions into the HA lattice leads to the formation of non-
stoichiometric HA particles. When heat treatment is performed on this form, decomposition 
products are formed eg. tricalcium phosphate and calciumcarbonate. 
 
 
Figure 2.1.: Crystal structure of HA – adapted from Ishikawa, 2000. 
 
Synthetic calcium hydroxyapatite can be used as tablet and capsule diluent and as described in 
Chapter 1, calcium hydroxyapatite is used in the manufacturing of bone implants due to its 
biocompatibility. Furthermore they are devoid of local or systemic toxicity, do not elicit an 
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inflammatory or foreign body response what indicates that calcium hydroxyapatite is a bio-
safe material (Jarcho, 1986). 
Calcium hydroxyapatite is practically insoluble in water and has a melting point around 
1670°C (Rowe et al., 2003). 
 
2.3. METHODS 
2.3.1.  Production of porous tablets  
¾ Direct compression followed by sintering 
Tablets (∅ 18 mm, flat edged, 550 mg) consisting of HA, a pore former and magnesium 
stearate (2%) were prepared via direct compression (14.5 kN) using an instrumented eccentric 
press (Korsch type EK0, Berlin, Germany). Microcrystalline cellulose, corn starch or sorbitol 
were added as pore formers. Prior to compression powder blends were prepared via physical 
mixing (using a tumbling mixer) of the materials as received from the suppliers or after a 
preprocessing step. During preprocessing, agglomerates of HA and pore formers were 
removed to ensure a homogeneous distribution of the pore former inside the tablet. Therefore, 
50 g HA was suspended in 150 ml acetone and this suspension was grinded in a ball mill 
(containing 25 grinding balls, ∅ 10 mm) (Pulverisette 6, Fritsch, Idar-Oberstein, Germany) 
during 15 min (grinding speed 500 rpm). Afterwards the pore forming agent was added to the 
suspension and grinded for 5 min at 250 rpm. After evaporation of the acetone fraction, 2% 
magnesium stearate was added to the HA/pore former-mixture.  
After compression the tablets were sintered in a chamber furnace (Thermoconcept, Bremen, 
Germany) at 800, 1000 and 1250°C (heating rate: 125 °C/h) during 1, 3 and 5 h. After cooling 
down (90 °C/h) to room temperature the properties of the porous tablet were evaluated.  
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¾ Modified gelcasting followed by sintering 
These tablets were manufactured in cooperation with the Flemisch Instititute for 
Technological Research (VITO, Mol, Belgium). 
Gelcasting, originally developed to manufacture dense ceramic components (Omatete et al., 
1991), can be modified for the production of highly porous ceramics as a result of aeration of 
the ceramic suspension containing gelling and foaming agents (modified gelcasting). 
Conventially, the gelling of foamed suspensions resulted from in-situ polymerization of 
water-soluble (mostly acryl-based) monomers (Sepulveda and Binner, 1999); however due to 
the toxicity of the monomers, alternative gelling agents have been introduced, eg. gelatine, 
pectines, carrageenan and agar (Millan et al., 2001; Luyten et al., 2003; Mouazer et al., 2004). 
 
 
Figure 2.2.: Flowchart of the modified gelcasting procedure. 
 
Hydroxyapatite (100 g), Tergitol TMN 10 (0.85 g) and Targon 1128 (1 g) were preheated to 
HA suspension + foaming agents + gelling agents 
foaming of the mixture 
moulding 
gelation 
demoulding 
drying 
calcination + sintering 
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80°C. Agar (2.14 g) was dissolved in water (85.6 g) at a temperature of 90°C, followed by 
cooling down to 70°C. Benecel® (0.17 g) was added to the agar-solution in order to increase 
the viscosity. The HA powder, Tergitol TMN 10 and Targon 1128 were blended with the 
solution and intensively mixed using a planetary Hobart N 50 mixer at 285 rpm (Hobart, 
Sydney, Australia) during 4 min or using a hand mixer (Philips electronics, Bruges, Belgium) 
during 3 and 10 min in order to form a foam. The foamed slurry was poured into a mould and 
was placed for 15 min at room temperature. Subsequently, the mould was placed in the 
refrigerator for 30 min to obtain a solid gel phase. After demoulding, the wet green 
component was dried during 3 days in a climate test chamber (Weiss Gallenkamp Indutrial, 
Leicestershire, UK) at 25°C and 70% relative humidity. The dry green mass was calcinated at 
500°C whereby all organic material was burned out, followed by sintering (heating rate: 240 
°C/h) at a temperature of 1350°C during 3 h. After cooling down (60 °C/h) the sintered block 
was cut into tablets (Ø 13 mm, height 3 mm). 
 
2.3.2. Tablet evaluation 
¾ Tablet strength  
Based on the diametrical crushing strength of the tablets determined using a tensile strength 
bench (Type L1000R, Lloyd Instruments, Fareham, United Kingdom) operating at a 
crosshead speed of 8 mm/min, the tensile strength of the tablets (n=10) was calculated 
according to Fell and Newton (Fell and Newton, 1970).  
 
¾ Tablet friability 
The tablet friability was determined in a Pharmatest-friabilator (PTFE, Hainburg, Germany) 
using the method described in the European Pharmacopoeia 5 (i.e. rotating 20 tablets inside a 
drum for 4 min at 25 rpm). 
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¾ Tablet porosity 
The tablet porosity was calculated based on the skeletal volume (Vs) and the apparent volume 
(Va) of the tablets (Eq. 1). The skeletal volume was measured using helium pycnometry 
(Accupyc 1330, Norcross, GA, USA), while the apparent volume was calculated from the 
height and radius of the tablet. 
  [(Va-Vs)/Va] x 100 = porosity (%)      (1) 
 
¾ Pore size distribution 
The pore size distribution (0.003-360µm) of the sintered tablets was determined using 
mercury intrusion porosimetry (Autopore III, Norcross, GA, USA). The sample size (2 - 3 g) 
was adjusted in order to use between 20 and 80% of the stem volume. The sample was 
evacuated to 50 mm Hg, followed by low pressure mercury intrusion in a pressure range from 
4.3 to 193 kPa, with a mercury filling pressure of 4.3 kPa, maximal intrusion volume of 0.03 
ml/g and equilibration time of 10 s. Next high pressure intrusion was performed in a pressure 
range from 207 to 41.104 kPa, with a maximal intrusion volume of 0.03 ml/g and equilibration 
time of 10 s. 
 
¾ Scanning electron microscopy (SEM) 
SEM was used to visualize the porous structure of the tablets. Tablets were coated with a gold 
layer using a sputter coater (Autofine Coater, JFC-1300, JEOL, Tokyo, Japan) to assure 
conductivity. The SEM micrographs were obtained using a scanning electron microscope 
(JSM-5510, JEOL, Tokyo, Japan). 
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¾ Internal pore structure 
For the determination of the 3-dimensional internal structure of the samples, the nano-
computed tomography (nano-CT) scanner of the UGCT facility (www.ugct.ugent.be) was 
used. This scanner combines a transmission x-ray tube (Feinfocus) with a focal spot size of 
900 nm and as X-ray detector, a 4008x2667 pixel CCD camera (Photonic Science). The 
commercially available reconstruction software “Octopus” was used for conversion of the raw 
images into the reconstructed cross-section. Data about the 3D structure were obtained using 
the 3D analysis software “µCTanalySIS (Cnudde et al., 2004) providing parameters such as 
total porosity, number of pores, volume of each pore together with its maximum inscribed and 
equivalent diameter. The maximum inscribed diameter is defined as the diameter of the 
largest sphere that can be enclosed in the volume and the equivalent diameter is the diameter 
of a spherical pore with the same volume as the (non-spherical) pore being examined. 
Combining the data of the maximum inscribed diameter (dmax) and the equivalent diameter 
(de) provides information about the structure of the pores.  
 
¾ X-ray diffraction 
To determine the thermostability of hydroxyapatite at high temperatures, the X-ray pattern of 
tablets sintered at 1250°C and 1350°C were compared with the X-ray pattern of pure 
unsintered hydroxyapatite powder. The X-ray patterns were obtained using a D5000 Cu Kα 
Diffractor (λ = 1,54 A) (Siemens, Karlsruhe, Germany) with a voltage of 40 mA in the 
angular range of 10°<2θ<60° using a step scan mode (step width = 0.02°, counting time = 1 
s/step) 
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2.3.3. Drug-loading of porous tablets and evaluation of drug-loaded tablets 
¾ Drug-loading 
Metoprolol tartrate was incorporated in the tablets as highly water soluble model drug. 
Therefore, 100 µl of an aqueous drug solution of metoprolol tartrate (1.5, 4, 15 and 40%, w/v) 
was spiked on one side of the tablet. After absorption of the liquid into the porous inner 
structure of the tablet, they were oven-dried for 8 h at 40°C. Afterwards, the same procedure 
was done at the other side of the tablet.  
 
¾ Surface tension of the drug solutions 
The surface tension of the drug solutions was determined via a dynamic ‘Wilhelmy Plate’ 
method whereby a strip of cellulose chromatography paper (Whatman Chr 1, smooth surface, 
0.18 mm tick with a linear flow rate for water of 130 mm/30min) is lowered into the solution. 
The plate was brought in the solution during 10 s for stabilization and then slowly pulled out 
of the solution. The surface tension of the solution is determined from the downward force 
directed on the strip.  
 
¾ Content uniformity of drug-loaded tablets  
The content uniformity of the drug-loaded tablets was determined by soaking a tablet (n=10) 
during 24 h in 50 ml water, followed by stirring during 15 min. The drug concentration was 
measured using UV spectrophotometry (λ= 222 nm). 
 
¾ Drug distribution 
Riboflavin sodium phosphate was incorporated in the tablets by spiking 100 µl of an aqueous 
riboflavin sodium phosphate solution (3.75 %, w/v) onto one side of the tablet, after drying 
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the same procedure was performed on the other side. Its yellowish colour allowed a visual 
determination of the drug distribution in the tablet. 
 
¾ Differential scanning calorimetry 
In order to determine the physical state of the drug after incorporation in the porous tablet, 
thermograms of the raw materials, a physical mixture and the drug-loaded tablet were 
recorded via differential scanning calorimetry (DSC, TA 2920, T.A. Instruments, New Castle, 
USA). The samples (8-12 mg in a hermetically sealed Al-pan) were heated from 0 to 200°C at 
a rate of 10 °C/min using a refrigerated cooling system (RCS, TA Instruments, New Castle, 
USA). 
 
¾ X-ray diffraction 
To confirm the results obtained via DSC, X-ray diffraction patterns of the raw materials, a 
physical mixture and the drug loaded tablet were determined using a D5000 Cu Kα Diffractor 
(λ = 1,54 A) (Siemens, Karlsruhe, Germany) with a voltage of 40 mA in the angular range of 
10°<2θ<60° using a step scan mode (step width = 0.02°, counting time = 1 s/step) 
 
¾ In vitro drug release 
Drug release from the porous tablets was determined using the USP II method (VanKel VK 
8000, VanKel Industries, New Jersey, USA) with a paddle speed of 50 rpm and at a 
temperature of 37±0.5°C. Demineralised water, phosphate buffer pH 6.8 and 0.1N 
hydrochloric acid were used as dissolution media. Sink conditions were maintained. Samples 
were collected at 5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 min and analysed using an 
UV/VIS double beam spectrophotometer (Perkin-Elmer, Zaventem, Belgium) at 222 nm for 
metoprolol tartrate. 
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¾ Modelling of the drug release 
Fick’s second law of diffusion, considering axial as well as radial mass transfer in a cyclinder 
was used to quantitatively describe the experimentally measured drug release profiles: 
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where c is the drug concentration, t represents time; r, z denote the radial and axial 
coordinates and θ the angle perpendicular to the r-z-plane; D represents the apparent diffusion 
coefficient of the drug within the porous tablet. 
Using infinite series of exponential functions this partial differential equation can be solved 
considering the respective initial and boundary conditions [homogeneous drug distribution 
before exposure to the release medium (t=0), high drug solubility and perfect sink conditions], 
as well as symmetries (e.g., there is no concentration gradient with respect to θ), leading to 
(Vergnaud, 1993): 
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where Mt and M∞, represent the absolute cumulative amounts of drug released at time t and 
infinite time, respectively; qn are the roots of the Bessel function of the first kind of zero order  
[J0(qn)=0], and R and H denote the radius and height of the cylinder. 
In case drug release leveled off below 100 %, the experimentally determined plateau value 
(amount of mobile drug) was considered as 100 % reference value for drug diffusion. 
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2.3.4. Stability study 
Porous tablets formulated with 50% w/w Avicel PH 200 as pore forming agent and 
manufactured by direct compression and sintering (using the protocol previously described) 
were selected for stability testing, according to the USP guidelines. The porous tablets were 
stored at 25°C/60 ± 5 % relative humidity (RH) and at 40°C/75 ± 5 % RH and after 0, 3, 6, 9 
and 12 months the drug release profile and water content of the tablets were determined. 
Dissolution tests (n=3) in demineralized water were performed under the conditions described 
in paragraph 2.3.3. The area under the curve (AUC0-3h) values of the dissolution profiles were 
statistically evaluated with a one-way ANOVA at a significance level of 0.05. The normality 
of the data was checked by means of a Kolmogorov-Smirnov test and the homogeneity of 
variances by means of the Levene test. SPSS 16.0 for Windows was used. 
The water content of the porous tablets was determined using a Mettler DL35 Karl Fisher 
titrator (Mettler-Toledo, Beerse, Belgium) in combination with a Mettler DO337 oven 
operated at 150°C (n=3). The samples were placed in a Pyrex vessel inside the oven. During  
10 min the moisture evaporated from the sample was carried to the titration vessel by a 
nitrogen stream (300 ml/min), after which the titration was started. Hydranal® Composite 5 
(Riedel-de Haën, Seelze, Germany) with a theoretical titer of 2 mg H2O/ml was used as titrant 
solution. 
 
2.4. RESULTS AND DISCUSSION 
2.4.1.  Manufacturing and characterization of porous tablets 
¾  Porous tablets manufactured via direct compression and sintering 
In order to obtain a solid structure when the organic pore former was removed during heat 
treatment, the amount of pore forming agent in the tablets was limited: 50% (w/w) for Avicel 
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PH 200 and corn starch and 37.5% for sorbitol. Using higher concentrations adhesion 
between the HA particles was not sufficient to obtain strong tablets. 
Physical mixing of HA and the pore former (using a tumbling mixer) resulted in a poor 
blending uniformity. Consequently the removal of agglomerates of pore former during heat 
treatment yielded a potholed surface texture of the tablets. To deagglomerate these lumps and 
to obtain a homogeneous distribution of the pore forming agent, a suspension of HA and the 
pore former in acetone was grinded in a ball mill. After evaporation of the organic solvent and 
production of porous tablets via direct compression and sintering, this procedure resulted in 
tablets with a smooth surface. 
Porosity of the sintered tablets depended on the amount of pore former and on the sinter 
temperature (Table 2.1.). Increasing the amount of pore forming agent resulted in a higher 
porosity as the pore forming agent was removed during the heat treatment. Increasing the 
sinter temperature decreased the porosity. The lowest porosity values were recorded for 
tablets processed at 1250°C.  
 
Table 2.1.: Porosity of porous calcium hydroxyapatite tablets containing different ratios of pore 
forming agent (Avicel PH 200, corn starch or sorbitol), sintered at 800, 1000 and 
1250°C during 3h. 
Pore former  % (w/w) Sinter temperature (°C) 
 800 1000 1250 
Avicel PH 200  50 79.3 ± 0.5 73.7 ± 0.4 52.5 ± 0.6 
corn starch  20 64.5 ± 0.3 60.1 ± 0.9 26.0 ± 2.2 
corn starch  37.5 74.6 ±0.9 70.5 ± 0.6 43.0 ± 1.1 
corn starch  50 79.2 ± 0.2 76.5 ± 1.0 48.6 ± 0.9 
sorbitol  37.5 71.6 ± 0.3 65.2 ± 0.7 52.7 ± 0.9 
 
During the initial phase of heat treatment (<1000°C) the HA particles only coalesced (without 
densification), whereas at sinter temperatures above 1000°C densification of the material 
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occurred (Raynaud et al., 2002; Bernache-Assollant et al., 2003). This densification correlated 
with the shrinking of the tablets: after 3h sintering at 1250°C the tablet diameter and height 
had decreased by 24.6 and 28.0%, respectively. 
For tablets sintered at 1250°C, the type of pore forming agent and a variable sinter time 
(range: 1 to 5 h) had no effect on tablet porosity. 
The SEM micrographs of the tablet surface and the 3-dimensional images of the internal 
structure of the porous tablet (via nano CT-scan) are shown in Fig. 2.3. The analysis of the 
CT-scan images is given in Table 2.2. Within the fraction of the tablet evaluated via nano CT-
scan one pore system was detected for all tablets. For each formulation the equivalent 
diameter was larger compared to the maximum inscribed diameter, indicating that the internal 
pore structure is branched. The larger pore size detected for tablets formulated with 50% 
Avicel PH 200 is correlated with the larger size of the microcrystalline cellulose fibres (200 
µm versus 25 µm and 165 µm for corn starch and sorbitol, respectively). The pore system 
detected in tablets formulated with 50% Avicel PH 200 or corn starch represented more than 
90% of the total porosity, indicating that an interconnecting pore network was formed. In 
contrast, the pore system in tablets using sorbitol as pore forming agent accounted for only 
63.9% of the total porosity. As no other pore classes were detected which contributed to more 
than 2% of the total pore volume, the rest of the porosity is attributed to individual pores.  
 
Table 2.2.:  Nano CT-scan analysis of the 3-dimensional internal structure of the porous tablets. 
Pore forming 
agent  
% 
(w/w) 
maximum inscribed 
diameter (µm) 
equivalent diameter 
(µm) 
porosity represented by 
pore system (%) 
Avicel PH 200  50 102 322 93 
corn starch  50 27 188 98 
sorbitol  37.5 36 300 64 
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Figure 2.3.: SEM micrographs of the porous surface and 3-dimensional images of the internal 
structure of sintered tablets (3h, 1250°C) whereby (a) 50% (w/w) Avicel PH 200, 
(b) 50% (w/w) corn starch or (c) 37.5% (w/w) sorbitol was used as pore forming 
agent. 
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In contrast to the pore size detected via nano CT-scan the pore size distribution determined 
via mercury porosimetry was much smaller, the majority of the pores being smaller than 10 
µm (Fig. 2.4.).  
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Figure 2.4.: Pore size distribution, obtained by mercury intrusion, of porous tablets with an initial 
diameter of 13.5mm after sintering during 3h at 1250°C whereby 50% (w/w) Avicel 
PH 200 (▲), 50% (w/w) corn starch (▲) or 37.5% (w/w) sorbitol (▲) was used as 
pore forming agent. 
 
However, comparison between both techniques is difficult since their approach is different. 
Nano CT-scan analysis provides only the maximum inscribed diameter which represents the 
largest pore volume, whereas the entire pore size distribution is detected via mercury 
porosimetry. In addition, mercury porosimetry could underestimate the actual pore size due to 
the ink bottle effect.  
Despite the porous structure of the tablets, their mechanical strength after sintering was high 
(tensile strength ranging between 3.9 and 7.1 MPa). However, only sintering at 1250°C 
resulted in tablets having a low friability.  
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Table 2.3.: Friability of porous calcium hydroxyapatite tablets formulated with different ratios of 
pore forming agent (Avicel PH 200, corn starch or sorbitol), sintered at 800, 1000 and 
1250°C during 3h. 
Pore former  % (w/w) Sinter temperature (°C) 
 800 1000 1250 
Avicel PH 200  50 5.5 3.9 1.2 
corn starch  20 -* 0.7 0.2 
corn starch  37.5 3.8 3.2 0.7 
corn starch  50 -* -* 0.5 
sorbitol  37.5 1.1 0.7 0.4 
* tablets fragmented during friability testing 
 
 
Figure 2.5.: X-ray diffraction pattern of pure calcium hydroxyapatite powder before sintering 
() and crushed porous tablets obtained by direct compression followed by 
sintering at 1250°C ( ). 
 
Stoichiometric (Ca/P-ratio: 1.67) hydroxyapatite (used as the main component in the tablets) 
is thermostable at high temperatures (Muralithran and Ramesh, 2000; Raynaud et al., 2002).  
The X-ray pattern of HA after sintering at 1250°C (Fig. 2.5.) showed only diffraction peaks 
corresponding to HA, indicating that no decomposition products and additional phases like α- 
and β-TCP, tetracalciumphosphate and CaO were formed during sintering and that no fraction 
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of the pore forming agent remained after sintering. The diffraction peaks of the sintered 
material were sharper and higher, indicating a higher crystallinity and the presence of larger 
crystals, respectively.  
 
¾ Porous tablets manufactured via modified gelcasting and sintering 
Porous carriers having larger pores were manufactured using a modified gelcasting technique 
resulting in tablets with a median pore size of 20, 80 and 100 µm (determined via mercury 
porosimetry) (Fig. 2.6.). Mixing during 3 min and 10 min with a hand mixer and 4 min with 
the planetary mixer resulted in a median pore size of 100, 20 and 80 µm, respectively. Mixing 
during 10 min resulted in a smaller pore size, due to the breaking up of larger air bubbles 
when a longer mixing time was applied. 
 
0
20
40
60
80
100
0.001 0.01 0.1 1 10 100 1000
pore diameter (µm)
cu
m
ul
at
iv
e 
in
tru
si
on
 (%
)
 
Figure 2.6.: Pore size distribution, obtained by mercury intrusion, of porous tablets manufactured 
via modified gelcasting. Median pore diameter: 20 µm (▲), 80 µm (▲) and 100 µm 
(▲).  
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Similar X-ray diffractograms were obtained as for the tablets prepared by direct compression. 
Hence the higher sinter temperature used to manufacture these porous matrices (1350°C) had 
no effect on the composition of the hydroxyapatite.  
A porosity of 55.6 ± 0.4%, 68.8 ± 0.4% and 75.6 ± 0.5% was obtained for porous tablets with 
a median pore diameter of 20, 80 and 100 µm, respectively. Nano CT-scan for visualisation of 
the porous structure (Fig. 2.7.) detected two pore systems with a branched structure 
(equivalent diameter > maximum inscribed diameter) (Table 2.4.). These pore systems 
represented 92.5% of the total porosity volume, indicating that nearly all pores are 
incorporated in an interconnected network.  
 
Table 2.4.: Nano CT-scan analysis of the 3-dimensional internal structure of a porous tablet 
(median pore diameter: 80 µm) obtained by modified gelcasting. 
maximum inscribed diameter 
(µm) 
equivalent diameter  
(µm) 
porosity represented by pore 
system (%) 
156 306 23 
178 359 70 
 
 
     
Figure 2.7.: 3-dimensional images of the internal structure and SEM micrograph of the porous 
surface of a tablet (median pore diameter: 80 µm) manufactured by a modified 
gelcasting technique.  
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Also for the porous tablets obtained by modified gelcasting, a high mechanical strength (6.8 ± 
0.2, 5.2 ± 0.1 and 4.2 ± 0.3 MPa) in combination with a low friability (1.1 %, 1.0 % and 1.2% 
for tablets with a median pore diameter of 20, 80, and 100 µm, respectively) was obtained.  
 
2.4.2. Porous tablets as drug carriers 
¾ Drug loading  
For the tablets obtained by direct compression followed by sintering, the formulations with 
the highest concentration of each pore forming agent (50% Avicel PH 200, 50% corn starch, 
37.5% sorbitol) were selected as drug carriers as these tablets sintered at 1250°C combined a 
high porosity with a low friability.  
For the tablets obtained by modified gelcasting followed by sintering each formulation   
(median pore diameter: 20, 80 or 100 µm) was evaluated as drug carrier. 
Carriers formulated with Avicel PH 200 and corn starch were able to completely absorb a 
volume of 100 µl spiked on the surface of the tablet as the interconnected pore network 
allowed the drug solution to penetrate and distribute in the tablet. In contrast, the carrier 
formulated with sorbitol failed to completely absorb 100 µl drug solution. The results of the 
nano CT-scan showed that not all the pores were part of the pore network what decreased 
their ability to absorb the drug solution. The fastest absorption was observed for the carrier 
formulated with Avicel PH 200 as these tablets had the largest pores.  
After spiking 100 µl of drug solution on the surface of the porous tablets obtained via 
gelcasting and sintering, the solution was immediately and completely absorbed by all type of 
tablets, no difference between the tablets was observed. The interconnected pore network in 
combination with large and spherical shaped pores allowed the drug solution to penetrate and 
distribute fast and easily in the tablets. 
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For all formulations, manufactured by direct compression and sintering, spiking the tablets 
with 150 µl drug solution to increase the drug load was unsuccessful since the porous matrix 
became saturated and liquid leaked through the tablet. This effectively limits the application 
of these carriers to the formulation of low-dosed dosage forms. Although it was possible to 
increase the drug load by spiking both sides of the tablet (with an intermediate drying step), 
the drug load in this application was limited to 30 mg metoprolol tartrate. Repetitive drug 
loading (up to 11 times, with intermediate drying steps) of tablets obtained by modified 
gelcasting and sintering was performed, hence higher drug loads were obtained (up to 165 mg 
metoprolol tartrate/tablet), but such a time-consuming procedure would obviously have 
limited application. 
 
The content uniformity test was only performed on tablets manufactured via direct 
compression and sintering, using 50% (w/w) Avicel PH 200 as pore former. The result 
showed an average drug concentration of 100.7% (RSD 2.7%) of the theoretical concentration 
for metoprolol tartrate loaded tablets.  
 
In addition to the volume spiked on the porous carriers the drug load will also be determined 
by the concentration of the drug solution. Therefore, porous tablets formulated with 50% 
(w/w) Avicel PH 200 and processed via direct compression and sintering were spiked with 
differently concentrated metoprolol tartrate solutions (1.5, 4, 15 and 40%). When tablets were 
spiked with 100 µl of a 1.5% and 4% solution (applied on each side of the tablet), immediate 
and complete absorption was observed, whereas for the 15% and 40% solution the drug 
uptake was complete but slower.  
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Table 2.5.: Surface tension values (n=10) of metoprolol tartrate solutions with different 
concentration. 
(%, w/w) Surface tension 
(mN/m) 
1.5 59.21 ± 0.45 
4 60.45 ± 0.58 
15 45.58 ± 0.16 
40 44.55 ± 0.12 
 
The surface energy of all MPT solutions was lower compared to pure water (71.36 ± 0.14 
mN/m), the highest drug concentration having the lowest surface tension indicating that the 
drug molecules have some tensio-active properties. Based on this observation an improved 
liquid penetration into the tablets would be expected at higher drug concentration. However, 
besides the surface tension (air-liquid) the uptake of the solution is also determined by the 
phase tension between the solid phase (tablet surface) and the liquid phase (drug solution). 
Due to the hydrophilic tablet surface (hydroxyl groups in hydroxyapatite) there will be 
competition between the tablet surface and the aqueous phase (water) to interact with the 
hydrophilic part of the drug molecules; a factor which increases the phase tension between 
liquid and solid phase. Since this competition will increase at higher drug concentrations in 
the solution, the increasing phase tension in function of drug concentration accounts for the 
slower absorption of these drug solutions (Barnes and Gentle, 2005). 
Based on the yellow colour of riboflavin sodium phosphate it was visually observed that the 
drug was homogeneously distributed throughout the entire tablet.  
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Figure 2.8.: DSC thermograms of a crushed unloaded porous tablet (A), metoprolol tartrate (B), a 
physical mixture of crushed porous tablet containing metoprolol tartrate (C) and of a 
crushed porous tablet containing metoprolol tartrate. 
 
 
Figure 2.9.: X-ray diffraction patterns of a porous tablet loaded with metoprolol tartrate (), 
metoprolol tartrate (), a physical mixture of a crushed porous tablet containing 
metoprolol tartrate () and without metoprolol tartrate (). 
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DSC thermograms (Fig. 2.8.) showed that the crystalline structure of metoprolol tartrate did 
not change after incorporation in the tablet. The melting peak of metoprolol tartrate in the 
loaded tablet (around 124°C) was identical to the melting peak of metoprolol tartrate in the 
physical mixture. These data were confirmed via X-ray diffraction (Fig. 2.9.).  
 
¾ In-vitro drug release 
Due to the fast and complete absorption of the aqueous drug solution in porous tablets 
formulated with 50% (w/w) Avicel PH 200 as pore forming agent and in tablets obtained by 
modified gelcating, these tablets were evaluated as drug carriers during dissolution 
experiments.  
Fig. 2.10. shows the dissolution profiles of metoprolol tartrate in water, phosphate buffer pH 
6.8 and 0.1N HCl.  
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Figure 2.10.: Drug release from sintered (1250°C, 3h, using 50% (w/w) Avicel PH 200 as pore 
forming agent) porous tablets containing 30 mg metoprolol tartrate in 0.1N HCl (▲), 
water (▲) and phosphate buffer pH 6.8 (▲)  
 
Based on the highly porous nature of these tablets an immediate drug release was anticipated. 
However, the burst release from these tablets was very limited in all media. Metoprolol 
tartrate release in 0.1N HCl was the fastest (79% within 60 min) as the HA tablets partly 
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dissolved in acid medium. In contrast, HA tablets remained intact in water and phosphate 
buffer pH 6.8, reducing drug release after 60 min to 46% and 52%, respectively.  
The slower drug release from the tablets was strictly related to the porous structure of the 
matrices (the release rate depending on pore size, shape and connectivity) since drug 
dissolution of crushed samples was immediate (showing that there was no interaction between 
HA and drug).  
The drug release from porous tablets obtained by modified gelcasting followed by sintering is 
shown in Fig. 2.11. The drug release was faster from tablets having a larger pore size, 
whereas an immediate drug release was obtained from porous tablets with a median pore 
diameter of 100 µm.  
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Figure 2.11.: Drug release in demineralised water from porous tablets obtained by direct 
compression (median pore size of 5µm (▲)) and by a modified gelcasting technique 
(median pore size of 20 (▲), 80 (▲) and 100 µm (▲)), containing 30 mg metorpolol 
tartrate. 
 
The enhanced release rate from these gelcasted tablets was due to the larger pore size (which 
promoted water penetration and drug diffusion) and to the regular shape of the pore channels 
(which decreased the tortuosity of the matrix). The fact that the drug release was strongly 
influenced by these parameters was explained via drug modelling. 
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Fitting an appropriate analytical solution of Fick’s second law of diffusion (considering axial 
as well as radial mass transport in cylinders, Equation 3) to the experimentally measured 
metoprolol tartrate release profiles obtained in water from tablets processed via direct 
compression (using 50% (w/w) Avicel PH 200 as pore forming agent, median pore diameter: 
5 µm) and modified gelcasting (median pore diameter: 20 and 80 µm) resulted in good 
agreement between theory and experiment (Fig. 2.12.).  
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Figure 2.12.: Drug release in demineralised water from sintered porous tablets containing 30mg 
metoprolol tartrate. Tablets processed via direct compression and formulated with 
50% Avicel PH as pore forming agent (▲). Tablets processed via gelcasting and 
having a pore size of 20 (▲) and 80 µm (▲). Predicted (curves, Equation 2) and 
experimental (symbols) dissolution profiles.  
 
The apparent diffusion coefficients of metoprolol tartrate within the porous tablets increased 
with increasing pore size : 6.2x10-7, 1.2x10-6 and 5.5x 10-6 cm²/s for porous tablets with a 
median pore size of 5, 20 and 80 µm, respectively.  
Fig. 2.13. shows the effect of the initial drug content (3, 8, 30 and 80 mg) on the release of 
metoprolol tartrate from porous tablets prepared with 50% (w/w) Avicel PH 200. Clearly, the 
release rate decreased with increasing drug loading.  
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Figure 2.13.: Effects of initial drug content (3 mg (▲), 8 mg (▲), 30 mg (▲) and 80 mg (▲)) on 
release of metoprolol tartrate from sintered porous tablets (1250°C, 3h, pore forming 
agent: Avicel PH 200, 50% (w/w)) in water: Predicted (curves, Equation 2) and 
experimental (symbols) dissolution profiles. 
 
Interestingly, the presented analytical solution of Fick’s second law of diffusion (Equation 3) 
can be used to quantitatively describe the experimentally measured drug release kinetics in all 
case (curves and symbols in Fig. 2.13.). Based on these calculations, the following apparent 
diffusion coefficients of metoprolol tartrate in the porous tablets exposed to water could be 
determined: 3.5x10-6, 1.2x10-6, 5.4x10-7 and 6.2x10-7 cm²/s for tablets containing, 3, 8, 30 and 
80 mg, respectively. The decrease in drug mobility with increasing drug content might be due 
to a concentration-dependent metoprolol tartrate diffusion coefficient in water-filled pores of 
the tablets and/or to limited solubility effects (Ginebra et al., 2006b).  
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2.4.3. Stability study 
 (a) 25 °C/60 % RH 
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(b) 40 °C/75 % RH 
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Figure 2.14.: Mean drug release profiles (± S.D.) of porous tablets obtained by direct compression 
followed by sintering, containing 30 mg metoprolol tartrate, stored during 0 (-), 3 (■), 
6 (▲), 9 (x) and 12 (♦) months at (a) 25 °C/60 ± 5 % RH and at (b) 40 °C/ 75 ± 5 % 
RH 
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Figure 2.14. shows that the porous tablets were stable for at least 12 months during storage at 
25 °C/60 % RH and at 40 °C/75 % RH. Statistical comparison of the AUC0-3h-values 
indicated no significant difference between the dissolution curves obtained before and after 
storage at the different conditions. 
The water uptake during storage (Table 2.5.) was limited. 
 
Table 2.5: Water content (n=3) of porous tablets stored under controlled conditions. A: 25 °C/ 
60% RH and B: 40 °C/ 75% RH 
Time (months) Moisture content (%) 
 A B 
0 0.25 ± 0.01 0.25 ± 0.01 
3 0.43 ± 0.18 0.55 ± 0.11 
6 0.72 ± 0.15 1.05 ± 0.13 
9 1.13 ± 0.05 1.31 ± 0.12 
12 1.16 ± 0.12 1.81 ± 0.23 
 
2.5. CONCLUSION 
Direct compression or modified gelcasting in combination with sintering allowed to 
manufacture porous tablets, which can be used as an alternative carrier for low-dosed drugs. 
The drug was incorporated into the pore network via spiking of the drug solution on the 
tablet, whereby the drug uptake depended on the pore volume, the presence of interconnecting 
pores and the drug concentration. As the drug dose per tablet only depended on the volume 
spiked on each tablet and small volumes of liquid can be dosed with high accuracy, the risk of 
drug inhomogeneity is minimal. Hence these tablets are an innovative carrier for low dosed 
drugs. Furthermore, as the drug is incorporated in the porous tablets after compression, this 
manufacturing technique is also very promising for processing drugs with poor tabletting 
characteristics. 
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The drug release from the porous carrier was primarily diffusion controlled, the apparent drug 
diffusivity depended on the pore size and tortuosity of the porous network. 
Furthermore, drug release from these porous tablets was stable for at least 12 months. 
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In vitro and in vivo evaluation of porous 
3
tablets 
        
3.1. INTRODUCTION 
Chapter 2 demonstrated the development of porous tablets consisting of hydroxyapatite. 
These tablets are promising drug carriers for low-dosed drugs as they ensure a good content 
uniformity and furthermore as the drug is spiked onto the tablet surface, drug with poor 
compaction properties can easily be incorporated in tablet-shaped carriers. 
The drug release from the porous tablets in aqueous medium was purely diffusion-controlled, 
whereby the apparent drug diffusivity depended on the pore size and the tortuosity of the 
porous network. 
As the specific conditions along the gastrointestinal (GI) tract (pH conditions, GI transit time, 
hydrodynamic flow, mechanical destructive forces) can affect the drug release, an in vivo 
study in dogs was performed to determine the bioavailability of metoprolol tartrate after oral 
administration of tablets having a different internal pore structure. In addition, the influence 
of hydrodynamic flow and stress and the effect of physiological relevant dissolution media on 
the in vitro drug release of the porous tablets were evaluated in order to explain the obtained 
in vivo results. 
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3.2. MATERIALS 
For tablets manufactured via direct compression and sintering, hydroxyapatite was obtained 
from Acros Organics (Geel, Belgium), Avicel PH 200 from FMC Biopolymer (Cork, Ireland) 
and magnesium stearate from Alpha Pharma (Zwevegem, Belgium).  
For tablets manufactured via modified gelcasting and sintering, hydroxyapatite was supplied 
by Bekaert (Zwevegem, Belgium), Tergitol TMN 10 by Sigma Aldrich (Bornem, Belgium), 
Targon 1128 by BK Giulini (Ladenburg, Germany), Benecel by Hercules (Beringen-Paal, 
Belgium) and agar by Fagron (Waregem, Belgium).  
Metoprolol tartrate (10 µm) was supplied by Esteve Quimica (Barcelona, Spain). 
Pancreatin, bile salts and sodium taurocholate were purchased from Sigma-Aldrich (St-Louis, 
USA). Egg-phosphatidylcholine (Lipoid E PC) was a gift from Lipoid (Ludwigshafen, 
Germany). Potassium dihydrogen phosphate, potassium chloride, sodium hydroxide and 
sodium chloride were obtained from Merck (Darmstadt, Germany). 
Hydrochloric acid (37%) was supplied by VWR (Leuven, Belgium). Sodium lauryl sulphate 
(SLS) was received from Fagron (Uitgeest, The Netherlands). 
Lopresor® was obtained from Novartis (Brussels, Belgium). Each tablet contained 100 mg 
metoprolol tartrate. 
 
3.2.1. Metoprolol tartrate 
Metoprolol tartrate (aqueous solubility: > 1 mg/ml) is a Class 1 drug according to the 
Biopharmaceutics Classification System and is a β1-selective adrenoreceptor antagonist used 
in the treatment of hypertension and coronary diseases such as angina pectoris. When 
metoprolol is administered orally it is almost completely absorbed form the gastro-intestinal 
tract. The absorption from the stomach is minimal, hence metoprolol is primarily absorbed 
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throughout the small intestine and colon (Godbillon et al., 1985; Jobin et al., 1985; Vidon et 
al., 1985). 
 
Figure 3.1.: Structure of metoprolol tartrate 
 
3.3. METHODS 
3.3.1. Production of the porous tablets 
Porous tablets, manufactured via direct compression and sintering, were formulated with 
Avicel PH 200 as pore forming agent (50%, w/w). The tablets were prepared according to the 
method described in Chapter 2 (section 2.3.1.). 
Porous tablets with a median pore diameter of 100 µm were obtained by modified gelcasting 
followed by sintering as described in Chapter 2 (section 2.3.1.). 
Tablets were spiked (as described in Chapter 2, section 2.3.3.) with 2 x 100 µl of a 15 or 20% 
(w/v) metoprolol tartrate solution, resulting in a drug content per tablet of 30 and 40 mg, 
respectively.  
 
3.3.2. In vivo study 
All procedures were performed in accordance with the guidelines of and after approval by the 
Ethics Committee of the Institute for Agricultural and Fisheries Research (ILVO) (Merelbeke, 
Belgium). Male mixed-breed dogs (n=6) (weight 20.5-40.5 kg) were used in this study. A 100 
mg MPT dose was administered using the following formulations: 
_________________________________________________________________________ 
In vitro and in vivo evaluation of porous tablets 
73
- F-1: 3 porous tablets (median pore diameter: 5 µm) manufactured via direct compression 
and sintering (equivalent to 100 mg metoprolol tartrate: 2 tablets containing 30 mg 
metoprolol tartrate per tablet and 1 tablet containing 40 mg metoprolol tartrate per 
tablet). 
- F-2: 3 porous tablets (median pore diameter: 100 µm) manufactured via modified gel 
casting and sintering (equivalent to 100 mg metoprolol tartrate: 2 tablets containing 
30 mg metoprolol tartrate per tablet and 1 tablet containing 40 mg metoprolol 
tartrate per tablet). 
- F-3: Lopresor®, a commercially available immediate release formulation, one tablet 
containing 100 mg metoprolol tartrate . 
 
The formulations were administered in a cross-over sequence with a wash out of at least 5 
days. On the experimental days the dogs were fasted since the previous day at 7 pm, although 
water was available ad libitum. Before administration of the formulations, an intravenous 
cannula was placed in the lateral saphenous vein and a blank blood sample was obtained. 
Each formulation was orally administered with 20 ml water. Blood samples were obtained at 
0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24h. The blood samples were collected in dry heparinized 
tubes and centrifuged for 5 min at 1500g within 1 h of sampling. The plasma was stored at -
20°C until assay of metoprolol tartrate. No food was administered to the dogs during blood 
sampling. Water could be taken freely. 
 
3.3.3. Metoprolol tartrate assay 
The metoprolol tartarte plasma concentrations were determined by a validated HPLC-
fluorescence method (Fang et al., 2004). All chemicals were of analytical or HPLC grade. 
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Twenty microlitres of an internal standard solution (3.33 µg/ml alprenolol in distilled water), 
680 µl phosphate buffered saline (PBS) and 300 µl plasma were transferred into a borosilicate 
glass tube and mixed. The drug was extracted using a solid phase extraction (SPE) method. 
The SPE columns were conditioned consecutively with methanol (1 ml), water (1 ml) and 
phosphate buffer saline (1 ml). Next, the plasma samples were transferred to the SPE 
columns. The columns were rinsed with water (1 ml) and metoprolol tartrate was eluted with 
methanol (1 ml). The eluates were evaporated to dryness under a nitrogen flow, the residue 
was reconstituted in 150 µl water and injected onto the column. The metoprolol tartrate 
concentrations were determined via a calibration curve. For the standard curve, spiked 
samples were prepared by mixing 280 µl plasma with 20 µl of a standard solution containing 
a known concentration of metoprolol tartrate in distilled water. Afterwards 20 µl internal 
standard solution and 680 µl PBS were added to the spiked plasma samples. These mixtures 
were extracted as described above. 
The HPLC equipment (Merck, Darmstadt, Germany) consisted of a solvent pump (L-7110 
pump) set at a constant flow rate of 0.8 ml/min, a variable wavelength fluorescence detector 
(L-7480) set at 275 nm as excitation wavelength and 300 nm as emission wavelength, a 
LiChrospher® 100 CN 5 µm column (250 mm x 4 mm) and precolumn (4 mm x 4 mm) an 
autosampler (Gilson 234 autoinjector, Middleton, Wisconsin, USA) with a 50 µl loop (Valco 
Instruments, Houston, Texas, USA) and an automatic integration system (L-7000). The SPE 
equipment consisted of OASIS HLB (1 ml, 30mg) cartridges (Waters, Zellik, Belgium) and a 
16-port vacuum manifold (Alltech Europe, Laarne, Belgium). The mobile phase consisted of 
an acetonitrile/sodium dihydrogen orthophosphate buffer (2M)/water-mixture (5/0.5/94.5 
v/v), adjusted to pH 3.0 with phosphoric acid. The injection volume was 20 µl. 
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3.3.4. Validation of the HPLC method 
The HPLC analysis method was validated based on the guidelines of the International 
Conference on Harmonisation (ICH) for validation of analytical procedures: Text and 
Methodology (2005). The following characteristics were considered: specificity, linearity, 
accuracy, precision, recovery, detection and quantification limit. 
 
Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of interfering 
components (Chan, 2004). It was assessed by comparing the chromatogram of blank plasma, 
a chromatogram obtained after extraction of blank plasma spiked with metoprolol tartrate and 
alprenolol (internal standard) and a chromatogram analyzed after administration of an 
metoprolol tartrate tablet (Fig. 3.1). Since no interfering peaks were observed, it is clear that 
the method is selective to determine metoprolol tartrate in plasma. 
 
a 
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b 
 
 
 
c 
 
 
Figure 3.1.: Specificity of the HPLC method. Chromatogram after extraction of (a) blank plasma, 
(b) blank plasma spiked with metoprolol tartrate (retention time: 18.45 min) and 
alprenolol hydrochloride (retention time: 50.10 min), (c) dog plasma after intake of a 
metoprolol tartrate tablet (Lopresor®). 
 
Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between the 
true value and the determined value (Chan, 2004) and is expressed as the percent agreement 
between the mean determined value and the true concentration. 
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The accuracy was evaluated at three concentration levels on plasma spiked with known 
amounts of analyte. The accuracy was determined within the same day as well as between 
different days. The mean accuracies (± S.D.) are listed in Table 3.1. 
 
 Table 3.1.: Mean accuracies (± S.D.) of the HPLC method (n=6). 
Concentration (ng/ml) Accuracy (%) 
 Within-day Between-day 
37.5 108.1 ± 9.6 110.0 ± 9.2 
150 89.8 ± 9.1 91.8 ± 10.3 
1500 112.2 ± 6.2 99.4 ± 11.1 
 
Since all mean values were within ± 15% of the actual concentration, this analytical method 
meets the acceptance criteria for accuracy (Shah et al., 1992). 
 
Precision 
The precision expresses the closeness of agreement between repeated determinations and can 
be determined at three levels: repeatability (intra-assay precision, which is the precision under 
the same operating conditions over a short time interval), intermediate precision (within 
laboratory precision, which expresses within-laboratory variations like different days, 
analysts, equipment, etc.) and reproducibility (between laboratory precision, which is the 
precision between laboratories). Since the measurements were performed in the same 
laboratory, by the same person using the same equipment only the repeatability (within-day 
and between-day) of the measurements was evaluated. 
Precision is expressed as the coefficient of variation (%) of a series of measurements of the 
calibration standards (Lee, 2004) (Table 3.2.). As recommended by Shah et al. (1992), the 
acceptance criteria are coefficients of variation (CV) less than 15%, except for the lowest 
concentration, where it should not exceed 20% CV. 
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 Table 3.2.: Precision (expressed as coefficient of variation) of the HPLC method (n=6) 
Concentration (ng/ml) Precision (%CV) 
  Within-day Between-day 
37.5 13.3 10.8 
75 - 3.5  
150 8.5 9.8 
300 - 6.7 
750 - 5.1 
1500 8.5 11.1 
 
Recovery 
The amount of analyte in biological samples can be reduced during sample treatment like 
extraction with organic solvents, etc. The recovery was determined for the calibration 
standards (at three concentration levels) and the internal standard, and was expressed as the 
closeness of agreement (in %) between the surface areas of an extracted sample versus a non-
extracted sample. The mean recoveries (± S.D.) for the calibration standards and the internal 
standard are listed in Table 3.3. 
 
Table 3.3.: Mean recoveries (n=6) (± S.D.) for the calibration standards and the internal standard. 
 Concentration (ng/ml) Recovery (%) 
metoprolol tartrate 37.5 61.8 ± 16.1 
 150 65.0 ± 7.1 
 1500 81.2 ± 9.2 
   
alprenolol  444 63.3 ± 12.1 
 
Linearity 
The linearity of an analytical procedure is its ability - within a given range - to obtain test 
results which are directly proportional to the analyte concentration in the sample (Chan, 
2004). 
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During validation of the HPLC method and analysis of the samples, several calibration curves 
were analysed. The linearity of the calibration curves was evaluated by the determination 
coefficient R2, its value (n = 7) was 0.9994, indicating that the relationship between response 
(y) and concentration (x) was linear within the tested concentration range (37.5–1500 ng/ml). 
The equation of the mean calibration curve was: 
 y = 4.2598x + 0.1128 
 
Detection and quantification limit 
The detection limit of an analytical procedure is the lowest amount of analyte in a sample 
which can be detected but not necessarily quantified as an exact value. The quantification 
limit is the lowest amount of analyte in a sample which can be adequately determined with 
suitable precision and accuracy. Both values were estimated from the mean calibration curve 
(International Conference on Harmonisation, 2005): 
 
DL = 3.3 x σ / S 
QL = 10 x σ / S 
with DL = detection limit 
 QL = quantification limit 
 σ = standard deviation of the Y-intercept of the mean calibration curve 
 S = slope of the mean calibration curve 
 
The detection and quantification limits of metoprolol tartrate in dog plasma were determined 
at 40 and 140 ng/ml, respectively. 
Since the calculated limit of quantification was higher than the lowest concentration of the 
calibration curve and the accuracy and precision at the lowest metoprolol tartrate 
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concentration (37.5 ng/ml) were within the accepted limits (Shah et al., 1992), a concentration 
of  37.5 ng/ml was considered as limit of quantification. 
 
3.3.5. Data and statistical analysis 
The extent of drug absorption (AUC0-24h), the peak plasma concentration (Cmax) and the time 
to reach Cmax (tmax) was calculated using the MW-PHARM program version 3.0 (Mediware 
1987-1991, Utrecht, The Netherlands). The AUC0-24h was calculated using logarithm and 
linear trapezoidal rules. The relative bioavailabilty of the porous tablet formulations (Frel, %) 
was calculated as the ratio of AUC0-24h between a porous tablet formulation and Lopresor®. 
The effect of metoprolol tartrate formulation on the bioavailibility was assessed by repeated-
measurements ANOVA (univariate analysis). To further compare the effects of the different 
formulations, a multiple comparison among pairs of means was performed using Bonferroni 
post-hoc test with P < 0.05 as significance level. The sphericity of covariances was tested 
with Mauchly’s test. SPSS 16 software (SPSS, Chicago, USA) was used to perform the 
statistical analysis.  
  
3.3.6. In vitro evaluation  
In order to explain the in vivo results after administration of the porous tablets, in vitro 
dissolution testing was performed using conditions that simulate the gastro-intestinal 
conditions. All dissolution tests (n=6) were performed in a VK 7000 dissolution bath with a 
VK 8010 autosampler (VanKel Industries, NJ, USA). The system operated at 37±0.5°C using 
the paddle method (USP 27). Sink conditions were maintained. Samples (5ml) were taken at 
5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 min. The drug concentration in the samples was 
measured at 222 nm with an UV/VIS double beam spectrophotometer (Perkin-Elmer, 
Zaventem, Belgium).  
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In order to examine the influence of the hydrodynamic flow and stress in the gastro intestinal 
tract, different paddle speeds (10, 50 and 150 rpm) were used during dissolution testing, using 
900 ml demineralized water as dissolution medium. Furthermore a dissolution test was 
performed using the reciprocating cylinder method (USP III) (Bio-Dis, Vankel, New Jersey, 
USA) at a dip speed of 21 dips/min using 250 ml demineralised water as dissolution medium 
(37±0.5°C) (Katori et al., 1995). 
To evaluate the influence of the composition of the dissolution medium, tests were performed 
in 900 ml Simulated Intestinal Fluid USP 27 (SIF), Simulated Gastric fluid USP 27 (SGF), 
Fasted State Simulated Intestinal fluid (FaSSIF), Fed State Simulated Intestinal Fluid 
(FeSSIF) (Table 3.4.) (Dressman et al., 1998; Galia et al., 1998) and an aqueous 4% bile salt 
solution (consisting of a mixture of sodium cholate and sodium deoxycholate) at a paddle 
speed of 50 rpm.  
 
Table 3.4.: Composition of Fasted State and Fed State Simulated Intestinal Fluid 
Fasted State Simulated Intestinal Fluid 
(FaSSIF) 
Fed State Simulated Intestinal Fluid  
(FeSSIF) 
pH 
Osmolality  
Sodium taurocholate 
Lecithin 
KH2PO4  
KCl  
NaOH                          qs  
Demineralized water    qs     
 
6.5 
270±10 mOsm 
3 mM 
0.75 mM 
3.9 g 
7.7g 
pH 6.5 
1 L 
pH                        
Osmolality                  
Sodium taurocholate          
Lecithin                    
KH2PO4   
KCl 
NaOH                           qs 
Demineralized water    qs       
5.0 
635±10 mOsm 
15 mM 
3.75 mM 
8.65g 
15.2 g 
pH 5.0 
1 L 
 
As it was impossible to determine the metoprolol tartrate concentration 
spectrophotometrically in these media, a validated HPLC-fluorescence method (as described 
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in section 3.3.4.) was used, whereby the samples were injected directly onto the column after 
filtration using 0.2 µm Whatman filters (Spartan, regenerated cellulose).  
To investigate the influence of surface tension of the dissolution medium, a dissolution was 
performed in 900 ml FaSSGFSLS (consisting of 0.25% sodium lauryl sulphate, 0.05 M HCl 
and 0.2% sodium chloride) (Anwar et al., 2005) using a paddle speed of 50 rpm. The 
metoprolol tartrate concentration in the samples was determined using UV-
spectrophotometry. 
The AUC0-3h-values of the dissolution test were statistically evaluated with a one-way 
ANOVA at a significance level of 0.05. The normality of the residuals was checked using the 
Kolmogorov-Smirnov test and the homogeneity of variance using the Levene’s test 
(significance level=0.05). SPSS version 16.0 was used to perform the statistical analysis. 
 
3.4. RESULTS AND DISCUSSION 
3.4.1. In vivo study 
Fig 3.1. shows the in vitro drug release profiles of metoprolol tartrate from Lopresor® and 
porous tablets with a median pore diameter of 5 and 100 µm. Immediate drug release was 
obtained from the commercially available reference product and from the porous tablet with a 
median pore diameter of 100 µm, whereas from the porous tablet with a median pore diameter 
of 5 µm a slow drug release was obtained. 
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Figure 3.1.: Mean drug release profiles (± S.D.) (n=3) in demineralised water at 50 rpm of 
metoprolol tartrate from Lopresor® (▲) and porous tablets with a median pore 
diameter of 5 µm (▲) and 100 µm (▲). 
 
Fig. 3.2. shows the mean plasma concentration-time profiles in dogs after oral administration 
of 100 mg metoprolol tartrate via porous tablets and Lopresor®-tablets. The pharmacokinetic 
parameters are given in Table 3.5.  
 
Table 3.5.: Mean pharmacokinetic parameters (± S.D., n=6) in dogs after oral administration of 
100 mg metoprolol tartrate as porous tablets with a medium pore diameter of 5 µm (F-
1), as porous tablets with a median pore size of 100 µm (F-2) and as Lopresor®- 
tablets.  
 Cmax 
(µg/ml) 
tmax 
(h) 
AUC0-24h 
(µg.h/ml) 
F-1 9.2 ± 5.7 2.3 ± 0.9 45.6 ± 30.1 
F-2 14.4 ± 8.1 1.5 ± 0.4 47.7 ± 26.1 
Lopresor® 11.8 ± 5.2 1.3 ± 0.4 38.6 ± 19.7 
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Figure 3.2.: Mean plasma concentration-time profiles ((± S.D., n=6) in dogs after oral 
administration of 100 mg metoprolol tartrate as porous tablets with a median pore size 
of 5 µm (▲), as porous tablets with a median pore size of 100 µm (▲) and as 
Lopresor®- tablets(▲). 
 
The plasma concentration–time profiles of F-1 and F-2 are similar to Lopresor®. The relative 
bioavailability (Frel) of the porous formulations to Lopresor® was 117.1 ± 35.1% and 120.2 ± 
24.4% for the porous tablets with a median pore diameter of 5 µm and of 100 µm, 
respectively. 
 
Table 3.6.: Results of the statistical analysis of the pharmacokinetic parameters by a multiple 
comparison among pair of means using Bonferroni post hoc test (P= 0.05). 
  Mean difference 95% CI P value 
 F1-F2 2.56 0, 5.096 0.05 
Cmax (µg/ml) F1-F3 -2.66 -8.87, 3.55 0.57 
 F2-F3 -5.22 -10.56, 0.13 0.06 
 F1-F2 -1.08 -2.33, 0.16 0.08 
tmax (h) F1-F3 -0.17 -1.25, 0.92 1.00 
 F2-F3 0.92 -0.48, 2.32 0.21 
 F1-F2 -6.98 -23.90, 9.95 0.62 
AUC0-24h(µg.h/ml) F1-F3 -9.06 -21.89, 3.78 0.17 
 F2-F3 -2.08 -19.06, 14.91 1.00 
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No significant mean difference was found for AUC0-24h, Cmax and tmax of these formulations, 
indicating that similar drug concentrations were available at the absorption site after 
administration of the porous tablets and an immediate release reference. 
The results of the present in vivo study showed that the porous formulations have a similar in 
vivo drug release compared with a commercial immediate release formulation (Lopresor®). 
For the porous tablets with a median pore diameter of 100 µm, this is in agreement with their 
in vitro drug release. However, the in vitro drug release from the porous tablets with a median 
pore diameter of 5 µm was slow and incomplete.  
 
3.4.2. In vitro study 
In order to explain the discrepancy between in vitro and in vivo behaviour of the porous 
tablets with a median pore diameter of 5 µm, dissolution tests were performed using different 
experimental conditions.  
 
¾ Influence of hydrodynamic flow and stress 
The influence of hydrodynamic stress and flow on the drug release rate of the porous tablets 
was evaluated via dissolution experiments run at different paddle speeds (10, 50 and 150 rpm) 
and using the reciprocating cylinder method.  
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Figure 3.4.: Mean drug release profiles (± S.D.) (n=6) of metoprolol tartrate from the porous 
tablets using the paddle method at 10 (▲), 50 (▲) and 150 (▲) rpm and using the 
reciprocating method (▲). 
 
The dissolution profiles (Fig 3.4.) showed that the influence of the hydrodynamic flow of the 
gastro-intestinal fluids and the hydrodynamic stress in the gastro-intestinal tract was 
negligible. This indicated that the hydrodynamic flow and stress did not contribute to the 
immediate in vivo drug release, what was confirmed when intact porous tablets were 
recovered from the dog faeces.  
Furthermore, it is known that the influence of hydrodynamic stress on diffusion-controlled 
drug delivery systems is negligible (Lindner and Lippold, 1995). 
 
¾ Influence of dissolution medium 
The effect of six physiologically relevant dissolution media (SGF USP 27, SIF USP 27, 
FeSSIF, FaSSIF, bile salt solution and FaSSGFSLS) on drug release from the porous tablets 
was investigated. SGF USP 27 and SIF USP 27 contain pepsine and pancreatin, respectively.  
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Table 3.7.: Influence of physiologically relevant dissolution media on AUC0-3h (± S.D.) (n=6) of  
 the dissolution profiles of porous tablet with a median pore diameter of 5 µm. 
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 a,bMean AUC is not significantly different (P>0.05, Scheffé test) 
Dissolution medium AUC0-3h (± S.D.) 
water 151.2 ± 8.5a 
SGF 218.9 ± 29.5b 
SIF 163.4 ± 10.0a 
FaSSIF 175.6 ± 15.4a 
FeSSIF 222.5 ± 19.9b 
bile salts 124.4 ± 8.2a 
FaSSGFSLS 225.7 ± 2.6b 
 
 
They were selected to investigate the influence of enzymes on drug release. FaSSIF and 
FeSSIF are dissolution media representing the fasted and fed state in the upper jejunum, 
containing lecithin and sodium taurocholate to form mixed micelles (Dressman et al., 1998; 
Galia et al., 1998). An aqueous bile salt solution consisting of a mixture of sodium cholate 
and sodium deoxycholate was also used. FaSSGFSLS was used as the surface tension of this 
fluid is similar to the surface tension of stomach fluid during the fasted state (i.e. about 35 
mN/m) (Anwar et al., 2005; Aburub et al., 2008).  
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Figure 3.5.: Mean drug release profiles (± S.D.) (n=6) of metoprolol tartrate from a porous tablet 
(pore diameter 5 µm) in Simulated Gastric Fluid (▲), Fed State Simulated Intestinal 
Fluid (▲), Fasted State Simulated Gastric Fluid (▲) and demineralised water (▲).  
 
The release from the porous tablet was significantly increased in SGF, FeSSIF and 
FaSSGFSLS compared to water (p<0.05) (Fig 3.5. and Table 3.7.). The other dissolution media 
had no significant influence on the drug release from the porous tablets (drug release profiles 
not shown). As the pH of SGF is about 1.2, the tablet was partly dissolved what contributed to 
a faster in vitro drug release. However, the gastric pH in dogs is around 5-7, hence the higher 
in vivo release can not be attributed to a low pH (Lui et al., 1986; Sagara et al., 1992). FeSSIF 
represents the fed state in the upper jejunum and contains lecithin and sodium taurocholate 
with tension active properties what can explain the higher in vitro drug release in this 
medium. However, as the dogs were fasted during the in vivo experiment the concentration of 
lecithin and sodium taurocholate in the upper jejunum will have been low, hence this factor 
will not contribute to the faster in vivo drug release.  
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Table 3.8. shows the surface tension values of some dissolution media used in this study. 
 
Table 3.8.: Surface tension values of dissolution media. 
Dissolution medium Surface tension 
(mN/m) 
water 64.3 
SGF 50.8 
bile salts 46.5 
FaSSGFSLS 33.3 
 
The surface tension value of a fasted state stomach (35 mN/m) (Vertzoni et al., 2007) is 
considerably lower than the surface tension of water and the only dissolution medium having 
a comparable surface tension as the fasted stomach of a dog is FaSSGFSLS.  
As the drug release from the porous tablets is pure diffusion-controlled, the initial step of drug 
release after immersion in the dissolution medium is wetting of the matrix and penetration of 
the dissolution medium into the porous structure. These processes will be positively 
influenced by a lower surface tension of the dissolution medium (Luner, 2000), hence a faster 
drug release from the porous tablets with a median pore diameter of 5 µm was observed in 
FaSSGFSLS. This could explain the faster in vivo drug release of these tablets as the low 
surface tension of the gastric fluid of a fasted dog enhanced drug release. 
 
3.5. CONCLUSION 
Although the in vitro drug release depended on pore size and pore shape, in vivo an 
immediate drug release was observed from all porous tablets as the bioavailability of these 
tablets was similar to the in vivo behavior of an immediate release formulation.  
Dissolution tests simulating the gastro-intestinal conditions showed that the faster drug 
release was mainly attributed to the low surface tension of the gastric fluid of fasted dog. 
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4.1. INTRODUCTION 
As described in Chapter 1, multiparticulate systems such as pellets are often used as oral solid 
dosage form since they offer therapeutic as well as technological advantages over single unit 
dosage forms. They disperse freely in the gastro-intestinal tract, what contributes to maximum 
drug absorption, reduced peak plasma fluctuations and less side effects. Furthermore, pellets 
also allow the formulator to modify the drug release by coating the pellets and a mixture of 
pellets with different release characteristics can be used to obtain the desired release profile 
(Bechgaard and Hagermann, 1978; Ghebre-Selassie, 1989; Krämer and Blume, 1994). Several 
methods can be used for pellet preparation whereby extrusion/spheronization is commonly 
used. This method involves different preparation steps: a wet mass is formed of a uniform 
powder mixture of drug and excipient(s) by addition of a liquid binder. Next the wet mass is 
pressed through an extrusion screen to form cylindrical extrudates (extrusion), which are 
subsequently broken up into smaller cylindrical rods and rounded into spheres by means of 
fast rotating friction plate (spheronization) followed by drying. 
The objective of the study described in this chapter is to develop porous pellets which allow 
the incorporation of a significant drug fraction (deposited inside the porous structure or 
layered on the surface of the pellets). To this end pellets consisting of Avicel PH 101 and 
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sodium chloride were manufactured by extrusion/spheronization and after removal of the 
NaCl fraction via extraction porous pellets were obtained. Their potential as drug carriers was 
tested using three techniques to incorporate drugs in the porous pellets: fluid-bed layering, 
immersing the pellets in a drug solution and supercritical fluid impregnation.  
 
4.2. MATERIALS 
Avicel PH 101 (microcrystalline cellulose) (50 µm) was obtained from FMC Biopolymer 
(Cork, Ireland). Sodium chloride (NaCl) (Alpha Pharma, Zwevegem, Belgium) was used as 
pore forming agent. 
Metoprolol tartrate (Esteve Quimica, Barcelona, Spain) was used as model drug using 
immersion of the pellet in a drug solution as loading technique. Ibuprofen (BASF, 
Ludwigshafen, Germany) was used as model drug using supercritical fluid impregnation as 
drug loading technique. Paracetamol (Alpha Pharma, Zwevegem, Belgium) and 
hydroxypropylmethylcellulose (HPMC, Methocel E3) (Colorcon, Kent, UK) were used as 
model drug and binder, respectively, using fluid-bed layering as drug loading technique. 
 
4.3. METHODS 
4.3.1. Manufacturing of porous pellets 
NaCl was grinded in a ball mill (Pulverisette 6, Fritsch, Idar-Oberstein, Germany) during 10 
min and the sieve fraction <125 µm was collected. Avicel PH 101 and NaCl were dry mixed 
(30/70, w/w) in a planetary mixer (Kenwood Major Classic). Next 42.5 % (w/w) water was 
added to the mixture and the wet mass was granulated for 10 min. Extrusion was performed 
using a single screw extruder (Dome extruder lab model DG-L1, Fuji Paudal, Tokyo, Japan) 
at 50 rpm, equipped with a 1 mm perforated screen. The extrudates were spheronized on a 
spheronizer (Calvea model 15) with a cross-hatched friction plate, operating at 1000 rpm with 
_________________________________________________________________________ 
Chapter 4 
96
a residence time of 5 min. The pellets were oven-dried at 40°C, followed by sieving whereby 
the 710-1400 µm pellet fraction was collected. The NaCl fraction was removed from the 
pellets by aqueous extraction: 30 g pellets were brought onto a 500 ml bottle top filter (0.22 
µm) (Corning, New York, USA), the filter was placed on a 2 L flask and connected to a 
vacuum pump. 2 L water was brought onto the filter in steps of 250 ml to extract the NaCl 
fraction. Next, the pellets were oven-dried at 40°C.  
 
4.3.2. Pellet evaluation 
¾ Atomic emission spectroscopy 
To determine the residual NaCl content after extraction, the amount of Na+-ions in the porous 
pellets was determined using atomic emission spectroscopy (AES) (Jenway PEP 7, Essex, 
England). Porous pellets (1 g) were soaked in 100 ml demineralised water and after 
disintegration of the pellets (using magnetic stirrer) and centrifugation, the Na+-concentration 
in the supernatant was determined (emission λ = 589 nm).  
 
¾ Pellet friability 
The friability was determined by placing 10 g pellets (Fs) in a abrasion wheel (together with 
200 glass beads, Ø 4 mm) of a friabilator (PTFE, Hainburg, Germany). The pellets were 
subjected to falling shocks at a rotational speed of 25 rpm during 10 min. Afterwards the fines 
were removed by sieving through a 250 µm sieve for 5 min (2 mm amplitude). The fraction 
above 250 µm (Fa) was used to calculate the friability (Eq.1): 
   Friability (%) = [(Fs-Fa)/Fs]*100     (1) 
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¾ Pellet porosity and pore size distribution 
The porosity and pore size distribution (0.003-360 µm) of the pellets was determined using 
mercury intrusion porosimetry (Autopore III, Norcross, GA, USA) and compared with 
conventional non-porous microcrystalline pellets (Pharmatrans Sanaq, Basel, Switzerland). 
Sample size (0.6 - 1.4 g) was adjusted in order to use 20-80% of the stem volume. The sample 
was evacuated to 50 mm Hg, followed by low pressure mercury intrusion in a pressure range 
from 4.3 kPa to 193 kPa, with a mercury filling pressure of 4.3 kPa, maximal intrusion 
volume of 0.03 ml/g and equilibration time of 10 s. Next high pressure intrusion was 
performed in a pressure range from 207 kPa to 41 x 104 kPa, maximal intrusion volume of 
0.03 ml/g and equilibration time of 10 s. 
 
¾ Pellet sphericity 
Pellet size and shape were determined using an image analysis system. Photomicrographs 
were taken with a digital camera (Camedia C-3030 Zoom, Olympus Optical, Tokyo, Japan). 
The obtained images were processed by image analysis software (AnalySIS®, Soft Imaging 
System, Münster, Germany) to characterize each individual pellet by mean Feret diameter 
(FD) (average of 180 calliper measurements with an angle of rotation of 1°), aspect ratio (AR) 
(ratio of longest Feret diameter and its longest perpendicular diameter) and two-dimensional 
shape factor (eR) (Podczeck and Newton 1994): 
   eR = 
2
12 ⎟⎠
⎞⎜⎝
⎛−−
l
b
P
r
m
π         (2) 
where r is the radius, Pm the perimeter, l the length (longest Feret diameter) and b the width 
(longest perpendicular diameter to the longest Feret diameter) of the pellet. 
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¾ Atomic force microscopy 
The surface roughness of the pellets was evaluated using Atomic Force Microscopy 
(Autoprobe® CP AFM, Park Scientific Instruments, Sunnyvale, USA). Scanning was 
performed in contact mode with a cantilever (UL20 B) operating at a scan rate of 1 Hz. The 
maximum peak-to-valley distance (Rp-V), the average roughness (Rave = ∑
=
N
1n
 -n 
N
zz
, i.e. the 
average deviation of all heights zn measured in the scanned region from the mean height), the 
median and mean height (calculated from all heights measured in the scanned region) were 
determined. 
 
¾ Scanning electron microscopy 
Scanning electron microscopy (SEM) (JSM-5510, JEOL, Tokyo, Japan) was used to visualize 
the porous structure of the pellets. Pellets were coated with a gold layer using a sputter coater 
(Autofine Coater, JFC-1300, JEOL, Tokyo, Japan) to assure conductivity.  
 
¾ Internal pore structure 
For the determination of the 3-dimensional internal structure of the samples, the nano-
computed tomography (nano-CT) scanner of the UGCT facility (www.ugct.ugent.be) was 
used (as described in Chapter 2, section 2.3.2.). Combining the data of the maximum 
inscribed diameter (dmax) and the equivalent diameter (de) provides information about the 
structure of the pores.  
 
4.3.3. Drug-loading 
Three techniques were evaluated to incorporate drugs into the pellets: immersing the pellets in 
a drug solution, supercritical fluid impregnation and fluid-bed layering. 
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¾ Immersion of the pellets in the drug solution 
Soaking the pellets in a drug solution is the simplest method to incorporate drugs inside the 
pellet. The drugs are dissolved in an appropriate solvent and pellets are soaked in solution 
during a certain time (Byrne and Deasy, 2002). 
Porous pellets (1 g) (n=3) were added to 100 ml of a metoprolol tartrate solution (15% and 
30%, w/v). After 5 min, 24 and 48h the pellets were separated using a sieve (250 µm) and 
oven-dried at 40°C. 
 
¾ Supercritical fluid impregnation 
Carbon dioxide (CO2) has many properties that makes it an attractive solvent: low toxicity, 
nonflammability and an environmentally benign nature. Under supercritical conditions, CO2 
offers mass transfer advantages over conventional organic solvents owing to its gaslike 
diffusivities, low viscosity and vanishing interfacial tension. Furthermore, supercritical fluids 
have the additional benefit of “solvent tunability”; a small change in pressure or temperature 
leads to changes in solvent properties (Panza and Beckman, 2004). Supercritical fluid 
technology has already proven its applicability to the preparation of pharmaceutical 
formulations: particle formation (reviewed by Jung and Perrut, 2001), purification of proteins 
(Yeo et al., 1993), preparation of liposomes (Frederiksen et al., 1997) and submicronization of 
drugs (Young et al., 2000). Recently, supercritical impregnation was explored for the 
formulation of drug delivery systems (Kikic and Vecchione, 2003). This technique offers a 
number of advantages since it avoids organic solvents and heat. Generally, for successful 
impregnation, the drug should have a sufficient solubility in the supercritical carrier and the 
partition coefficient should be favorable to enable drug loading in the matrix (Berens et al., 
1992; Elvira et al. 2004; Diankov et al., 2007; Duarte et al., 2007). It is important to 
distinguish two different mechanisms in such impregnation process. The first involves 
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deposition of a substance soluble in supercritical fluid into the polymer matrix upon 
depressurizing the cell containing supercritical fluid solution. In this case, even a solute that 
has low affinity to the polymer matrix can be trapped within the polymer matrix. This 
approach often results in the formation of re-crystallized substances within the polymer 
matrix. Another mechanism utilizes the high affinity of the substance dissolved in the 
supercritical fluid for the polymer matrix. This could result in a high partition coefficient of 
solute between the polymer and the fluid phases. Furthermore, specific interactions between 
solute and matrix will result in molecularly dispersed solute within the polymer matrix (Kikic 
and Vecchione, 2003). 
Supercritical fluid (scCO2) was used to impregnate porous pellets with ibuprofen using 
Separex® equipment (Champigneulles, France).  
 
Figure 4.1.: Schematic overview of the SEPAREX® equipment: (1) chiller, (2) pump, (3) valve(s), 
(4) heater and (5) reactor. 
 
At a pressure between 80 to 220 bar and a temperature from 35 to 45°C the solubility of 
ibuprofen in scCO2 was found to be in a range from 10-5 to 10-3 mole fraction (Kazarian and 
Martirosyan, 2002). During the impregnation experiment scCO2 (in which ibuprofen is 
dissolved) enters the pores of the pellets under pressure. Following a depressurization step, 
the drug is deposited in the internal pore structure of the pellet. The impregnation vessel 
(volume: 17 ml) was filled with 500 mg porous pellets. Ibuprofen was placed on top of the 
pellets and during 45 min the vessel was pressurized at a constant operating temperature. To 
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optimize the impregnation process, the influence of the experimental parameters (temperature, 
pressure and amount of ibuprofen relative to the amount of pellets used) was studied using an 
experimental design. Preliminary experiments were carried out to establish appropriate ranges 
for the processing variables. The amount of ibuprofen varied from 50 to 150 % relative to the 
amount of pellets used, the pressure varied between 150 and 250 bar while the temperature 
varied from 35 to 45°C. The upper limit of the amount of ibuprofen was limited to avoid 
overfilling of impregnation vessel. In addition the upper and lower limits of temperature and 
pressure were selected in order to ensure the solubility of ibuprofen in scCO2. Because 
interaction between the variables were expected, the following quadratic model was proposed 
Eq. (3) for modeling the response variable (i.e. the amount of ibuprofen impregnated in the 
pellets) in function of the process variables: 
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where Y is the response, Xi and Xj the set points of the process variables ‘i’ and ‘j’, 
respectively, and β0, βi, βij and βii the coefficients. 
The designs points were chosen by the software (Design-Expert version 6.0.10, Stat-Ease Inc., 
Minneapolis, USA). Eighteen experiments were carried out using a face-centered central 
composite statistical design for the study of the three variables, each at three levels (Table 
4.1.).  
Repeated observations (n=4) at the center point (temperature: 40°C, pressure: 200 bar, 
ibuprofen concentration: 100% w/w) were used to estimate the experimental error. Manual 
regression was performed. The highest order significant polynomial (significance threshold: 
0.05) was selected, where only significant model terms were included without destroying the 
model hierarchy. Outlier-t limit was set at 3.5. 
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Table 4.1.: Process parameters of the face-centered central composite design experiments. 
Run Factors 
 A B C 
 Temperature (°C) 
Pressure 
(bar) 
Drug amount 
(%) 
1 35 250 50 
2 40 150 100 
3 40 200 50 
4 40 200 100 
5 45 200 100 
6 40 200 100 
7 45 250 150 
8 45 150 150 
9 35 200 100 
10 35 150 150 
11 40 200 100 
12 40 200 150 
13 45 150 50 
14 35 150 50 
15 40 200 100 
16 45 250 50 
17 35 250 150 
18 40 250 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The probability plot of the residuals was performed in order to evaluate the model and to 
detect outliers. The model provided several comparative measures for model selection: (a) R² 
statistics, which give a correlation between the experimental and predicted response, should 
be high for a particular model to be significant; (b) adjusted R², which gives a similar 
correlation after ignoring the insignificant model terms, should have a good agreement with 
predicted R² for the model to be fit (Hicks and Turner, 1999); (c) predicted and adjusted R-
squares should be within 0.20 of each other. Contour plots for the response were drawn. 
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¾ Fluid-bed layering 
Pellets are fluidized in the fluid-bed system and a drug solution or suspension is sprayed on 
the pellets. The Wurster fluid-bed is a circulating fluid-bed which differs from conventional 
fluid-beds by its hydrodynamic features attributed to its grid and tube design. Four zones with 
distinctly different solid movement patterns can be identified: the up-bed region, the 
deaccelaration region, the down-bed region and the horizontal transport region. The coating 
process consists of three phases: the start-up phase, the coating phase and the drying phase. 
The start-up phase consists of an optional preheating of the equipment and a heating of the 
substrate. During the coating phase, the coating is applied to the substrate. A spray nozzle in 
the middle of the grid delivers drops (average diameter: 10-30 µm) of coating 
solution/suspension on the surface of the particles. The drying of the film starts as the solvent 
evaporates from the film droplets in the spray mist and continues from the film droplets 
adhered to the substrate. The space above the inner tube offered to the particles is enlarged, 
the air velocity decreases and the particles fall down in the annular part. In this region the 
coating film must be dry enough to avoid sticking and agglomeration. In the lower part, on the 
grid, the particles form a dense bed from where they are aspirated towards the inner tube for a 
new cycle (Guignon et al., 2003; Christensen and Bertelsen, 1997). 
 
 
Figure 4.2.: Schematic representation of the substrate motion in a Wurster fluid-bed. 
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Aqueous coating solutions containing 1% (w/w) paracetamol and 0, 0.5, 1 or 1.5% (w/w) 
(relative to the amount of pellets used, i.e. 250 g) HPMC (Methocel E3) were prepared. 4L of 
each coating solution was sprayed on the pellets (batch size: 300 g) in a fluid-bed (GPCG 1, 
Glatt, Binzen, Germany) using a Wurster setup. The operating conditions during coating were 
set at 20 g/min spray rate, 1.5 bar atomization pressure, 38°C outlet temperature and 4 h 
process time. The same procedure was performed using non-porous microcrystalline cellulose 
pellets (Pharmatrans Sanaq, Basel, Switzerland). Based on the theoretical amount of 
paracetamol layered on the pellets, the coating efficiency was calculated. 
 
4.3.4. Characterization of the drug-loaded pellets 
The distribution of the drug throughout the pellets was evaluated by Raman spectroscopic 
mapping. A pellet was cut into two halves and the inner surface of the pellet was scanned in 
point-by-point mapping mode with a step size of 50 µm in both the x and y directions using a 
long working distance objective lens (spot size laser = 50 µm). The detection system used in 
this study was a RamanRxn 1 Microprobe (Kaiser Optical Systems, Ann Arbor, USA), 
equipped with an air cooled CCD detector (back-illuminated deep depletion design). The laser 
wavelength during the experiments was the 785 nm line from a 785 nm Invictus NIR diode 
laser. All spectra were recorded at a resolution of 4 cm-1 using a laser power of 400 mW and a 
laser light exposure time of 15 s per collected spectrum. Before data analysis, spectra were 
baseline corrected. Data collection and data analysis was done using the HoloGRAMSTM data 
collection software package, the HoloMAPTM data analysis software package and the Matlab® 
software package (version 6.5). 
Furthermore, the Raman spectra of the loaded pellets were compared with the Raman spectra 
of the raw materials in order to obtain information about the solid state of the drug on the 
pellet surface as well as inside the pellet. 
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For the determination of the loading yield (mg drug/g pellets), the pellets were crushed, 
placed in a solvent (water for metoprolol tartrate and paracetamol, phosphate buffer pH 7.2 
for ibuprofen) and stirred during 30 min, followed by centrifugation. The amount of drug in 
the supernatant was determined by UV spectroscopy. 
 
4.3.5. Drug release 
Drug release from the porous pellets was determined using the USP II method (VanKel VK 
8000, VanKel Industries, New Jersey, USA) with a paddle speed of 50 rpm and at a 
temperature of 37±0.5°C. Phosphate buffer pH 7.2 was used as dissolution medium for 
ibuprofen pellets and water for metoprolol tartrate and paracetamol pellets. Samples were 
collected at different time points and analysed using a UV/VIS double beam 
spectrophotometer (Perkin-Elmer, Zaventem, Belgium) at 265, 222 and 243 nm for ibuprofen, 
metoprolol tartrate and paracetamol, respectively.  
The following analytical solution of Fick’s second law of diffusion was used to describe 
metoprolol tartrate and ibuprofen release from the porous pellets (Crank, 1975). This model 
considers that drug release is purely diffusion-controlled, that the drug is homogeneous 
distributed within the pellets at t = 0 and that perfect sink conditions are maintained 
throughout the experiments: 
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where M∞ and Mt denote the absolute cumulative amounts of drug (mg) released at infinite 
time and time t, respectively; R represents the radius of the pellets and D the apparent 
diffusion coefficient of the drug within the system.  
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4.4. RESULTS AND DISCUSSION 
4.4.1. Characterization of porous pellets 
Preliminary experiments were carried out to determine the maximum concentration of pore 
forming agent (NaCl) that could be incorporated into the pellet formulation. The results 
showed that the concentration was limited to 70% (w/w) as at a higher sodium chloride 
fraction the mass could not be extruded. 
Image analysis revealed an AR (n=303, ±SD) of 1.15 ± 0.08, an eR of 0.94 ± 0.03 and FD of 
946 ± 142 µm, indicating that spherical pellets were obtained, and 89.1% of the pellets was 
found in the 710-1400 µm size range. 
Most of the sodium chloride fraction was removed during aqueous extraction as analysis of 
the porous pellets by AES determined the residual sodium chloride content at 4%. 
The porosity and median pore diameter of the porous microcrystalline cellulose pellets were 
33.2 ± 0.8% and 0.7 ± 0.2 µm, respectively, whereas the corresponding values of 
conventional non-porous MCC pellets were 15.1 ± 1.2 % and 0.02 ± 0.01 µm. Although 
almost 70% NaCl was removed from the porous pellets by extraction, their porosity was only 
33.2% due to shrinkage of the pellets during drying. Despite their high porosity, the porous 
pellets were sufficiently strong to withstand the friction forces during handling as the friability 
was below 0.1%. Atomic Force Microscopy (AFM) showed that the surface of the porous 
pellets was more irregular and rough compared with non-porous pellets: all AFM parameters 
(Rp-V, average roughness, mean and median height) were higher in case of porous MCC 
pellets (Table 4.2.).  
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Table 4.2.: Analysis of surface structure via atomic force microscopy of conventional non-porous 
pellets and porous pellets.  
 Rp-V (µm) Rave (µm) mean height (µm) median height (µm) 
non-porous pellet 1.33 0.12 0.55 0.28 
porous pellets 3.47 0.47 1.86 1.77 
Rp-V : maximum peak-to-valley distance 
Rave : the average deviation of all heights zn measured in the scanned region from the mean height 
 
a 
  
      
   
 
b           
      
Figure 4.3.: SEM micrographs of the surface of a conventional non-porous pellet (a) and a porous 
pellet (b) (manufactured by means of NaCl extraction). 
 
The difference in porosity between the conventional non-porous and porous pellets was 
visualised by SEM (Fig. 4.3.). 
Nano CT-scanning of the porous structure (Fig. 4.4.) detected one pore system with a 
branched structure (equivalent diameter > maximum inscribed diameter) (Table 4.3.). These 
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pore system represented 99% of the total porosity volume, indicating that nearly all pores are 
incorporated in an interconnected network.  
 
       
 
Figure 4.4.: 3-dimensional images of the internal structure of porous pellets. 
 
Table 4.3.: Nano CT-scan analysis of the 3-dimensional internal structure of a porous pellet 
obtained by NaCl extraction. 
maximum inscribed diameter 
(µm) 
equivalent diameter  
(µm) 
porosity represented by pore 
system (%) 
59 340 99 
 
4.4.2. Drug-loading experiments 
Several drug loading techniques were tested to maximize drug deposition in the porous 
structure of the pellets. For each technique a model drug was used that had a good solubility 
in the solvent used. 
 
¾ Immersion of the pellets in the drug solution 
After soaking the porous pellets during 5 min in a 15 and 30% (w/v) metoprolol tartrate 
solution (n=3) the drug load was 208 ± 7 and 489 ± 2 mg/g pellets, respectively. A longer 
soaking time resulted in a higher drug load: 273 ± 13 mg/g pellets and 616 ± 21 mg/g pellets 
after 24 h in a 15 and 30% (w/v) metoprolol tartrate solution (n=3), respectively. However, 
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after 48 h soaking the drug load did not further increase. Raman spectroscopy revealed that 
this technique allowed to deposit drug in the inner pore structure since the solution can easily 
penetrate inside the porous network and after drying the drug is deposited in the pores. Fig. 
4.5. shows that the Raman signal of metoprolol tartrate (encircled peaks in the spectrum, 
spectral range 627-652 and 806-867 cm-1) was detected at the surface of the pellets as well as 
inside the pellets, indicating that the drugs was homogeneously distributed after 24 h 
immersion of the pellets in a 15% metoprolol tartrate solution. 
 
a 
 
x104 
 
b 
 
x104 
Figure 4.5.: Raman spectra of porous pellets loaded via immersion in a 15% (w/v) 
metoprololtartrate solution. Spectra recorded at (a) surface of the pellet and (b) 
inside the pellet. 
 
Furthermore, the sharp peaks in the spectrum of the drug-containing pellets corresponded with 
the peaks in the spectrum of crystalline metoprolol tartrate, indicating that metoprolol tartrate 
in the drug-loaded pellets was crystalline. 
All drug-loaded pellets had a friability below 1%. 
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¾ Supercritical fluid impregnation 
Supercritical fluid impregnation was evaluated as a second drug loading technique. Analysis 
of variance of the response factor (Table 4.4.) indicated that the response surface model 
developed for drug loading was significant, without significant lack of fit.  
The model summary statistics for the selected significant model showed that R² (0.9987), 
predicted R² (0.9905) and adjusted R² (0.9972) are in good agreement, resulting in a reliable 
model.  
 
Table 4.4.: ANOVA results of face-centered control composite statistical design for drug loading 
of porous pellets via supercritical fluid impregnation. 
Source Sum of squares Mean square F Value Prob > F 
 
Model 
 
7.37 
 
0.92 
 
664.48 
 
< 0.0001
A: Temp 5.15 5.15 3716.10 < 0.0001
B: Pressure 0.053 0.053 38.57 0.0004
C: IBU (%) 0.82 0.82 590.29 < 0.0001
A² 1.57 1.57 1131.00 < 0.0001
B² 0.053 0.053 37.96 0.0005
C² 0.043 0.043 30.95 0.0008
AB 0.084 0.084 60.43 0.0001
AC 0.099 0.099 71.32 < 0.0001
Residual 9.700 E-003 1.386 E-003  
Lack of fit 3.458 E-003 8.646 E-004 0.42 0.7922
Pure error 6.241 E-003 2.080 E-003  
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Table 4.5.: Response results for process design. 
Run Factors Response 
 A B C  
 Temperature (°C) 
Pressure 
(bar) 
Drug amount 
(%) 
Drug Loading 
(%) 
1 35 250 50 2.2 
2 40 150 100 23.0 
3 40 200 50 15.1 
4 40 200 100 18.3 
5 45 200 100 17.1 
6 40 200 100 17.4 
7 45 250 150 23.4 
8 45 150 150 34.2 
9 35 200 100   17.4(*) 
10 35 150 150 5.3 
11 40 200 100 17.2 
12 40 200 150 27.8 
13 45 150 50 23.3 
14 35 150 50  8.4(*) 
15 40 200 100 19.0 
16 45 250 50 15.2 
17 35 250 150 5.9 
18 40 250 100 18.8 
(*): classified as an outlier 
 
The drug loading of runs 9 and 14 was classified as an outlier.  
The fitted response surface model in terms of coded factors for the drug loading was: 
Ln (drug loading)= 2.89 + 0.94 * A – 0.084 * B + 0.33 * C – 0.98 * A² + 0.15 * B² 
+ 0.14 * C² – 0.12 * A * B – 0.13 * A * C      (4) 
where A is the temperature, B the pressure and C the amount of ibuprofen relative to the 
amount of pellets used. The contour plot based on Eq. (4) and the 3D surface plots are 
presented in Fig. 4.6. 
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b 
      
c 
        
Figure 4.6.: Contour plots and 3D plots for drug loading at a) constant ibuprofen amount (100%, 
relative to the amount of pellets used), b) constant pressure (200 bar) and c) constant 
temperature (40°C). 
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Within the set of parameters tested, the highest ibuprofen concentration (342 mg/g pellets) 
was achieved when the temperature and pressure were set at 45°C and 150 bar, and when 
150% (w/w) ibuprofen (relative to the amount of pellets used) was used (Table 4.5.). 
At constant drug amount dissolved in supercritical CO2 (Fig. 4.6.a), maximum drug load was 
obtained at low pressure and high temperature. Fig 4.6.b showed that when a constant 
pressure was applied, a higher drug load was obtained when drug amount and temperature 
were increased.  
The solubility of ibuprofen in supercritical carbon dioxide increased with pressure and 
temperature (Charoenchaitrakool et al., 2000). In addition, the sorption of carbon dioxide in 
the matrix also increased with pressure. Hence, more solute uptake was anticipated a higher 
pressure. However, combining a high temperature and a high pressure did not result in the 
highest drug load despite the higher solubility of ibuprofen in scCO2 under these conditions. 
This could be indicative that at high pressure the interaction between ibuprofen and 
supercritical fluid is stronger compared to the interaction between drug and pellet since a 
stronger interaction between solute and carbon dioxide is detrimental for the bonding forces 
between solute and matrix (Duarte et al., 2007).  
The loading experiment at the centre point was carried out four times, yielding a mean drug 
load of 180 ± 8.5 mg ibuprofen/g pellets was found, indicating that this procedure was 
reproducible.  
The friability of pellets after drug loading via scCO2 impregnation was below 0.1%. Raman 
spectroscopy of the pellets with the highest drug load (342 mg ibuprofen/g pellets) revealed 
that drug was deposited on the surface as well as inside the porous pellet as for all mapped 
areas the specific spectrum of ibuprofen (spectral range: 624-645, 731-762 and 808-843 cm-1) 
was detected (Fig. 4.7.). Raman spectroscopy revealed sharp peaks indicating that most 
ibuprofen that was deposited at the surface and inside the pellet was crystalline. 
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Figure 4.7.: Raman spectra of porous pellets loaded with ibuprofen via supercritical fluid 
impregnation. Spectra recorded at (a) surface of the pellet and (b) inside the pellet. 
 
¾ Fluid-bed layering 
Layering of porous pellets with a drug solution using fluid-bed coating was also examined for 
drug loading since this technique is commonly used for loading inert spheres with drugs. The 
coating efficiency after 4 h layering with a 1% (w/v) paracetamol solution and increasing 
amounts of binder (Methocel E3) is given in Fig. 4.8. 
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Figure 4.8.: Coating efficiency (%) of paracetamol on non-porous (▲) and porous pellets (▲) in 
function of Methocel E3 concentration in the coating solution. 
 
The difference in coating efficiency between the non-porous (16.5%) and porous pellets 
(61.7%) is most pronounced without binder, resulting in a drug load of 97.6 mg paracetamol/g 
porous pellets. The irregular surface of the porous pellets compared to the non-porous pellets 
contributed to the difference in drug loading when no binder was used. Furthermore, the 
irregular surface of the porous pellets facilitated sticking of the drug particles to the surface 
compared to the smoother surface of conventional non-porous pellets. When a binder was 
added to the coating solution the drug particles attached to the pellet surface independently of 
the morphology of their surfaces. The friability of the porous pellets after drug loading was in 
all cases < 0.1%, whereas for the non-porous pellets the friability was higher (0.9%). Due to 
the irregular surface of the porous pellets, the drug particles were better protected against 
friction during friability testing. A layering experiment was performed whereby the spray rate 
was gradually increased until agglomeration of the pellets occurred, in order to investigate the 
maximum spray rate that could be obtained. For porous pellets a maximum spray rate of 35 
g/min was obtained. In contrast, for non-porous pellets agglomeration already occurred at a 
spray rate of 20 g/min. The irregular surface of the porous pellets facilitated the evaporation 
of the coating liquid and its porous structure was able to improve the drainage of water from 
its surface. Raman spectroscopy (Fig. 4.9.) of the pellets coated with a 1% (w/v) paracetamol / 
1% (relative to the amount of pellets used) Methocel E3 solution identified that paracetamol 
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(spectral range: 1587-1673 cm-1) was only present at the surface of the pellet. The absence of 
drug inside the pellets was probably due to limited penetration of the drug solution within the 
pellets as most of the water evaporated once the droplet was distributed on the pellet surface.  
 
 a       
 
x104 
b 
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Figure 4.9.: Raman spectra of porous pellets loaded with paracetamol via fluidised bed layering. 
Spectra recorded at (a) surface of the pellet and (b) inside the pellet. 
 
The sharp peaks presented in the Raman spectrum of the loaded pellets corresponded with the 
peaks found in the spectrum of pure crystalline paracetamol, indicating that paracetamol was 
layered on the pellet surface in a crystalline form. 
 
4.4.3. Drug release from porous pellets 
Fig. 4.10. shows the in vitro release profile of ibuprofen from porous pellets loaded by 
supercritical fluid impregnation. Clearly, most of the drug was released within less than 10 
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min. Even higher release rates were observed with metoprolol tartrate-loaded pellets, 
irrespective of the concentration of the soaking solution (Fig. 4.11.). Fitting of an appropriate 
analytical solution of Fick’s second law of diffusion (considering the given initial and 
boundary conditions, Eq. 4) to the experimentally determined drug release kinetics, showed a 
good agreement between theory and experiment.  
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Figure 4.10.: In vitro drug release from ibuprofen-loaded, porous pellets: experimental (symbols, 
n=3) versus theoretical (curve, Eq.1) profiles. 
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Figure 4.11.: In vitro drug release from metoprolol tartrate-loaded, porous pellets: experimental 
(symbols, n=3) versus theoretical (curve, Eq.1) profiles. 
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Diffusion was the governing mass transport mechanism in these systems, irrespective of the 
type of drug and concentration. Based on these calculations the apparent diffusion coefficients 
of the drugs within the porous pellets could be determined: 4.8 ± 0.2x10-8 cm²/s for ibuprofen 
and 1.5 ± 0.1x10-6 cm²/s for metoprolol tartrate. 
The paracetamol release from layered porous pellets was immediate (Fig. 4.12.). As 
paracetamol was only present on the pellet surface, no diffusion mechanisms were involved in 
drug release. 
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Figure 4.12.: Mean drug release profiles (n=3, ±SD) of from porous pellets loaded with paracetamol 
via fluid-bed layering. 
 
4.5.  CONCLUSION 
Porous pellets manufactured by extraction of NaCl from Avicel PH 101-NaCl pellets can be 
used as drug carriers. The drug loading studies have shown that immersing the pellets in a 
drug solution and supercritical fluid impregnation are able to deposit drugs inside the porous 
pellets, whereas after fluid-bed coating drug was only found on the surface of the porous 
pellets. Drug release from the porous pellets was immediate and primarily controlled by 
diffusion. 
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In vivo evaluation of porous pellets 
        
5.1. INTRODUCTION 
In Chapter 4 the application of porous microcrystalline cellulose pellets as drug carriers was 
investigated and the in vitro drug release from these matrices was characterized as immediate 
and diffusion-controlled, independent on the model drug.  
In this chapter the bioavailability of metoprolol tartrate and ibuprofen in dogs was determined 
after oral administration of a hard gelatin capsule containing porous microcrystalline cellulose 
pellets. To examine the influence of the drug solubility on the in vivo drug release from 
porous pellets, metoprolol tartrate and ibuprofen were used as drugs with a high and low 
aqueous solubility, respectively.  
 
5.2. MATERIALS 
To prepare porous pellets, Avicel PH 101 (microcrystalline cellulose) was obtained from 
FMC Biopolymer (Cork, Ireland) and sodium chloride (NaCl) (Alpha Pharma, Zwevegem, 
Belgium) was used as pore forming agent. Metoprolol tartrate (Esteve Quimica, Barcelona, 
Spain) and ibuprofen (BASF, Ludwigshafen, Germany) were used as model drugs.  
Commercially available metoprolol tartrate and ibuprofen dosage forms were used as 
reference formulations during in vivo testing: Lopresor® (100 mg metoprolol tartrate per 
immediate-release tablet; Novartis, Brussels, Belgium), Ibuprofen EG 600 mg (600 mg 
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ibuprofen per immediate-release tablet; Eurogenerics, Brussels, Belgium) and Ibu-Slow® 600 
(600 mg ibuprofen per controlled-release tablet; Therabel, Brussels, Belgium). 
 
5.2.1. Ibuprofen 
Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a non-steroidal agent with anti-
inflammatory, analgesic and antipyretic properties used to treat rheumatoid arthritis, 
osteoarthritis and mild to moderate pain. Owing the presence of a single asymmetric carbon 
atom, the molecule exists as (S)-(+) (dextro) or (R)-(-) (laevo) isomer. Conventional ibuprofen 
occurs as a racemic mixture of the two isomers, whereby the (S)-(+) isomer possesses the 
majority of the pharmacological activity, as measured by inhibition of prostaglandin 
synthesis. The process whereby the (R)-(-) isomer is converted into the (S)-(+) isomer is chiral 
inversion, an enzymatic reaction that occurs in a unidirectional manner. The solubility of 
ibuprofen increases with pH, being largely insoluble at low pH values (pH range 1-4: 0.058 ± 
0.004 mg/ml) whereas a rapid and continuous increase in solubility is observed as the pKa is 
approached and thereafter (Shaw et al., 2005). Ibuprofen is rapidly absorbed, maximum 
ibuprofen plasma concentrations are achieved 1-2 hours after ingestion of the drug, but due to 
its short half life (about 2 hours) therapeutic blood concentrations can only be maintained if 
the drug is administered frequently (Higton, 1999). Ibuprofen displays extensive (99%) 
binding to plasma proteins (Lin et al., 1987), consequently a relative low distribution volume. 
Ibuprofen is extensively metabolized to pharmacologically inactive metabolites (Brocks and 
Jamali, 1999). 
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 Figure 5.1.: Structure of ibuprofen 
 
5.3. METHODS 
5.3.1. Production of porous pellets 
The porous pellets were prepared according to the method described in Chapter 4 (section 
4.3.1.). Next, the pellets were loaded with metoprolol tartrate by soaking the pellets in a 
metoprolol tartrate solution (7.5% w/v) or with ibuprofen via supercritical fluid impregnation 
as described in Chapter 4 (section 4.3.3.). 
 
5.3.2. In vivo study 
All procedures were performed in accordance with the guidelines and after approval of the 
Ethics Committee of the Institute for Agricultural and Fisheries Research (ILVO) (Merelbeke, 
Belgium). Male mixed-breed dogs (weight 20.5-40.5 kg) were used in this study. 
 
5.3.2.1. Metoprolol tartrate 
Each dog (n=4) received porous pellets (F-1) (filled into hard gelatine capsules) containing 
100 mg metoprolol tartrate. The in vivo data obtained after administration of Lopresor® 
(containing 100 mg metoprolol tartrate) as described in Chapter 3 were used as reference 
formulation with immediate drug release. Administration of the formulation to dogs and 
sampling was identical to the methods described in Chapter 3 (section 3.3.3). Sample analysis 
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was carried out as described in Chapter 3 (section 3.3.3.) using a validated HPLC-
fluorescence method (section 3.3.4.). 
 
5.3.2.2. Ibuprofen 
The following formulations were administered to each dog (n=6) : 
- F-1: porous pellets (filled into hard gelatine capsules) containing 300 mg ibuprofen 
- F-2: ½ tablet of Ibuprofen EG® 600 mg (immediate release formulation) 
- F-3: ½ tablet of Ibu-Slow® 600 mg (controlled release formulation) 
 
The formulations were administered in a cross-over sequence with a wash-out of at least 8 
days. On the experimental days the dogs were fasted for 12 h prior to the study period, water 
was available ad libitum. Before administration of the formulations a blank sample was 
obtained from the saphenous vein. The formulations were administered with 10 ml water. 
Blood samples were obtained at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24h. The blood samples 
were collected in dry heparinized tubes and centrifuged for 10 min at 1450g within 1h of 
sampling. The plasma was stored at -20°C until assay of ibuprofen.  
 
¾ Ibuprofen assay 
The ibuprofen plasma concentrations were determined by a validated HPLC-UV method. All 
chemicals were of analytical HPLC grade. 
Fifty microlitres of an internal standard solution (30 µg/ml indomethacin in ethanol), 50 µl 
ethanol and 500 µl plasma were transferred into a borosilicate glass tube. After 1 min of 
vortexing, 100 µl HCl (2 N) was added and homogenized by 1 min vortexing. Afterwards, 
4ml hexane/ether mixture (4/1, v/v) was added. After 3 min vortexing and 5 min centrifuging 
at 2500g, the upper organic layer was transferred into a new glass tube and evaporated to 
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dryness under a nitrogen stream. The residue was dissolved in 200 µl mobile phase and 50 µl 
of this solution was injected onto the column. The ibuprofen plasma concentrations were 
determined via a calibration curve. The standards for the calibration curve were extracted 
using the same procedure as described above: 500 µl blank plasma was spiked with 50 µl of 
the internal standard solution and 50 µl of a standard solution with a known concentration of 
ibuprofen in ethanol (0, 3, 6, 12, 30, 60, 90, 180 and 240 µg/ml). 
The HPLC equipment (Hitachi, Tokyo, Japan) consisted of a solvent pump (L-7100), set at a 
constant flow-rate of 1.5 ml/min, a variable wavelength UV-detector (L-7400) set at 220 nm, 
a reversed-phase column and precolumn (LiChroCART® 125-4 and 4-4, LiChrospher® 100 
RP-18 (5µm); Merck, Darmstadt, Germany) and an auto-sampler injection system (L-7200) 
with a 50 µl loop (Valco Instruments Corporation, Houston, Texas, USA) equipped with an 
automatic integration system (D-7000 Multi-Manager). The mobile phase consisted of 0.1 M 
KH2PO4 (adjusted to pH 7.0 with 2 M NaOH)/acetonitrile (12/3, v/v). 
 
¾ Validation of the HPLC method 
The HPLC method for ibuprofen analysis was validated based on the guidelines of the 
International Conference on Harmonisation (ICH) for validation of analytical procedures: 
Text and Methodology (2005). The following characteristics were considered: specificity, 
linearity, accuracy, precision, recovery, detection and quantification limit (as defined in 
Chapter 3). 
 
Specificity 
The absence of interference between ibuprofen, internal standard and endogenous plasma 
components was confirmed after comparing the chromatograms of a blank serum sample (a), 
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a blank serum sample spiked with ibuprofen and indomethacine (b) and a plasma sample 
obtained after oral administration of ibuprofen to dogs (c) (Fig. 5.1.). 
a 
 
b 
 
c 
 
Figure 5.1.: Specificity of the HPLC method. Chromatograms after extraction of (a) blank plasma, 
(b) blank plasma spiked with ibuprofen (retention time: 12.4 min) and indomethacine 
(retention time: 34.7 min) and (c) dog plasma after intake of an ibuprofen tablet (½ 
tablet of Ibu-Slow® 600 mg). 
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Accuracy 
Table 5.1. lists the mean within-day and between-day accuracy of the HPLC method. All 
values were within ± 15% of the actual concentration (i.e. acceptance criteria recommended 
by Shah et al., 1992) ,independent of the ibuprofen concentration. 
 
Table 5.1.: Mean accuracy (± S.D.) of the HPLC method (n=6) in function of ibuprofen 
concentration 
Concentration (µg/ml) Accuracy (%) 
 Within-day Between-day 
0.5 104.6 ± 3.7 109.1 ± 4.4 
7.5 107.6 ± 4.8 95.5 ± 8.7 
40 106.5 ± 7.1 102.6 ± 6.6 
 
 
 
Precision 
The coefficient of variations used to assess precision are listed in Table 5.2. Since CV values 
below the limit recommended by Shah et al. (1992) (i.e. CV<15%), the method used for 
determination of ibuprofen in dog plasma is precise. 
 
Table 5.2.: Precision (expressed as coefficient of variation) of the HPLC method (n=6) 
Concentration (µg/ml) Precision (%CV) 
 Within-day Between-day 
0.5 
1 
2.5 
5 
13.1 
- 
- 
- 
7.7 
8.5 
11.9 
11.2 
7.5 
15 
20 
10.7 
- 
- 
9.1 
14.8 
11.9 
40 12.1 10.9 
 
_________________________________________________________________________ 
In vivo evaluation of porous pellets 
129
Recovery 
Recovery was presented as the mean value of repeated analyses (n=6) of different calibration 
standards (at three concentration levels) and the internal standard (Table 5.3.). 
 
Table 5.3.: Mean recovery (n=6) (± S.D.) of the calibration standards and the internal standard 
 Concentration (µg/ml) Recovery (%) 
ibuprofen 0.5 89.2 ± 4.1 
 7.5 101.1 ± 8.4 
 40 86.2 ± 6.2 
indomethacine 2.5 78.3 ± 11.3 
 
Linearity 
During validation of the HPLC method and analysis of the samples, several calibration curves 
were analyzed. The linearity of the calibration curves was evaluated via the determination 
coefficient R²: 0.9997 ± 0.0013 (n=7), indicating that a linear relationship between response 
(y) and concentration (x). The equation of the mean calibration curve was: 
 y= 0.2202x – 0.0075 
 
Detection and quantification limits 
Detection and quantification limits were calculated from the mean calibration curve based on 
the equations presented in Chapter 3 (section 3.3.4.). Using this specific HPLC method, the 
detection limit of ibuprofen in dog plasma was 0.78 µg/ml and the quantification limit was 2.4 
µg/ml. Since the calculated quantification limit was higher than the lowest concentration of 
the calibration curve and the accuracy and precision at a concentration of 0.5 µg/ml were 
within the accepted limits (Shah et al. 1992), a concentration of 0.5µg/ml was considered as 
limit of quantification. 
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5.3.3. Data analysis 
The extent of drug absorption (AUC0-24h), the peak plasma concentration (Cmax) and the time 
to reach Cmax (tmax) was calculated using the MW-PHARM program version 3.0 (Mediware 
1987-1991, Utrecht, The Netherlands). The AUC0-24h was calculated using logarithm and 
linear trapezoidal rules. The relative bioavailibility (Frel, %) was calculated as the AUC0-24h 
ratio between the porous pellets and a reference formulation.  
For the porous pellets loaded with ibuprofen, the sustained-release characteristics were 
evaluated by the time span during which the plasma concentrations were at least 50% of the 
Cmax value (HVDt50%Cmax, the width of the plasma concentration profile at 50% of Cmax) 
(Meier et al., 1974; Steinijans, 1990). The HVDt50%Cmax values were determined from the 
individual plasma concentration-time profiles. The ratio between the HVDt50%Cmax values of 
the test formulation (i.e. porous pellets) and the immediate release reference formulation (i.e. 
Ibupofen 600 EG) (expressed as RD) is indicative for the sustained release effect of the porous 
pellets: a ratio of 1.5, 2 and >3 indicating a low, intermediate and strong sustained release 
effect, respectively (Meier et al., 1974). 
 
5.3.4. Statistical analysis 
The data obtained after administration of metoprolol tartrate were statistically analysed using 
SPSS 16 software (SPSS, Chicago, USA). A comparison between the pellet and reference 
formulations was carried out by a paired t-test (P<0.05). All data were tested for normality 
using Kolmogorov-Smirnov test. 
The effect of ibuprofen formulation on the bioavailibility was assessed by repeated-
measurements ANOVA (univariate analysis). To further compare the effects of the different 
formulations, a multiple comparison among pairs of means was performed using Bonferroni 
post-hoc testing with P< 0.05 as significance level. The sphericity of covariances was tested 
_________________________________________________________________________ 
In vivo evaluation of porous pellets 
131
with Mauchly’s test. SPSS 16 software (SPSS, Chicago, USA) was used to perform the 
statistical analysis.  
 
5.4. Results and discussion 
5.4.1. In vivo evaluation of porous pellets containing metoprolol tartrate 
The mean plasma concentration-time profiles after oral administration of 100 mg metoprolol 
tartrate to 4 dogs as a porous pellet formulation and as Lopresor® are presented in Fig. 5.1. 
The pharmacokinetic parameters are given in Table 5.4. 
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Figure 5.1.: Mean plasma concentration-time profiles (± S.D., n=4) in dogs after oral 
administration of 100 mg metoprolol tartrate as a porous pellet formulation (F-1) (▲) 
and as Lopresor® -tablet (▲). 
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Table 5.4.: Mean pharmacokinetic parameters (± S.D., n=4) in dogs after oral administration of 
100 mg metoprolol tartrate as porous pellet formulation (F-1) and as Lopresor®- 
tablets.  
 Cmax 
(µg/ml) 
tmax 
(h) 
AUC0-24h 
(µg.h/ml) 
F-1 15.7 ± 3.3 1.3 ± 0.5 60.1 ± 13.5 
Lopresor® 14.7 ± 3.2 1.4 ± 0.5 50.2 ± 10.8 
 
 
Table 5.5.:  Statistical analysis of the pharmacokinetic parameters by paired sample t-test (P= 
0.05). 
  Mean 
difference 
95% CI P value 
Cmax (µg/ml) F1- Lopresor® 1.0 -7.8, 9.7 0.7 
tmax (h) F1- Lopresor® 
 
-0.1 -1.4, 1.2 0.8 
AUC0-24h (µg.h/ml) F1- Lopresor® 9.9 -3.8, 23.6 0.1 
 
The plasma concentration–time profiles after administration of porous pellets containing 100 
mg metoprolol tartrate are similar to Lopresor®. No statistically significant mean differences 
of AUC0-24h, Cmax and tmax were found between both formulations (Table 5.5.), indicating that 
similar drug concentrations were available. The relative bioavailability (Frel) of porous pellets 
compared to Lopresor® was 120.9 ± 21.2%.  
 
5.4.2. In vivo evaluation of porous pellets containing ibuprofen 
Fig. 5.2. presents the mean plasma concentration-time profiles after oral administration of 300 
mg ibuprofen to 6 dogs as a porous pellet formulation, Ibuprofen EG® 600 mg (½ tablet) and 
Ibu-Slow® 600 mg (½ tablet). The pharmacokinetic parameters are reported in Table 5.6. 
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Figure 5.2.: Mean plasma concentration-time profiles (± S.D., n=6) in dogs after oral 
administration of 300 mg ibuprofen as Ibuprofen EG® 600 mg (½ tablet) (F-1) (▲) 
and Ibu-Slow® 600 mg (½ tablet) (F-2) (▲) and as a porous pellet formulation (F-3) 
(▲). 
 
Table 5.6.: Mean pharmacokinetic parameters (± S.D., n=6) in dogs after oral administration of 
300 mg ibuprofen as Ibuprofen EG® 600 mg (½ tablet) (F-1) and Ibu-Slow® 600 mg 
(½ tablet) (F-2) and as a porous pellet formulation (F-3). 
 Cmax 
(µg/ml) 
tmax (h) AUC0-24h 
(µg.h/ml) 
 
HVDt50%Cmax 
(h) 
Frel* 
(%)
RRD
F-1 50.7 ± 9.5 2.4 ± 0.6 256.4 ± 51.3 3.6 ± 0.7 - - 
F-2 19.0 ± 5.3 6.6 ± 3.3 174.8 ± 36.6 10.7 ± 5.0 - 3.0 ± 1.7 
F-3 29.0 ± 6.6 3.8 ± 1.7 224.5 ± 82.6 6.8 ± 1.9 136.0 ± 59.6 2.0 ± 0.5 
-: not applicable 
* Ibu-Slow® 600 (½ tablet) 
 
With regard to the extent of absorption, the mean AUC0-24h of the pellet formulation, 
Ibuprofen EG® 600 mg and Ibu-Slow® 600 mg was 224.5, 256.4 and 174.8 µg/ml, 
respectively; yielding a relative bioavailability of the porous pellets versus Ibu-Slow® 600 mg 
of 136.0%. The statistical analysis of these data is reported in Table 5.7. 
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Table 5.7.:  Statistical analysis of the pharmacokinetic parameters via multiple comparison among 
pairs of means using the Bonferroni post hoc test (P= 0.05). 
  Mean difference 95% CI P value 
 F1-F2 31.7 17.0, 46.4 0.002 
Cmax (µg/ml) F1-F3 21.8 2.9, 40.6 0.029 
 F2-F3 -9.9 -20.4, 0.5 0.060 
 F1-F2 -4.3 -8.8, 0.3 0.062 
tmax (h) F1-F3 -1.3 -3.9, 1.2 0.378 
 F2-F3 2.9 -1.4, 7.2 0.184 
 F1-F2 81.6 -38.9, 202.2 0.186 
AUC0-24h(µg.h/ml) F1-F3 28.4 -84.4, 141.3 1.000 
 F2-F3 -53.2 -179.7, 73.3 0.592 
 F1-F2 -7.1 -15.5, 1.3 0.093 
HVDt50%Cmax (h) F1-F3 -3.2 -5.4, -0.9 0.013 
 F2-F3 3.9 -2.9, 10.7 0.295 
RRD F3-F2 -1.7 -3.0, -0.3 0.026 
 
A significant mean difference of Cmax was observed between Ibuprofen EG® 600 mg (F-1) 
and Ibu-Slow® 600 mg (F-2) and between porous pellets (F-3) and Ibuprofen EG® 600 mg (F-
1). No significant mean difference between the formulations was found for tmax and AUC0-24h. 
A significant mean difference of HVDt50%Cmax was detected between Ibuprofen EG® 600 mg 
(F-1) and the pellets.  
The in vivo behavior of the pellet formulation was similar to the Ibu-Slow® tablets and its RD 
value of 2 indicated that an intermediate sustained release effect was obtained. However the 
in vitro ibuprofen release profile (Chapter 4, section 4.4.3.) in phosphate buffer pH 7.2. was 
immediate. As the drug release from porous pellets is diffusion–controlled, ibuprofen release 
from the porous matrix was determined by drug solubility: at pH 7.2 the higher solubility 
(4.48 ± 0.08 mg/ml, De Brabander et al., 2003) resulted in an immediate release, whereas the 
lower in vivo solubility unexpectedly induced a sustained release effect. Although the 
residence time of pellets is limited in the stomach, the delay of drug release probably could be 
_________________________________________________________________________ 
In vivo evaluation of porous pellets 
135
attributed to the gastric fluid. As the pellets absorb the gastric fluid when passing through the 
stomach, the pores are filled with this acid medium, creating an acid microenvironment which 
limited the solubility of  ibuprofen. Neutralization of the acids during gastro-intestinal 
passage gradually increased drug solubility, creating a slow and sustained drug release. 
The importance of drug solubility on the in vivo drug release from porous pellets was 
confirmed by the plasma concentration-time profiles after administration of porous pellets 
loaded containing metoprolol tartrate: in vivo release of the highly soluble metoprolol tartrate 
release was immediate.  
 
5.4. Conclusion 
The in vivo drug release from porous pellets depended on the solubility of the incorporated 
drug: release of drugs with a high aqueous solubility was immediate, whereas, diffusion from 
the porous matrix in case of drugs with a low aqueous solubility was slow, yielding plasma 
concentration similar to a sustained-release tablet. 
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Porous pellet formulation of F4 
fimbriae for oral vaccination of suckling 
piglets against E. coli infections 
 
6.1. INTRODUCTION 
Enterotoxigenic Escherichia coli (ETEC) infections are implicated as an important causal 
agent in diarrhea and mortality in domestic animals and humans. Especially, E. coli infections 
in pigs, immediately after birth or post-weaning, are responsible for significant economic 
losses in pig farming (Fairbrother et al., 2005). Neonatal infections can be prevented by 
passive colostral and lactogenic immunity (Deprez et al., 1986; Rutter and Jones, 1973), but 
active intestinal immunization is needed for protection of newly weaned piglets since they are 
deprived of passive lactogenic immunity. Active intestinal immunization can occur following 
oral infection but is not obtained by parenteral immunization, which tends to stimulate the 
systemic rather than the mucosal immune system (Moon and Blum, 1993). Therefore 
vaccination of piglets against post-weaning infections is still an important challenge; there is 
clearly a need for competent oral vaccines to induce mucosal protection. 
Some of the ETEC strains bear F4 fimbriae, a surface antigen which enables the bacteria to 
adhere to F4-specific receptors (F4R) present on the brush borders of the villous enterocytes 
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and subsequently to colonize the small intestine. The presence or absence of F4R is 
genetically determined, whereby it is known that piglets without the F4 receptor are resistant 
to F4+ E. coli infections, indicating that F4-mediated adhesion is a prerequisite for infection 
(Rutter et al., 1975; Gibbons et al., 1977). Antibodies against these fimbriae prevent ETEC 
adhesion in a direct or indirect manner (van Zijderveld et al., 1998). Consequently these 
fimbriae are possible antigens to induce a protective mucosal immune response. It has been 
demonstrated that newly weaned F4R-positive piglets can be orally immunized with purified 
F4 fimbriae in solution (Van den Broeck et al., 1999a). However, to prevent post-weaning 
diarrhea, an active mucosal immunity is needed at the moment of weaning. Therefore, the 
piglets have to be immunized during the suckling period using a vaccine formulation that can 
be mixed with creep food to facilitate administration. Previously, enteric coated pellets have 
been used for oral administration of vaccines, as they protect F4 fimbriae against the 
detrimental effects in stomach and duodenum. However, incompatibility between the protein 
and the enteric coating polymer was noticed (Huyghebaert et al., 2005). 
In the study described in this chapter, the use of porous pellets for oral vaccination of suckling 
piglets with F4 fimbriae was evaluated in vitro and in vivo. As the pellets consisted of an 
interconnected pore network, the F4 fimbriae can penetrate in the porous matrix of the pellets 
which can offer protection to against acids, bile, enzymes, antibodies etc. during gastro-
intestinal transit, thus ensuring release of the protein at the target site (major inductive sites; 
jejunal Peyer’s patches) in an immunizing conformation (Snoeck et al., 2006). Since binding 
of F4 to the F4 receptor on the villous enterocytes is a prerequisite for the induction of a 
protective intestinal immune response, the correct F4 confirmation is of crucial importance to 
ensure this binding. The application of this system to obtain mucosal immunization after oral 
administration is investigated. 
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6.2. MATERIALS  
To manufacture porous pellets, microcrystalline cellulose (Avicel PH 101) was obtained from 
FMC Biopolymer (Cork, Ireland) and sodium chloride (NaCl) (Alpha Pharma, Zwevegem, 
Belgium) was used as pore forming agent. 
To prepare the F4 stock solution, F4 fimbriae of enterotoxigenic E. coli bacteria were isolated 
as described by Van den Broeck et al. (1999b). The protein concentration of the isolated 
solution was determined using the Bicinchoninic Acid Protein Assay kit (Sigma-Aldrich, 
Bornem, Belgium). The purity was assessed by electrophoresis on SDS-12% polyacrylamide 
slab gels. 
 
6.3. METHODS 
6.3.1. Production and loading of the porous pellets 
The porous pellets were prepared according to the method described in Chapter 4 (section 
4.3.1.). 
In order to load the pellets with F4 fimbriae, vials (15ml) were filled with 500 mg pellets 
(glass type 1, Gaash Packaging, Mollem, Belgium) and spiked with 500 µl F4 solution (3.35 
mg/ml). As the solution was completely absorbed by the porous pellets, each vial contained 
1.68 mg F4. The pellets were dried by freeze-drying (Amsco-Finn Aqua GT4, Amsco, 
Germany). The samples were frozen to -45°C within 175 min. Primary drying was performed 
during 13 h at -15°C and at a pressure varying between 0.8 and 1 mbar, followed by 
secondary drying for 7 h at elevated temperature (10°C) without changing the pressure. After 
freeze-drying the vials were closed and kept on ice until analysis or administration. 
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6.3.2. Evaluation of the pellets 
¾ F4 biological activity 
In order to investigate if F4 fimbriae retained their activity during the manufacturing process, 
500 mg freeze-dried pellets (n=3) were soaked in 100 ml PBS. After crushing the pellets 
(using a magnetic stirrer) and centrifugation at 2500g, the supernatant was collected and 
stored at -20°C until analysis. 
The amount of biologically active F4 was determined via ELISA, as described by Verdonck 
et al. (2004). Briefly, the wells of a 96-well microtiter plate (NUNC® Brand Products, 
Polysorp Immuno Plates, Life Technologies, Merelbeke, Belgium) were coated with F4-
specific swine polyclonal antiserum in PBS. This polyclonal antiserum was able to bind 
native as well as denaturated F4 fimbrial FaeG. After 2 h incubation at 37°C, the remaining 
binding sites were blocked overnight with PBS + 0.2% Tween® 80. Subsequently the F4 stock 
solution and the samples (previously diluted until the same concentration as the stock solution 
was obtained, taking a complete release from the porous pellets in consideration) were added 
in series of two-fold dilutions (1-0.001 µg/ml) in ELISA buffer (PBS, pH 7.4 with 0.2% 
Tween® 20 and 3% BSA). The dilution of the stock solution started at a concentration of  
1µg/ml. Thereafter, an optimal dilution of the FaeG-specific monoclonal antibody IMM01 
(MAb) was added to the wells for 1 h at 37°C. Subsequently, rabbit anti-mouse horseradish 
peroxidase (HRP) conjugated serum (Dakon, Denmark) diluted in ELISA buffer and 
supplemented with 2% (v/v) pig serum was brought onto the plates for 1 h at 37°C. An ABTS 
(2,2’-azinobis 3-ethylbenzthiazoline-6-sulfonic acid) solution containing H2O2 was added, 
resulting in a colorimetric reaction (eq.1): 
     (eq.1.) 
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The optical density was measured spectrophotometrically at 405 nm.   
 
¾ Distribution of F4 in the porous pellet 
Pellets were fixed in formol. A cassette containing the pellets was placed overnight in a 
Tissue-Tek-VIP machine and consecutively soaked in different media (formol-ethanol-
methanol) in order to dehydrate the pellets. Next, the pellets were rinsed in xyleen, followed 
by embedding in paraffin (Medite TBS 88 paraffin embedding system, Klinipath). Slices (4 
µm) were made and dried during 10 min at 60°C. 
To visualize the F4 fimbriae, the slices were immunostained by incubating them with anti-F4 
rabbit antiserum followed by adding anti-rabbit IgG (whole molecule)/FITC antiserum 
(Sigma-Aldrich, Schneldorf, Germany). In order to ensure that no background fluorescence 
was detected, slices incubated in PBS followed by adding anti-rabbit IgG/FITC antiserum 
were used as control. The slices were examined using a fluorescence microscope. 
 
6.3.3. In vitro F4 release from the porous pellets 
¾ In vitro dissolution testing 
To simulate feed preparation 500 mg pellets (containing 1.675 mg F4) were immersed  for 5 
min in a pH 7.4 phosphate buffer saline (PBS) solution. The amount of F4 released after 5 
min was determined via ELISA. 
Secondly, after removing the pellets from PBS, a dissolution test was performed using the 
reciprocating cylinder method (USP apparatus 3) (Bio-Dis, Vankel, NJ, USA) at a dip rate of 
21 dpm with two consecutive media (250 ml): during 2 h in simulated gastric fluid (SGF, pH 
3.0) (USP 27) and during 5 h in PBS pH 7.4 (Snoeck et al., 2004a) to simulate the gastric and 
intestinal passage, respectively. Samples were taken after 1 and 2 h in SGF and 1, 3 and 5 h 
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dissolution in PBS. As positive control, the same test was performed without pellets, but by 
adding 1 ml F4 solution (1.67 mg/ml) to the dissolution media. 
The amount of F4 in the samples was determined using ELISA. 
 
¾ In vitro assay for competitive inhibition of villous adhesion  
An in vitro villous adhesion/inhibition test was carried out to determine if the released F4 had 
the capacity to bind to the F4 receptor (Cox and Houvenaghel, 1993). Wells were coated with 
intestinal villi of an F4R+ pig. Supernatants after dissolution of the F4 pellets in PBS, F4 
solution (+ control) and PBS (- control) were added to the wells followed by incubation. 
Afterwards, F4 E. coli (GIS 26) was added followed by incubation. Villi were examined by 
phase contrast microscopy at 600x magnification and the adhesion of the bacteria was 
evaluated quantitatively by counting the number of bacteria adhering along a 50 µm villous 
brush border at 20 different places, after which the mean bacterial adhesion per 250 µm 
villous length was calculated. Adhesion of more than 30 bacteria per 250 µm villous length 
was noted as strong adhesion, less than 30 bacteria per 250 µm villous length was classified 
as weak adhesion.  
 
6.3.4. In vivo F4 release from the porous pellets: an oral immunization experiment 
For the in vivo study 17 F4R+ pigs were selected using a PCR-RFLP assay (Rasschaert et al., 
2007) what was confirmed after slaughter by a villous adhesion/inhibition test (Cox and 
Houvenaghel, 1993). At the age of 9 weeks (63 days), 5 animals received an oral dose of 1 
mg F4 fimbriae in 5 ml PBS on three successive days (orally administered using a syringe) 
(solution group). Seven animals received a similar immunization with F4 fimbriae (1.675 mg) 
formulated in porous pellets. The pellets were orally administered with 15 ml PBS (pellet 
group). Another 5 animals were not immunized (control group). Both vaccinated groups 
________________________________________________________________________ 
Chapter 6 
144
received a booster vaccination at day 15. Finally, at day 30, all animals were infected with a 
virulent F4+ETEC strain as described by Cox et al. (1991). Briefly, piglets were treated with 
florfenicol in PBS (20mg/kg/day) (Nuflor, Schering-Phough, Brussels, Belgium) at day 3 and 
2 pre-infection. They were fasted overnight and were deprived of water 3 h pre-infection. 
Subsequently, they were orally infected with 1010 F4+ETEC, 15-30 min after neutralizing the 
acidic gastric pH with 60 ml of NaHCO3 (1.4% (w/v) in distilled water).  
 
¾ F4-specific serum antibody response 
Blood was sampled on a weekly basis (during 7 weeks) from the jugular vein for determining 
the total antibody titer in serum. Serum was collected and inactivated at 56°C and 
subsequently treated with kaolin (Sigma-Aldrich, Bornem, Belgium) to decrease the 
background reading in ELISA.  
The wells of a 96-well microtiter plate were coated with a F4ac-specific MAb at a 
concentration of 1 µg/ml in coating buffer (PBS). After 2 h of incubation at 37°C, the 
remaining binding sites were blocked for 30 minutes at room temperature with PBS 
supplemented with 0.2% (v/v) Tween 80. Subsequently F4 antigen was added to the wells at a 
concentration of 50 µg/ml in ELISA dilution buffer and incubated for 1 h at 37°C. Then, 
treated sera were added in series of twofold dilution (1/10, 1/20,…), and the plates were 
incubated for 1 h at 37°C. Thereafter, the wells were treated for 1 h at 37°C with optimal 
dilutions of anti-swine IgG (H+L) (Bethyl Laboratories, Montgomery, Texas). Conjugates had 
been prepared by coupling anti-swine IgG (H+L) specific MAb to peroxidase with a 
peroxidase labeling kit (Boehringer Mannheim, Brussels, Belgium). The substrate, ABTS, 
was added, and the OD405 was spectrophotometrically measured after 15 min incubation at 
37°C (Van den Broeck et al., 1999b). 
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The obtained ODs of all sera (dilutions 1/10) at day 0 were averaged, and the standard 
deviation was calculated. The mean, increased by twice the standard deviation, was 
considered as cut-off value. The antibody titer was the inverse of the highest dilution which 
still had an OD405 higher than the calculated cutoff value. 
 
¾ Mucosal immune response 
• Isolation of monomorphonuclear cells (MC) in lymph nodes 
At the moment of slaughter (age 22 weeks), mesenteric lymph nodes were aseptically 
dissected. After removing surrounding fat from the tissue, MC were isolated by tearing the 
tissue apart, followed by lysis of the red blood cells with ammonium chloride. After 
centrifugation (270g at 4°C for 10 min), the pelleted cells were washed and resuspended at 
107 cells/ml in leukocyte medium (RPMI-1640 (GIBCO BRL, Life Technologies, Merelbeke, 
Belgium) containing foetal calf serum (5 %), 2-mercaptoethanol (5 x 10-5 M), nonessential 
amino acids, Na-pyruvate (100 µg/ml), L-glutamine (292 µg/ml), penicillin (100 IU/ml), 
streptomycin (100 µg/ml) and kanamycin (100 µg/ml)). 
 
• Preparing Peyer’s patches MC 
To isolate MC from Peyer’s patches, small intestine pieces (from ileum and jejunum) were 
washed and incubated in CMF/EDTA/DDT medium at 37°C for 30 minutes followed by 
collagenase and DNAse incubation (RPMI + 5% FCS + 20 mM HEPES + 0.015% 
collagenase (SERVA, polylab, Antwerp, Belgium) + 0.010% DNAse I (Boehringer, 
Mannheim, Brussels, Belgium)) at 37°C for 45 min. Subsequently, Peyer’s patches MC were 
collected by scrapping the Peyer’s patches, washing and resuspending in leukocyte medium at 
107 cells/ml. 
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• Elispot assay for F4-specific IgM- and IgA-secreting cells 
The wells of a 96-well microtiter plate were coated with F4-specific polyclonal antiserum in 
PBS. After 2 h incubation at 37°C, the remaining binding sites were blocked for 30 min at 
room temperature with PBS supplemented with 0.2% (v/v) Tween 80. Next, F4 antigen was 
added to the wells at a concentration of 10 µg/ml in ELISA dilution buffer and incubated for 1 
h at 37°C. Subsequently, MC suspensions at a concentration of 107 cells/ml leukocyte 
medium were added to 10 wells (100 µl/well) and plates were incubated for 3 h at 37°C in a 
humidified 5% CO2 atmosphere. After removing cells by three subsequent washes with PBS-
T, plates were treated with anti-swine IgM- and IgA-peroxidase conjugates for 1 h. Unbound 
conjugates were removed by three washes and the substrate solution, consisting of 4 volumes 
of 3-amino-9-ethylcarbazole (AEC) working solution (0.67 ml AEC stock solution (0.4% in 
dimethylformamide) in 10 ml sodium acetate (0.1 M, pH 5.2) + 10 µl 30% H2O2) and 1 
volume of 3% low melting agarose (BIOzym, Landgraaf, The Netherlands), was added. 
Brown spots were counted with an inverted microscope after plates had been incubated in the 
dark at least overnight at room temperature. For each MC suspension, spots in 10 wells (106 
MC/well) were counted, so that finally the amount of antigen-secreting cells (ASC) per 107 
MC was determined.                 
 
6.4. RESULTS AND DISCUSSION 
6.4.1. F4 biological activity 
As in our study F4 fimbriae were incorporated in the pellets after extrusion/sferonization, the 
only process that could influence the stability of the antigen during manufacturing of the 
formulation was freeze-drying. The ELISA results of the supernatant of crushed freeze-dried 
pellets and of a F4 solution (standard, 100% activity) were compared: 79.8 ± 3.8 % of the F4 
activity was recovered in the porous pellets. 
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Figure 6.1.: Influence of manufacturing process on stability of the F4 fimbriae (n=3): standard 
solution (----) and supernatant of crushed pellets (____). 
 
For both the standard solution and the pellets, sigmoid OD405 curves with a steep linear phase 
were found (Fig. 6.1., only linear part of the curve is shown). The slope of both curves was 
similar. A more shallow curve for the pellets would indicate a lower affinity of MAb for F4 
fimbriae, most likely due to a conformational change in the epitope recognized by MAb, 
resulting in a lower activity (Verdonck et al., 2004). As this was not observed, the decrease in 
F4 activity in the pellet formulation is mainly contributed to an incomplete release of F4 from 
the pellets. 
 
6.4.2. Distribution of F4 in the porous pellets 
To visualize the distribution of F4 in the porous pellets, slices were made from pellets which 
were incubated with a F4-specific antibody followed by adding a FITC-labeled anti-rabbit 
IgG antiserum. Fig. 6.2. shows that F4 was not only present on the surface of the pellets but 
was found in the entire pellet. After spiking the pellets with the F4 solution, the pellets 
absorbed the solution and due to the presence of an interconnected pore network, the solution 
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passes trough the entire pellet whereby F4 fimbriae becomes distributed throughout the entire 
pellet.  
 
a       b 
                                           
Figure 6.2.: Image obtained by fluorescence microscopy of a cross section of a porous pellet 
loaded with F4 fimbriae after incubation with (a) anti-F4 rabbit antiserum and (b) 
PBS, both followed by the addition of anti-rabbit IgG/FITC antiserum 
 
6.4.3. In vitro study: release of F4 fimbriae from the porous pellets 
During real-life use the pellets will be added to a solution before administration to the piglets. 
To simulate this procedure, pellets were immersed in a PBS solution during 5 min. During 
this procedure only a small amount (19 ± 5%) of F4 was released, indicating that F4 loss from 
the pellets during feed preparation is limited.  
To investigate the release of F4 in the stomach and the gut, a reciprocating dissolution test 
was performed on the pellets after immersing them for 5 min in PBS. 
The diffusion-controlled release during 2 h in SGF was slow (22 ± 8 %) whereas during 5 h in 
PBS 68 ±14 % of the F4 fraction was released. This indicated that most of F4, absorbed in the 
internal pellet structure will be protected during gastric passage as most of the F4 dose is only 
released in the intestine. Hence a large fraction of F4 fimbriae will be available for interaction 
with the mucosa at the jejunal Peyer’s patches, which are the major inductive site of the F4-
specific immune response (Snoeck et al., 2006).  
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As previous studies have shown that F4 fimbriae retain their antigenicity during at least 4 h at 
pH 3.0 as demonstrated by recognition with an F4 specific Mab (Snoeck et al., 2004b), the 
limited amount of F4 detected in SGF is only attributed to the slow release of F4 from the 
pellets and not to inactivation of F4 in SGF. Furthermore, pellets have a limited residence 
time in the stomach as their gastric emptying is similar to that of fluids. 
The slow release of F4 from the porous pellets can be attributed to the size of F4 fimbriae: 
27.5 kDa (0.1-1 µm length and 2.1 nm diameter) whereas the size of conventional drugs is in 
the Angstrom range (0.1 nm). 
A villous adhesion/inhibition assay was done on the supernatant of the porous pellets after 5 h 
dissolution in PBS to ascertain if the released F4 were able to adhere to F4 receptors. The 
mean number of bacterial adhesion per 250 µm villous length was 8.3 (weak adherence) and 
86 (strong adherence) for the F4 (positive control) and PBS solution (negative control), 
respectively. After dissolution of pellets in PBS the mean number adhered bacteria was 
determined at 8.5 (weak adherence), indicating that the F4 receptor on the brush borders were 
occupied by F4 fimbriae present in the sample. This indicated that F4 fimbriae released from 
the pellets in PBS solution retained their binding capacity (even after residence in an acid 
medium).   
 
6.4.4. In vivo study: oral immunization of piglets with F4 loaded porous pellets 
¾ Systemic F4-specific antibody response 
The solution as well as the pellet group were orally vaccinated at day 1, 2 and 3 (age of 63, 64 
and 65 days) and again at day 15 (age 78 days). The control group was not immunized. At day 
30 (age 93 days) all animals were inoculated with the virulent F4+ ETEC strain. The F4-
specific serum antibody response was analyzed till day 45 (age of 108 days).  
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Fig. 6.3. shows that following primary vaccination a similar increase in F4-specific antibody 
response was detected in the solution as well as pellet group, but not in the control group. 
The second vaccination resulted in a further increase in antibody titer for the pellet group 
whereas in the solution group no increase was observed. After challenge, all groups displayed 
an antibody response whereas the increase in antibody titer was most pronounced in the 
control group. From day 40 (age 103 days) the antibody titer in the control group further 
increased whereas in the solution and pellet group the antibody tended to stabilize. 
The results of this immunization experiment provided evidence that F4 fimbriae in solution 
and pellets were able to induce an immune response upon oral administration to suckling 
piglets, with the serum antibody response in the pellet group being higher than in the solution 
group. The boost response upon challenge was lower than in the control group suggesting a 
certain decrease in colonization and multiplication of F4+E.coli. 
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Figure 6.3.: Kinetics of the total antibody titer in the control group (▲), the pellet group (▲) and 
the solution group (▲). Primary vaccination on day 1, 2 and 3, second vaccination on 
day 15 and challenge with virulent F4+ ETEC on day 30. 
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¾ Mucosal immune response 
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Figure 6.4.: F4-specific IgA (■) and IgM (■) ASC in the ileal Peyer’s patches (IPP), the jejunal 
  Peyer’s patches (JPP) and the mesenteric lymph nodes (MLN) after vaccination with 
  F4 pellets (15), vaccination with F4 solution (10) and without vaccination (24).  
 
The piglet of the pellet group had high numbers of F4-specific IgM and IgA ASC in the ileal 
and jejunal Peyer’s patches and low numbers in the mesenteric lymph nodes, whereas the 
piglet receiving an F4 solution showed only a high response in jejunal Peyer’s patches 
suggesting a less pronounced priming compared to the F4 pellets. The control piglet only 
showed a weak response in the inductive sites, with mainly IgM in the mesenteric lymph 
nodes and very few IgA response. In contrast, both vaccination procedure had an IgA 
response, demonstrating a primary response in the control pig and a secondary response in 
immunized piglets. 
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6.5. CONCLUSION 
Since in vitro F4 release in simulated gastric fluid was limited and most of the F4 dose was 
released in PBS, this indicated that F4 fimbriae formulated in porous microcrystalline pellets 
are protected during gastric passage and that the antigens are available at the jejunal Peyer’s 
patches, the main target site for an F4 specific immune response.  
Systemic immune response after oral vaccination of piglets with F4-containing porous pellets 
was higher compared to oral vaccination via an F4 solution, suggesting that more active F4 
was released from the porous pellets at the inductive site. 
The high amount of IgA and IgM antigen-presenting cells found at the jejunal Peyer’s patches 
of the piglet vaccinated with F4 pellets indicated the efficiency of this procedure. However, 
the shedding of E. coli bacteria in the faeces has to be evaluated to determine which procedure 
is the most efficient to induce mucosal protection. 
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General conclusion and future 
perspectives 
 
The first part of this research work described the development and evaluation of porous 
tablets and evaluated the application of this porous dosage form for oral drug delivery. Direct 
compression of a powder mixture of a ceramic powder (hydroxyapatite) and space holding 
material (pore forming agent) yielded tablets which were transformed into a porous structure 
via a heat treatment (calcination-sintering). Modified gelcasting of a hydroxyapatite slurry 
followed by a heat treatment also resulted in a porous tablet structure. Drug loading of the 
porous tablets occurred by spiking a drug solution on the tablet surface, where drug 
absorption depended on pore size, pore volume, presence of an interconnected pore network 
and drug concentration of the solution. As small liquid volumes can be dosed with high 
accuracy, these porous tablets can be used as innovative carriers for low-dosed drugs with 
limited risk of drug inhomogeneity. Furthermore as the drug is incorporated in the porous 
tablets after compression, this technique is also promising for processing drugs with poor 
tabletting characteristics. Drug release from the porous tablets is diffusion-controlled whereby 
the apparent drug diffusivity depended on the pore size and tortuosity of the porous network. 
Larger and more regular shaped pores resulted in a faster drug release. The bioavailibility of 
metoprolol tartrate after oral administration of porous tablets to dogs was similar to the in vivo 
behavior of an immediate release metoprolol tartrate tablet. 
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The second part of this research work described the development of porous pellets and 
evaluated the use of these porous pellets for oral delivery of conventional drugs and vaccines. 
Pellets were prepared by extrusion/spheronization of a microcrystalline cellulose/sodium 
chloride mixture, followed by aqueous extraction of the sodium chloride fraction to obtain 
porous pellets. Drug loading via supercritical fluid impregnation and immersion of the pellets 
in a drug solution resulted in drug being distributed in the entire pellet. In vitro drug release of 
ibuprofen and metoprolol tartrate from porous pellets was immediate, whereas an in vivo 
study in dogs showed that drug release in the gastro-intestinal tract depended on the drug 
solubility: release of drugs with a high aqueous solubility was immediate, whereas diffusion 
from the porous matrix in case of drugs with a low aqueous solubility was slow, yielding 
plasma concentrations similar to a sustained-release tablet formulation. 
In addition porous pellets can be used as carriers for oral vaccination purposes. Spiking a 
solution of F4 fimbriae onto the porous pellets, followed by freeze-drying was a suitable 
technique for the production of a multi-particulate formulation of biologically active F4. This 
opened interesting perspectives for the large-scale production of oral vaccines. The in vitro F4 
release in simulated in vivo conditions revealed a promising release profile: a limited loss of 
F4 in simulated gastric fluid (about 20% after 2 h), while the largest fraction (± 68%) was 
only released in phosphate buffer pH 7.4, indicating that most of the F4 fraction will be 
available at the site of infection (i.e. jejunal Peyer’s patches) to induce a mucosal immune 
response. An in vivo study in piglets demonstrated that after oral vaccination with F4-
containing pellets a mucosal immune response was elicited. 
 
Although some interesting applications of porous scaffolds for oral drug and vaccine delivery 
have been identified in this research project, some additional major hurdles can be identified 
before large scale application of these dosage forms becomes feasible: 
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General conclusion and future perspectives 
- scale-up of the production process of porous tablets and pellets  
- scale-up and automatization of the drug loading process 
- confirmation of the mucosal immunization study by determining the shedding of E 
Coli in the faeces 
- applicability of porous pellets for oral vaccination using other antigens 
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Summary 
 
 
    As porous materials (polymers, metals and ceramics) have many interesting 
 physical and chemical properties, they have widespread applications in nearly every 
 technology sector. Chapter 1 described the main biomedical application of cellular 
materials: the use of porous ceramics, polymers and/or metals as bone implants for structural 
purposes as well as for local drug delivery. Several manufacturing techniques for porous 
ceramics are reviewed and the drug release from these porous devices is described. Chapter 1 
also summarizes the most important aspects of the manufacturing and formulation of 
conventional tablets and pellets since the overall aim of this research project was to evaluate 
the possible applications of porous tablets and pellets for oral drug delivery. More specifically 
the application of porous tablets for the manufacturing of tablets containing low-dosed drugs 
ited compression properties were investigated as well as the possibilities 
 pellets for oral delivery of conventional drugs as well as vaccines.  
1 
or drugs with lim
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 The development of porous tablets as possible drug carrier for oral drug delivery was 
 described in Chapter 2. To manufacture porous hydroxyapatite matrices which can be
 used as drug carrier two techniques were used: direct compression and modified 
gelcasting, both in combination with sintering to obtain a porous matrix. The influence of 
formulation (type and concentration of pore forming agent) and process parameters 
(temperature and duration of the sinter process) on the quality and porosity of the 
hydroxyapatite tablets was evaluated. Highly porous tablets were obtained via direct 
compression and sintering, where the porosity was determined by the type (microcrystalline 
cellulose, starch, sorbitol) and concentration of the pore forming agent as well as by the sinter 
temperature. These experiments also showed that direct compression of a mixture of 
microcrystalline cellulose (Avicel PH 200, pore forming agent) and hydroxyapatite (50/50, 
w/w) in combination with sintering at 1250°C resulted in porous tablets with suitable 
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characteristics for its application as oral drug delivery system: a low friability and high tensile 
strength, a median pore of 5 µm and an interconnected pore network. Modified gelcasting of 
hydroxyapatite slurry in combination with sintering at 1350°C also resulted in tablets having 
suitable properties for oral drug delivery: spherical pores with a median pore diameter that 
could be varied from 20 to 100 µm, all incorporated in an interconnected pore network, an 
acceptable friability and tensile strength. Furthermore, all tablets were able to easily absorb 
the drug solution whereby an acceptable content uniformity was obtained.  
To incorporate a drug in the porous tablet structure a limited volume of drug solution was 
spiked on the tablet surface (using metoprolol tartrate as model drug). The drug load in the 
tablet was determined by the drug concentration in the solution spiked on the porous matrix 
and by the number of loading steps, but this application was limited to the formulation of low-
dosed drugs. Absorption of the liquid in the internal pore structure was rapid due to the 
interconnected pore network in the tablets manufactured via direct compression and 
gelcasting. Drug release from the porous tablets was primarily diffusion controlled whereby 
the apparent drug diffusivity depended on the pore size and tortuosity of the porous network. 
A slow drug release was obtained from porous pellets manufactured via direct compression 
(median pore diameter: 5 µm) whereas the porous tablets prepared via modified gelcasting 
have larger and more regular shaped pores with a median pore diameter of 100 µm yielded a 
faster drug release. The porous tablets were at least 12 months stable when stored at 25°C/60 
% relative humidity (RH) and at 40°C/75 % RH.  
This study identified porous tablets as innovative carriers for oral delivery of low dosed drugs. 
Furthermore, as the drug is incorporated in the porous tablets after compression, this 
manufacturing technique is also promising for processing drugs with poor tabletting 
characteristics. 
 
 
Chapter 3 describes the bioavailibility of metoprolol tartrate after oral administration
 of porous tablets with a median pore diameter of 5 and 100 µm. During the in vivo 
 experiment an oral dose of 100 mg metoprolol tartrate was administered to dogs in a 
cross-over sequence. Porous tablets with a median pore diameter of 5 µm (manufactured by 
direct compression of microcrystalline cellulose/hydroxyapatite (50/50, w/w) and sintering at 
1250°C) and 100 µm (manufactured via modified gelcasting and sintering at 1350°C) were 
selected as test formulations. The tablets were loaded with metoprolol tartrate via spiking of a 
metroprolol tartrate solution and after drying a formulation containing 100 mg metoprolol 
3 
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tartrate was obtained. The bioavailibility of the test formulations was compared to a 
commercial immediate release formulation (Lopresor®, 100 mg metoprolol tartrate). 
Metoprolol tartrate plasma concentrations were determined with a validated HPLC-
fluorescence method. 
Oral administration of the porous tablets with a median pore diameter of 5 and 100 µm 
resulted in both cases in immediate drug release. Statistical analysis of the pharmacokinetic 
parameters showed no significant difference between the test and reference formulations, 
indicating that although the in vitro drug release depended on pore size (Chapter 2), in vivo an 
immediate drug release was obtained from all porous tablets. 
To explain the discrepancy between in vitro and in vivo drug release from the porous tablets 
after administration of the porous tablets, additional dissolution tests were performed using 
conditions that simulate the gastro-intestinal conditions. The influence of hydrodynamic flow 
and stress in the gastro-intestinal tract was examined using different paddle speeds as well as 
the reciprocating cylinder method. Furthermore, the effect of several physiological relevant 
dissolution media (SGF, SIF, 4% bile salts solution, FaSSIF, FeSSIF and FASSGFSLS) on the 
in vitro drug release was investigated. The resulting drug release profiles showed that the 
faster in vivo drug release from the porous tablets with a median pore diameter of 5 µm in 
comparison to its in vitro drug release was mainly due to the low surface tension of the gastric 
fluid in fasted dogs. 
 
 
            The development of porous pellets as potential drug carriers for oral drug delivery was 
 described in Chapter 4. Pellets were manufactured via extrusion/spheronization of a 
 mixture consisting of microcrystalline cellulose and NaCl (30/70, w/w). Afterwards 
the NaCl fraction was removed from the pellets by aqueous extraction and the pellets were 
dried to obtain porous drug carriers. Via this technique spherical pellets (aspect ratio < 1.2) 
with an acceptable friability (< 0.1%) and a porosity of 33.2% with a median pore diameter of 
0.7 µm were obtained. X-ray tomography showed that the pores formed an interconnected 
pore network. Drugs were incorporated in the porous pellets via three different drug loading 
techniques: immersion of the pellets in a drug solution (using metoprolol tartrate as model 
drug), supercritical fluid impregnation (using ibuprofen as model drug) and fluid-bed layering 
(using paracetamol as model drug). Raman spectroscopy showed that the drug was 
homogeneously distributed throughout the pellets (i.e. drug was deposited inside the porous 
pellets) after immersion of pellets in a drug solution or supercritical fluid impregnation, 
4 
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whereas after fluid-bed layering drug was only present on the pellet surface. Drug release 
from the porous pellets was immediately and in case of pellets with drug deposited in its 
internal pore structure drug release was primarily diffusion-controlled. 
 
 
 Chapter 5 evaluated the bioavailability of drugs after oral administration of drug-
  loaded porous pellets to dogs. Metoprolol tartrate and ibuprofen were used as model 
 drugs with a high and low aqueous solubility, respectively. Metoprolol tartrate (100 
mg) was administered to dogs in a cross-over study. As test formulation a hard gelatin capsule 
containing porous microcrystalline cellulose pellets loaded with 100 mg metoprolol tartrate 
was selected and the bioavailibility of this test formulation was compared to a commercial 
immediate release formulation (Lopresor®, 100 mg metoprolol tartrate). Ibuprofen (300 mg) 
was administered to dogs in a cross-over sequence. As test formulation a hard gelatin capsule 
containing porous microcrystalline cellulose pellets loaded with 300 mg ibuprofen was 
selected. The bioavailibilty of the ibuprofen test formulation was compared to a commercial 
immediate release formulation (½ tablet of Ibuprofen EG® 600 mg) and a commercial 
controlled-release formulation (½ tablet of Ibu-Slow® 600 mg). Metoprolol tartrate and 
ibuprofen plasma concentrations were determined with a validated HPLC-fluorescence 
method and a validated HPLC-UV method, respectively. Statistical analysis of the 
pharmacokinetic parameters after administration of metoprolol tartrate revealed no significant 
difference between the test and reference formulation, indicating that drug release in the 
gastro-intestinal tract was immediate. In contrast, ibuprofen release from the porous pellets 
was sustained as indicated by the pharmacokinetic parameters. These observations indicated 
that the in vivo drug release from porous pellets depended on the solubility of the incorporated 
drug: release of highly soluble drugs was immediate, whereas diffusion from the porous 
matrix in case of drugs with a low aqueous solubility was slow, yielding plasma concentration 
similar to a sustained-release tablet. 
5 
 
 
            Chapter 6 described the development of a porous pellet formulation containing F4
 fimbriae. It was shown that incorporation of F4 fimbriae in porous microcrystalline
 pellets (via spiking of a F4 solution on porous pellets in combination with freeze 
drying) resulted in a remaining F4 bioactivity of 79.8 ± 3.8%, whereby F4 fimbriae were 
6 
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distributed in the entire pellet. An in vitro study was performed to determine F4 release from 
the pellets under setting simulating in vivo conditions: pellets were initially immersed during 
5 min in a pH 7.4 phosphate buffer solution (PBS) to simulate the feed preparation, next the 
pellets were transferred for 2 h to simulated gastric fluid (SGF) and for 5 h to PBS pH 7.4 to 
simulate gastric and intestinal passage, respectively. The dissolution profile revealed that 
about 19% of F4 was lost during feed preparation and that 20% was released in SGF. 
However, the largest fraction (about 68%) was released in PBS and would be available at the 
intended site of action in the gastro-intestinal tract. Furthermore, a villous adhesion inhibition 
test showed that F4 released in PBS retained there antigenicity, indicating that F4 were 
protected during gastric passage. F4-loaded porous pellets were orally administered to piglets 
and the elicited immune response after oral vaccination with F4 pellets was compared with 
the immune response obtained after oral vaccination with an F4 solution and a placebo 
formulation (control group, non-vaccinated piglets). The F4-specific antibody titer was 
determined in blood samples, and the F4-specific IgM- and IgA-secreting cells (ASC) were 
determined in the ileal and jejunal Peyer’s patches and in the mesenteric lymph nodes. Oral 
vaccination of piglets with F4-containing porous pellets resulted in the highest systemic 
immune response, suggesting that more active F4 was released from the porous pellets at the 
site of infection, compared with the F4 solution. A high number IgA and IgM ASC were 
found at the major site of infection (jejunal Peyer’s patches) in the piglets vaccinated with F4 
pellets and F4 solution. However, in order to investigate if oral vaccination of piglets using 
the porous pellets is the most efficient procedure, shedding of E. coli bacteria in the faeces  
should be monitored. 
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Samenvatting 
 
 
    Poreuze materialen (polymeren, metalen en ceramische materialen) kennen omwille
 van hun interessante chemische en fysische eigenschappen verschillende 
 toepassingen. De belangrijkste biomedische toepassing van poreuze materialen wordt 
beschreven in Hoofdstuk 1: het gebruik van poreuze ceramische materialen, polymeren en/of 
metalen als botimplantaat bij structurele chirurgie enerzijds en als drager van geneesmiddelen 
voor een lokale geneesmiddelvrijstelling anderzijds. Verschillende productietechnieken voor 
poreuze ceramische materialen alsook de geneesmiddelvrijstelling uit de poreuze materialen 
worden beschreven. Eveneens wordt in Hoofdstuk 1 een kort overzicht gegeven van de 
belangrijkste aspecten bij de productie van conventionele tabletten en pellets omdat deze 
doctoraatsthesis de mogelijke toepassingen van poreuze tabletten en pellets voor orale 
geneesmiddeltoediening evalueert. Meer bepaald wordt het gebruik onderzocht van poreuze 
tabletten bij de ontwikkeling van laaggedoseerde geneesmiddelen of bij de aanmaak van 
tabletten die geneesmiddelen bevatten met beperkte compressie-eigenschappen, alsook de 
ssingen van poreuze pellets bij orale toediening van conventionele 
n vaccins. 
1 
mogelijke toepa
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 Hoofdstuk 2 beschrijft de ontwikkeling van poreuze hydroxyapatiet tabletten waarbij 
 twee technieken werden aangewend: directe compressie en gelgieten, beide in 
 combinatie met sinteren ten einde een poreuze matrix te bekomen. De invloed van 
formulatie- (type en concentratie porievormer) en procesparameters (temperatuur en duur van 
het sinterproces) op de kwaliteit en de porositeit van poreuze hydroxyapatiet tabletten werd 
onderzocht. Via directe compressie en sinteren werden poreuze tabletten bekomen waarbij de 
porositeit afhankelijk is van het type (microkristallijne cellulose, zetmeel of sorbitol) en de 
concentratie van de porievormer en de sintertemperatuur. Directe compressie van een mengsel 
bestaande uit microkristallijne cellulose (Avicel PH 200, porievormer) en hydroxyapatiet 
2 
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(50/50 g/g) in combinatie met sinteren bij 1250°C resulteerde in poreuze tabletten met een 
lage friabiliteit, hoge tabletsterkte, een mediaan poriëndiameter van 5 µm en bestaande uit een 
poriënnetwerk waarin de verschillende poriën met elkaar verbonden zijn. 
Gelgieten van een hydroxyapatiet-suspensie in combinatie met een sintertemperatuur van 
1350°C resulteerde eveneens in poreuze tabletten met geschikte eigenschappen om als 
geneesmiddeldrager aangewend te worden: sferische poriën met een mediaan poriëndiameter 
van 20 tot 100 µm allen deel uitmakend van een poriënnetwerk, een lage friabiliteit en hoge 
tabletsterkte. Het opladen van de poreuze tabletten met geneesmiddel gebeurde door een 
beperkt volume geneesmiddeloplossing (gebruik makend van metoprolol tartraat als 
modelgeneesmiddel) op het tabletoppervlak aan te brengen waarbij de oplossing snel en 
volledig geabsorbeerd werd door de aanwezigheid van een poriënnetwerk. De maximale 
geneesmiddelopname in de tablet werd bepaald door de geneesmiddelconcentratie van de 
oplossing en door het aantal opladingstappen. De geneesmiddelvrijstelling was diffusie-
gecontroleerd waarbij de diffusiesnelheid afhankelijk was van de poriëngrootte en de 
tortuositeit van het poriënnetwork. De geneesmiddelvrijstelling uit de poreuze tabletten, 
aangemaakt via directe compressie (mediane poriëndiameter: 5 µm) was traag. Daarentegen 
werd onmiddellijke geneesmiddelvrijstelling bekomen uit poreuze tabletten geproduceerd via 
gelgieten (mediane poriëndiameter: 100 µm). Dit toonde aan dat grotere en sferische poriën 
resulteerden in een snellere geneesmiddelvrijstelling. De poreuze tabletten waren stabiel 
gedurende 12 maanden bewaring bij 25°C en 60% relatieve vochtigheid (RV), evenals bij 
40°C en 75% RV. 
Deze studie toonde aan dat poreuze tabletten mogelijkheden bieden voor de orale toediening 
van laaggedoseerde geneesmiddelen, bovendien kunnen deze poreuze tabletten ook een 
oplossing bieden voor het produceren van tabletten met geneesmiddelen met slechte 
compressie-eigenschappen aangezien de poreuze matrix pas na compressie wordt opgeladen 
met geneesmiddel.  
 
 
De biologische beschikbaarheid van metoprolol tartraat na orale toediening van 
 poreuze tabletten (mediane poriëndiameter: 5 en 100 µm) werd behandeld in 
 Hoofdstuk 3. Hierbij werd 100 mg metoprolol tartraat toegediend aan honden in een 
‘cross-over’ studie. Poreuze tabletten met een mediane poriëndiameter van 5 en 100 µm, 
respectievelijk geproduceerd via directe compressie en sinteren van een 
hydroxyapatiet/microkristallijne cellulose mengsel (50/50, g/g) en via gelgieten en sinteren 
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van een hydroxyapatiet-suspensie, werden geselecteerd als testformulaties. De tabletten 
werden opgeladen met een metoprolol tartraat-oplossing. De biologische beschikbaarheid van 
de testformulaties werd vergeleken met een commercieel beschikbaar preparaat met 
onmiddellijke geneesmiddelvrijstelling (Lopresor®, bevat 100 mg metoprolol tartraat). De 
metoprolol plasmaconcentraties werden bepaald met een gevalideerde HPLC-fluorescentie 
methode. Orale toediening van poreuze tabletten met een mediane poriëndiameter van 5 en 
100 µm resulteerde in beide gevallen in een onmiddellijke geneesmiddelvrijstelling. 
Statistische evaluatie van de farmacokinetische parameters toonde geen significant verschillen 
aan tussen de test- en referentie-formulaties. Ondanks het feit dat de in vitro 
geneesmiddelvrijstelling afhankelijk was van de poriëngrootte (Hoofdstuk 2), wijzen de 
resultaten van de in vivo experimenten op een onmiddellijke vrijstelling onafhankelijk van de 
poriëngrootte. 
Om deze verschillen tussen de in vitro en in vivo resultaten te verklaren, werden bijkomende 
dissolutietesten uitgevoerd onder omstandigheden die de in vivo condities nabootsen. De 
invloed van hydrodynamiek en stress in het gastro-intestinaal kanaal werd nagegaan via 
dissoluties met verschillende mengintensiteit en door gebruik te maken van de Biodis 
methode. Bovendien werd de invloed van verschillende ‘fysiologisch relevante‘ 
dissolutiemedia uitgetest. Uit deze dissolutietesten werd besloten dat de snellere in vivo 
vrijstelling uit de poreuze tabletten met een mediaan poriediameter van 5 µm voornamelijk te 
wijten was aan een lagere oppervlaktespanning van het dissolutiemedium. Dit correleerde met 
in vivo data gelet op de lage oppervlaktespanning van het maagsap bij de hond in nuchtere 
toestand. 
 
 
De productie van poreuze pellets werd beschreven in Hoofdstuk 4, waarbij als 
 productietechniek werd geopteerd voor extrusie/sferonistie van een mengsel bestaande
 uit microkristallijne cellulose en NaCl (30/70, g/g). Vervolgens werd de NaCl fractie 
verwijderd via een waterige extractie en na drogen werden poreuze pellets bekomen. Via deze 
techniek werden sferische pellets (aspect ratio: 1.2) bekomen met een lage friabiliteit (< 
0.1%), een hoge porositeit (33.2%) en een mediane poriëndiameter van 0.7 µm. X-straal 
tomografie toonde aan dat de poriën deel uitmaken van één groot poriënnetwerk. De pellets 
werden opgeladen met geneesmiddel via 3 verschillende methodes: het onderdompelen van de 
pellets in een geneesmiddeloplossing (gebruik makend van metoprolol tartraat als 
modelgeneesmiddel), met behulp van superkritische vloeistoffen (ibuprofen als 
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modelgeneesmiddel) en via het omhullen van de pellets met een geneesmiddeloplossing 
(paracetamol als modelgeneesmiddel). Via Raman-spectroscopie werd aangetoond dat het 
geneesmiddel homogeen verdeeld was in de poriënstructuur van de pellet indien gebruik 
gemaakt werd van de onderdompelingsmethode en superkritische vloeistoffen om de pellets 
met geneesmiddel op te laden. Het gebruik van de omhullingtechniek resulteerde enkel in 
geneesmiddelafzetting aan het oppervlak van de pellet. Geneesmiddelvrijstelling uit de 
poreuze pellets was onmiddellijk en indien het geneesmiddel aanwezig was in de 
poriënstructuur van de pellets was de vrijstelling diffusie-gecontroleerd 
 
 
  De biologische beschikbaarheid van geneesmiddelen na orale toediening van poreuze
  pellets aan de hond werd behandeld in Hoofdstuk 5. Metoprolol tartraat en ibuprofen
  werden gebruikt als modelgeneesmiddelen met respectievelijk een hoge en lage 
wateroplosbaarheid. Metoprolol tartraat (100 mg) werd toegediend aan honden in een ‘cross-
over’ studie. Hiervoor werd een harde gelatinecapsule gevuld met poreuze pellets (equivalent 
met 100 mg metoprolol tartraat) en de biologische beschikbaarheid van deze testformulatie 
werd vergeleken met een commercieel beschikbaar preparaat met onmiddellijke 
geneesmiddelvrijstelling (Lopresor®, 100 mg metoprolol tartraat). Ibuprofen (300 mg) werd 
eveneens toegediend aan de honden in een ‘cross-over’ studie. De testformulatie was een 
harde gelatinecapsule gevuld met poreuze pellets (equivalent met 300 mg ibuprofen). De 
biologische beschikbaarheid van deze testformulatie werd vergeleken met de biologische 
beschikbaarheid na toediening van commercieel beschikbare ibuprofen-preparaten met een 
onmiddellijke en gecontroleerde vrijgave: respectievelijk ½ tablet Ibuprofen EG® 600 mg en 
½ tablet Ibu-Slow® 600 mg. De metoprolol tartraat en  ibuprofen plasmaconcentraties werden 
bepaald via respectievelijk een gevalideerde HPLC-fluorescentie en HPLC-UV methode. Na 
orale toediening van metoprolol tartraat pellets werd een onmiddellijke 
geneesmiddelvrijstelling bekomen aangezien er geen significant verschillen waren tussen de 
test- en referentie-formulaties. Dit in tegenstelling tot de in vivo vrijstelling van ibuprofen uit 
de poreuze pellets, waarvoor een vertraagde vrijstelling werd vastgesteld. Deze observaties 
tonen aan dat de in vivo geneesmiddelvrijstelling uit de poreuze pellets afhankelijk was van de 
oplosbaarheid van het geneesmiddel: een onmiddellijke vrijstelling voor een goed 
wateroplosbaar geneesmiddel, terwijl de diffusie van een geneesmiddel met een lage 
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wateroplosbaarheid uit de poreuze matrix traag verloopt, wat resulteert in een vertraagde 
geneesmiddelvrijstelling.  
 
 
6 Hoofdstuk 6 beschreef de ontwikkeling van een poreuze pellet formulatie van F4 fimbriae. Het bevochtigen van poreuze microkristallijne pellets met een F4-oplossing, 
gecombineerd met vriesdrogen was een geschikte techniek om F4 fimbriae over de 
gehele pellets te verdelen, waarbij na productie 79.8 ± 3.8% van de biologische activiteit van 
F4 bewaard bleef. In vitro experimenten werden uitgevoerd om de vrijstelling van F4 uit de 
poreuze pellets te bepalen onder omstandigheden die de in vivo condities nabootsen: F4 
pellets werden gedurende 5 min ondergedompeld in een fosfaatbuffer-oplossing (PBS, pH 
7.4) om het verlies van F4 tijdens voedselbereiding te simuleren. Vervolgens werd een 
dissolutietest uitgevoerd gedurende 2u in kunstmatig maagsap (pH 3) en gedurende 5u in PBS 
pH 7.4 om respectievelijk de passage van de pellets doorheen de maag en de darm te 
simuleren. Tijdens de voedselbereiding werd ongeveer 19% van de F4-dosis verloren, terwijl 
20% F4 werd vrijgesteld in kunstmatig maagsap. De grootste fractie (68%) werd echter 
vrijgesteld gedurende de 5u dissolutietest in fosfaatbuffer en is dus beschikbaar ter hoogte van 
de target. Bovendien werd met een villus adhesie inhibitietest bewezen dat F4 fimbriae 
vrijgesteld in PBS hun antigeniciteit behielden, wat wijst op een protectie van F4 gedurende 
de maagtransit. Na toediening van F4 pellets aan biggen werd de immuunrespons vergeleken 
met de immuunrespons na orale toediening van een F4 oplossing en een placebo-formulatie 
(controle-groep, niet-gevaccineerd). Naast de F4-specifieke antilichaamtiter in het bloed 
werden ook de F4-specifieke IgM en IgA secreterende cellen in de ileale en jejunale Peyerse 
platen alsook in de messentherische lymfeknopen, bepaald. Orale vaccinatie van de biggen 
met F4 pellets resulteerde in de hoogste systemische immuunrespons, wat aantoont dat ter 
hoogte van de inductieve plaatsen (jejunale Peyerse platen) meer actief F4 werd vrijgesteld in 
vergelijking met orale vaccinatie via een F4 oplossing. 
Het hoogste aantal antigen-secreterende cellen werd teruggevonden ter hoogte van de 
belangrijkste inductieve plaatsen (jejunale Peyerse platen) zowel bij biggen gevaccineerd met 
F4 pellets als bij biggen gevaccineerd met een F4 oplossing. Teneinde definitief te bepalen 
welke vaccinatie-procedure het meest efficiënt is, moet de uitscheiding van E. coli bacteriën 
via de faeces worden bepaald.  
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